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 II  Zusammenfassung 
Zusammenfassung 
 
Hämophilie A ist eine Störung der Blutgerinnung, die weltweit 400 000 Menschen betrifft. Neben 
verlängerten Blutungszeiten leiden Patienten unter spontanen und inneren Blutungen, die ihr tägliches 
Leben beeinflussen. Die Behandlung erfolgt mithilfe von therapeutischem FVIII, welcher entweder aus 
Plasma gewonnen oder rekombinant hergestellt wird. Ob eine Behandlung prophylaktisch oder nur bei 
Bedarf erfolgt, hängt von der Schwere der Krankheit und den Lebensumständen des Patienten ab. 
Obwohl die Behandlung den meisten Patienten ein nahezu normales Leben ermöglicht, können 
Patienten Inhibitoren gegen den therapeutischen FVIII entwickeln, die diesen inaktivieren. In den 
meisten Fällen kann dies durch eine Immuntoleranztherapie behandelt werden. Diese Therapie ist 
jedoch lang, strapaziös und sehr teuer. In den vergangenen Jahren wurden verschiedene rekombinante 
FVIII Produkte mit Modifikationen zur Verlängerung der in vivo Halbwertszeit entwickelt. Ein FVIII 
Produkt mit einer verringerten Immunogenität wurde jedoch noch nicht publiziert. Ein deimmunisierter 
FVIII könnte die Wahrscheinlichkeit einer Inhibitorentstehung verringern und so eine bessere Therapie 
für die Patienten ermöglichen. 
In dieser Thesis wird eine deimmunisierte FVIII Variante entwickelt. Die Arbeit umfasst die 
vollständige Entwicklung, begonnen mit den in silico Berechnungen, über die Produktion und Reinigung, 
bis zu den in vitro und in vivo Analysen. Der Deimmunisierungsansatz beruht auf einer Verringerung der 
FVIII-Peptidpräsentation auf der Oberfläche von antigenpräsentierenden Immunzellen. Dadurch soll 
verhindert werden, dass naive T-Zellen aktiviert werden. Ohne FVIII-spezifische T-Helferzellen können 
wiederum keine naiven B-Zellen aktiviert werden, was zu einem Ausbleiben von hochaffinen Inhibitoren 
führt. Dadurch wird die Produktion der Antikörper bereits auf der Ebene der T-Zellen unterbunden. 
Während der in silico Analyse wurden Peptide identifiziert, die mit hoher Affinität an den 
Haupthistokompatibilitätskomplex II binden, welcher für die Präsentation von Peptiden auf der 
Zelloberfläche benötigt wird. Anschließend wurden Aminosäureaustausche vorgeschlagen, um diese 
Bindung zu verringern. Der Einbau der Mutationen in die FVIII Sequenz wurde in drei Runden 
durchgeführt, begonnen mit dem Einbau von Einzelmutationen, gefolgt von der Kombination mehrerer 
Mutationen bis zur finalen Kombination aller Mutationen. Nur Mutationen, die zu einem funktionalen 
FVIII führten, wurden in die nächste Runde transferiert. Final konnten 19 Mutationen in die Sequenz 
eingebaut werden. Dies führte, basierend auf in silico Berechnungen, zu einer Reduzierung des 
Immunogenitätswerts von 7 auf -11. Eine vollständige Deimmunisierung war jedoch nicht möglich, da 
besonders aktivitäts-, faltungs- und interaktionsrelevante Regionen des FVIII nicht verändert werden 
konnten. Funktionale und strukturelle Analysen des mutierten FVIII zeigten Ähnlichkeiten zu einem 
Kontroll-FVIII und zu kommerziell erwerblichen FVIII Produkten.  
Zusätzlich wurde ein in vitro DC-T-Zell Test entwickelt, um die reduzierte Immunogenität der 
deimmunisierten FVIII Variante nachzuweisen, da dies mit den zur Verfügung stehenden in vivo 
Modellen nur begrenzt möglich war. Für diesen Test wurden DCs mit verschiedenen FVIII Produkten 
vorinkubiert und anschließend zusammen mit CD4+ T-Zellen kultiviert. Final wurde die Proliferation 
von CD4+ T-Zellen analysiert. Aus der untersuchten CD4+ T-Zell Population wurden vor der Kultivierung 
die regulatorischen T-Zellen depletiert. Dies wurde durchgeführt, um den Test sowohl mit Zellen von 
gesunden Spendern als auch von Hämophilie A Patienten durchführen zu können. Mit Zellen von 
gesunden Spendern bestätigte der Test eine signifikant verringerte Immunogenität des mutierten FVIII 
im Vergleich zum Kontroll-FVIII. Diese Ergebnisse müssen noch mit Zellen von Hämophilie A Patienten 
belegt werden. Leider konnte diese verringerte Immunogenität in vivo nur begrenzt nachgewiesen 
werden. Zwei Mausmodelle wurden getestet, jedoch hatten diese entweder ein humanes Immunsystem 
oder einen FVIII-Knockout. Eine Kombination aus beiden Modellen wäre optimal gewesen, war jedoch 
nicht verfügbar. 
Insgesamt zeigt diese Thesis den ersten deimmunisierten und aktiven FVIII mit 19 Mutationen, der 
in einem in vitro Test mit Zellen von gesunden Spendern eine verringerte Immunogenität aufweist. Wenn 
diese Ergebnisse in vivo bestätigt werden können, kann dieses Molekül die Therapie von Hämophilie A 
Patienten deutlich verbessern, indem es das Risiko einer Inhibitorentstehung verringert. Diese 
Verringerung der Inhibitorinzidenz würde zudem auch die Therapiekosten verringern, da Inhibitor-
negative Patienten keine teure Immuntoleranztherapie benötigen.  
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Abstract 
 
Hemophilia A is a bleeding disorder, affecting about 400 000 people worldwide. In addition to 
prolonged bleeding times, patients suffer from spontaneous and internal bleedings, affecting their 
everyday life. Patients can be treated by the application of therapeutic FVIII, either derived from plasma 
or recombinantly produced. Whether the treatment is prophylactic or on-demand depends on the 
severity of the disease and on the living conditions of the patients. Although treatment allows most of 
the patients to live a life as normal as possible, patients can develop inhibitory antibodies against the 
therapeutic FVIII, rendering the molecule inactive. In most cases, this situation can be overcome by an 
immune-tolerance-induction therapy. However, this therapy is long, strenuous and associated with very 
high costs. Different recombinant FVIII products evolved within the last years, containing modifications, 
in order to prolong the in vivo half-life of FVIII. However, a FVIII product with a reduced immunogenicity 
was not yet published. A deimmunized FVIII could reduce the probability of inhibitor development, 
providing a safer therapy for the patients and lower the costs for therapy. 
In this thesis, a deimmunized FVIII molecule is generated. The work comprises the full 
development, starting with in silico calculations of the FVIII sequence, through the production and 
purification, leading to final analyses in vitro and in vivo. The deimmunization approach is based on the 
reduction of FVIII-peptide presentation on antigen-presenting immune cells. This is supposed to lead to 
a prevention of naïve T cell activation. Without FVIII-specific T helper cells, naïve B cells cannot be 
activated, leading to the absence of high-affinity inhibitors.  
The in silico analysis of FVIII was based on the identification of peptides which bind with a high 
affinity to the major histocompatibility complex class II, which is required for cell surface-presentation 
of peptides. Amino acid exchanges were proposed, in order to reduce this binding. These mutations were 
incorporated into the FVIII sequence. This was performed in three rounds, starting with the incorporation 
of single mutations, followed by the combination of several mutations, to the final combination of all 
mutations in one molecule. Only mutations still leading to functional FVIII were finally incorporated. 
Based on this, 19 mutations could be incorporated into the molecule. This led to a reduction of the 
immunogenicity score of FVIII from 7 to -11, indicating a reduced immunogenicity based on in silico 
calculations. However, a total deimmunization of all epitopes was not possible, as some regions of FVIII, 
especially those important for activity, folding and binding, could not be altered. Functional and 
structural analyses of this mutated FVIII variant revealed similarity to a control FVIII as well as to 
commercially available recombinant FVIII products.  
Additionally, an in vitro DC-T cell Assay was developed, in order to determine a reduced 
immunogenicity of the deimmunized FVIII variant, as the available mouse models were limited. The DCs 
were primed with different FVIII products and the proliferative response of regulatory T cell-depleted 
CD4+ T cells to these DCs was measured. The regulatory T cells were depleted, in order to be able to 
perform this assay with cells derived from healthy donors as well as Hemophilia A patients. Using this 
DC-T cell Assay, cells from healthy donors proved the significantly reduced immunogenicity of the 
mutated FVIII variant by revealing less proliferation of T helper cells to this variant than to the control 
FVIII. These results have further to be proven with cells derived from Hemophilia A patients. 
Unfortunately, the detection of a reduced immunogenicity in vivo was limited. Two mouse models were 
tested but the models had either a FVIII knockout or a human immune system. However, a combination 
of these two models would have been optimal but was not available.  
Finally, this thesis presents the first deimmunized FVIII, containing 19 amino acid mutations, 
which is still active and proves to be less immunogenic in an in vitro assay with cells from healthy donors. 
Upon confirmation of these results in vivo, this molecule can highly improve the therapy of Hemophilia 
A patients by reducing the risk of inhibitor development in previously treated as well as in previously 
untreated patients. This reduced inhibitor incidence would also reduce the costs of therapy, as inhibitor-
negative patients would not require an expensive immune-tolerance-induction therapy. 
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1. Introduction 
 
Hemophilia A is a genetic bleeding disorder caused by the absence of sufficient amounts of active 
Factor VIII (FVIII). The disease is linked to the X-chromosome and occurs in 1 of 5000 newborn males1. 
In females, congenital Hemophilia A is very rare and most women are only carriers of one mutated X-
chromosome2. However, Hemophilia A can also occur spontaneously, due to an autoimmune response 
against FVIII. This acquired form of Hemophilia A affects women as well as men and is associated with 
other autoimmune diseases, increased age and pregnancy3,4. Patients with Hemophilia A suffer from 
longer bleeding durations, spontaneous and internal bleedings, affecting their everyday life5. Nowadays 
many different mutations are known, which lead to congenital Hemophilia A6. These include intron 
inversions, deletions and various point mutations, leading to frameshifts, premature stop-codons or 
missense mutations in the FVIII gene1. These mutations can result in a total absence of endogenous FVIII, 
in dysfunctional FVIII or in FVIII with reduced activity. Due to the fact that FVIII is one component of 
the clotting cascade, its absence or non-functionality leads to impaired blood clotting7. Although FVIII is 
not an enzyme, it is a very important co-factor to the activated coagulation Factor IXa (FIXa) and 
increases its activity dramatically8.  
Based on the amount of functional FVIII left in the patients, compared to a normal plasma level of 
1 U/ml, Hemophilia A is subdivided into a mild, a moderate and a severe form. Patients who suffer from 
severe Hemophilia A have less than 1 % of the normal FVIII plasma level. Compared to that, moderate 
Hemophilia A covers the range of 1-5 % of FVIII and patients with mild Hemophilia A still have 6-50 % 
of FVIII9. Depending on whether the patients suffer from mild, moderate or severe Hemophilia A, the 
treatment differs. Patients with mild and moderate forms have a low risk for spontaneous bleedings and 
are mainly treated on demand, for example after an injury or prior to a surgery. In contrast to that, many 
patients with severe Hemophilia A, especially children, with a high risk for spontaneous bleedings are 
treated prophylactically, in order to reduce the risk of internal bleedings and emerging disabilities10,11. 
Nevertheless, Hemophilia A treatment is mainly limited to developed countries, as the therapy is very 
expensive12. 
The FVIII products used for therapy are either purified from plasma of healthy donors or produced 
recombinantly in cell culture. Due to that, there are two general FVIII products, plasmatic FVIII (pFVIII) 
and recombinant FVIII (rFVIII). The main difference is that pFVIII products mostly contain von 
Willebrand Factor (vWF), the natural partner of FVIII, and other plasma proteins. In contrast to that, 
rFVIII products contain only FVIII13. All recent FVIII products are applied intravenously and suffer from 
the major drawback that they have a short half-life in the patients with an average of 12 hours, ranging 
between 6 and 24 hours14,15. Due to that, especially patients treated prophylactically, have to receive a 
FVIII injection every two to three days16. Therefore, one focus of ongoing FVIII research is on half-life 
extension of rFVIII products17. 
Another major drawback in FVIII therapy, next to the short half-life and the intravenous 
administration, are inhibitory antibodies, occurring in some patients. Antibodies against FVIII are 
produced when the immune system recognizes FVIII as a foreign protein18. Not all antibodies against 
FVIII affect its function and by that the therapy. Only if the antibodies bind to special regions, for example 
cleavage sites or binding sites, the FVIII becomes inactive19. These antibodies are called inhibitory 
antibodies or inhibitors. Mainly patients with severe Hemophilia A, up to 30 %, are affected by inhibitory 
antibodies. Nevertheless, inhibitors also occur in patients with mild or moderate forms but to a lesser 
extent compared to severe Hemophilia A patients20,21. In the case of inhibitor formation, the patients 
mostly undergo an immune-tolerance-induction (ITI) therapy. During this therapy very high doses of 
FVIII are applied to the patients, in order to exhaust the immune system and via that to induce 
tolerance22. This therapy is very cost-intensive as well as strenuous for the patients and their caregivers. 
During ITI, FVIII application occurs daily, in some cases even twice a day. In addition to the strenuous 
therapy, the number of bleeds are increased when inhibitors are present23. The aim to protect the patient 
from resulting disabilities, due to joint bleeds, impairs the social life of the patient as well as of the whole 
family24. This is why the second focus of FVIII research is on the development of rFVIII molecules, which 
do not induce an immune response in patients.  
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1.1. Coagulation Factor VIII 
 
FVIII is an important co-factor in the coagulation cascade. It is mainly produced by liver sinusoidal 
endothelial cells25,26 and secreted as a heterodimer27. In circulation FVIII is bound to vWF, which protects 
FVIII from early activation as well as degradation28. Normal FVIII plasma concentrations range between 
100 and 200 ng/ml29,30. Upon activation the heterodimer is cleaved into a heterotrimer, which builds a 
complex with FIXa and Factor X (FX), the tenase complex31. Inactivation of activated FVIII (FVIIIa) occurs 
either due to dissociation of a FVIII subunit or by activated protein C, a specific inhibitor of the clotting 
cascade32. 
 
 
1.1.1. FVIII gene and protein 
 
The FVIII gene is located on the X chromosome and consists of 26 exons, spanning approximately 
186 000 base pairs33. The resulting mRNA comprises about 9000 base pairs34, encoding 2332 amino acids 
of the FVIII protein plus additional 19 amino acids of the signal sequence27,35. The main site of FVIII 
production is the liver36 but FVIII production has also been determined in the kidneys, the spleen and 
endothelial cells25,37–39. The protein is synthesized as a single chain and consists of three A domains (A1-
A3), one B domain and two C domains (C1 and C2)35, interrupted by short acidic sequences (a1-a3). 
The resulting domain structure is A1-a1-A2-a2-B-a3-A3-C1-C2 (Figure 1-1, FVIII pro-protein)40. 
During post-translational modification, FVIII becomes glycosylated, sulfated and proteolytically 
processed. The whole FVIII protein contains 25 potential N-glycosylation sites. Nineteen of these sites 
are located in the B domain35 and six sites are spread along the rest of the protein29,41. As not all of these 
sites become glycosylated, FVIII possesses only 21 N-glycosylations42. Additionally, the B domain 
contains seven O-linked glycosylations42. The glycosylation of FVIII is very important for intracellular 
folding and transport43,44. Instead, sulfation is necessary for the extracellular interaction with different 
proteins, especially thrombin and vWF45. It takes place on six tyrosines in the acidic regions a1, a2 and 
a3 (Figure 1-1, Mature FVIII)46,47. Intracellular cleavage, by the serine protease furin, divides FVIII into 
a heavy chain (A1-a1-A2-a2-B) and a light chain (a3-A3-C1-C2). During this cleavage parts of the 
B domain can be lost27,48. Therefore, the light chain has a molecular weight of 80 kDa, whereas the heavy 
chain can be slightly heterogeneous, with a molecular weight around 210 kDa. The binding between 
heavy and light chain is not covalent but mediated by the divalent metal ion Cu2+ between the A1 and 
A3 domain (Figure 1-1, Secreted FVIII)49–52. 
 
 
Figure 1-1: Structure of FVIII. The FVIII pro-protein still contains the FVIII signal sequence and is not yet modified. The cleavage 
of the signal sequence and the post-translational modifications lead to the mature FVIII. Before secretion, FVIII is cleaved by 
furin. Secreted FVIII is bound to vWF and stabilized by a divalent cation. 
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Upon secretion into plasma, FVIII complexes with vWF via the a3, C1 and C2 domain (Figure 1-1, 
Secreted FVIII)47,53,54. About 95 % of circulating FVIII is bound to vWF. The interaction stabilizes the 
heterodimer, protects it from degradation28,55 and prevents cellular uptake56. Due to prevention of uptake 
and degradation, vWF is important for the prolongation of the FVIII half-life of up to 12 hours57,58. 
Additionally, the binding of vWF to FVIII shields binding sites of FVIII to negatively-charged 
phospholipids59,60 and FIXa61. 
 
 
1.1.2. FVIII and the coagulation cascade 
 
Coagulation is mainly started upon vascular injury, initiating the extrinsic pathway (Figure 1-2). 
The damaged cells expose tissue factor (TF) which binds to activated Factor VII (FVIIa), present in blood. 
This extrinsic tenase complex activates FX and FIX. In the following, the activated FX (FXa) activates 
prothrombin (FII) to thrombin (FIIa). However, the amounts of generated thrombin are too low to 
activate fibrinogen. Due to this, thrombin activates Factor V (FV), FVIII and Factor XI (FXI) of the 
intrinsic pathway, resulting in a positive feedback loop. Activated FXI (FXIa) increases the generation of 
FIXa. Further on, FIXa, FVIIIa and FX build the intrinsic tenase complex, which generates high amounts 
of FXa. Afterwards, FXa builds the prothrombinase complex with activated FV (FVa), generating high 
amounts of thrombin. Thrombin cleaves fibrinogen (FI) to fibrin (FIa) and Factor XIII (FXIII) to activated 
FXIII (FXIIIa). Fibrin is cross-linked by FXIIIa, in order to build the clot62,63. Alternatively, coagulation 
can be initiated via the intrinsic pathway (Figure 1-2). This cascade is started by contact activation of 
Factor XII (FXII) to activated FXII (FXIIa) on a charged surface. FXIIa further activates FXI leading to the 
cascade described above. However, in vivo coagulation is mainly triggered by TF exposure64. 
 
 
Figure 1-2: Coagulation cascade. The coagulation is initiated either by a damaged surface (intrinsic) or by exposed tissue factor 
(extrinsic). Both pathways lead to the activation of FX. Further on FXa generates thrombin. In the beginning, thrombin amplifies 
its own production by the activation of FV, FVIII and FXI. When enough thrombin is generated, it cleaves fibrinogen and FXIII. 
The generated fibrin is cross-linked by FXIIIa, leading to the fibrin clot. 
 4  Introduction 
The serine protease thrombin activates FVIII by cleavage at two sites located in the heavy chain, 
Arginine (R) 391 and R759, and at one site located in the light chain, R1708 (Figure 1-3, Secreted 
FVIII)65,66. The cleavage leads to the heterotrimeric form of FVIIIa, which consists of A1-a1, A2-a2 and 
A3-C1-C267. The B domain and the a3 acidic region are lost. In order to stabilize the new heterotrimeric 
form of FVIII and to alter the protein conformation for maximal activity, hydrogen bonds between A1A2 
and A2A368–70 are formed and Ca2+ or Mn2+ is incorporated (Figure 1-3, Activated FVIII)49,52,71,72. 
The structural changes in the tertiary structure mainly alter the interacting partners of FVIIIa, due 
to loss and exposure of various binding sites73. Especially, the loss of a3, an important binding site for 
vWF, results in the dissociation of vWF from FVIIIa74. This allows FVIIIa to bind to phospholipid 
membranes75,76, FIXa73 and FX77, which leads to the formation of the tenase complex. Although FVIIIa is 
only a co-factor to FIXa, it increases its activity up to 1.000.000-fold8,32 by bringing FIXa and FX in close 
proximity. 
 
 
Figure 1-3: Structure of FVIII. The secreted FVIII is activated by thrombin cleavage at three sites, resulting in the heterotrimeric 
activated form and loss of vWF. FVIIIa is inactivated by the dissociation of the A2 domain and by activated protein C, which 
cleaves FVIIIa at two sites. 
 
Inactivation of FVIIIa occurs mainly via dissociation of the A2 domain from the tenase complex, 
which represents the first step of FVIIIa degradation67. Apart from that, cleavage by activated protein C 
can inactivate FVIIIa (Figure 1-3, Inactivated FVIII)40. Further degradation occurs via receptor-mediated 
clearance, mainly depending on receptors of the low-density lipoprotein (LDL) family, especially the LDL 
receptor-related protein (LRP1)57. Furthermore, efficient binding of FVIII to LRP1 is facilitated by 
heparan-sulfate proteoglycans (HSPG)78. In addition to LRP1, the asialoglycoprotein receptor (ASGPR) 
was identified to take up FVIII via binding to the N-glycosylations of the B domain79 whereas the 
macrophage mannose receptor (MMR) clears FVIII via binding the C1 and C2 domain80. 
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1.1.3. FVIII products 
 
Therapeutic FVIII products are available since the 1960s81. These products contain FVIII purified 
from plasma of healthy donors. In addition to that, the first rFVIII was launched in 199282. The two main 
differences between the two kinds of FVIII products are their origin and the amount of additionally 
contained proteins. All rFVIII products are produced by cell lines, which are transfected with a plasmid 
coding for the FVIII sequence, and contain only the purified FVIII. In contrast to that, pFVIII products 
are purified from human plasma and contain additional plasma proteins in varying concentrations. 
Especially vWF is an important protein in plasma-derived products, as it stabilizes FVIII and is believed 
to lower the immunogenicity by reducing the uptake of the complex by antigen-presenting cells 
(APCs)56,83,84. However, one major advantage of rFVIII products is the independence from plasma, which 
can become a limiting resource13,85. 
The rFVIII products evolved since the 1990s (Table 1-1). First-generation products are produced 
in mammalian cell lines, mostly baby hamster kidney (BHK) cells or Chinese hamster ovary (CHO) cells. 
These products still contain proteins of human and animal origin, used to enrich the cell culture medium, 
and human albumin, used to stabilize the final product13. During the development of second-generation 
products albumin was replaced by chemical compounds for stabilization. This decreases the risk of 
transmission of infectious particles86,87. In addition to that, second-generation products contain an 
additional virus inactivation step and are mostly B domain-deleted (BDD) variants88. As the B domain is 
not essential for the activity of FVIII89–92 and is lost during activation, the deletion in rFVIII products is 
not reducing the functionality. Additionally, the B domain deletion reduces the size of the plasmid as 
well as the size of the whole protein, facilitating the production89,93. Third-generation products no longer 
contain any human or animal derived supplements but are still produced by non-human mammalian cell 
lines86,87. The last step, the development of fourth-generation products, keeps up the standards from the 
third-generation products regarding supplementation and purification but changes to human production 
cell lines like human embryonic kidney (HEK) cells94. This ensures proper post-translational 
modification42,95 similar to endogenous FVIII86. 
 
Table 1-1: Generations of rFVIII products and their characteristics. 
Generation FVIII length 
Production  
cell line 
Origin of medium 
supplements 
Virus inactivation 
1st Full-length 
Mammalian,  
non-human 
Animal No 
2nd 
Full-length and 
BDD 
Mammalian,  
non-human 
Human Yes 
3rd 
Full-length and 
BDD 
Mammalian,  
non-human 
Chemical Yes 
4th BDD Human Chemical Yes 
 
Until today, it is not finally elucidated whether rFVIII products are more immunogenic than pFVIII 
products. Studies with different outcomes were published in the recent years. The two observational 
studies CANAL96 and RODIN97 as well as the surveillance project EUHASS98 revealed no differences in 
inhibitor development in previously untreated patients (PUPs) treated with either pFVIII or rFVIII99. In 
contrast to that, the only randomized study SIPPET100 found a 87 % higher incidence for inhibitor 
development with rFVIII than with pFVIII. Nevertheless, all studies suffer from different drawbacks as 
group size, ethnicity of the enrolled patients, and considering all generations of rFVIII products as 
equivalent85,101. In addition to that, the ongoing development of rFVIII products makes it difficult to 
compare all rFVIII products to pFVIII in one single study. Furthermore, patients treated with fourth-
generation products, which are potentially less immunogenic, due to production in human cell lines, are 
not yet included in these studies85. 
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Apart from modifications affecting the production of FVIII, the protein itself is modified, mainly to 
overcome the short half-life of FVIII in vivo. Different approaches are followed to extend the half-life. 
These contain addition of polyethylene glycol (PEG)102, fusion of antibody-derived Fc-parts103,104 and 
single-chain rFVIII constructs105,106. However, for these products the half-life of vWF has to be considered 
as well, due to the fact that rFVIII builds a complex with vWF in vivo107. The FVIII Fc-fusion probably has 
the additional effect of being less immunogenic, as the Fc-part contains epitopes, called “Tregitopes”, 
which stimulate regulatory T cells108,109. However, the deimmunization of FVIII itself is an important part 
of ongoing research. Until now, no FVIII product with reduced immunogenicity has been launched. 
 
 
 
1.2. Immunogenicity of FVIII 
 
Patients suffering from Hemophilia A are treated either on-demand or in a prophylactic manner 
with a plasmatic or recombinant FVIII product. The kind of therapy and the dosage depends on different 
factors like severity, body weight and physical activity of the patients. Most patients apply their 
intravenous injections at home, offering them a way of life as normal as possible5. 
The major complication during Hemophilia A therapy is the development of inhibitory antibodies 
against the applied FVIII. These antibodies occur in up to 30 % of the patients suffering from severe 
Hemophilia A20 and to a lower extent, up to 13 %, in patients suffering from moderate and mild 
Hemophilia A21. These antibodies reduce the half-life or inhibit the activity of FVIII by blocking 
interaction sites52. Various genetic and environmental risk factors for inhibitor development are 
known110,111. However, not all of these risk factors, like the genetic background, can be influenced. 
The main treatment for patients with inhibitors is the ITI therapy. During this therapy the 
inhibitory antibodies are supposed to be depleted by the application of high amounts of FVIII22. This 
therapy is successful in up to 80 % of patients suffering from Hemophilia A with inhibitors112. 
The mechanism of the immune response against FVIII is based on a T cell dependent activation of 
B cells. These B cells produce antibodies with a high affinity towards FVIII113. However, it is still not 
known where the immune response is initiated and which danger signals activate the immune system114. 
Discussed interaction sites between FVIII and APCs are either the spleen or the bleeding site itself. Many 
APCs are present at both sites and the spleen is additionally known to filter blood-borne antigens. The 
APCs might further on present FVIII peptides to T cells and via that initiate the immune response115. 
 
 
1.2.1. Antibodies against FVIII and risk factors for antibody development 
 
Anti-FVIII antibodies are divided into inhibitory and non-inhibitory antibodies. Inhibitory 
antibodies decrease the activity or the half-life of FVIII, as they bind to essential cleavage and interaction 
sites. Many antibody-binding regions on FVIII are known, especially in the A2 and C2 domain19,116,117, 
but definite epitopes are still part of ongoing research118,119. The three-dimensional structure of the B 
cell epitopes renders the research complicated. In addition to that, not all patients develop antibodies 
against the same regions of FVIII or the same antibody diversity120,121. In contrast to inhibitory antibodies, 
non-inhibitory antibodies do not influence the activity of FVIII122. Interestingly, non-inhibitory antibodies 
against FVIII can also be detected in healthy people123,124.  
Until today, it is not yet completely understood why patients develop antibodies against 
therapeutic FVIII and which are the risk factors. Various studies try to link the development of inhibitors 
to genetic risk factors like the mutation, family history and ethnicity as well as environmental risk factors 
like the treatment, FVIII product and immune status of the patient18,110,111,125. However, it is always a 
mixture of risk factors, which influence the development of inhibitors126. 
An important reason for antibody production in Hemophilia A patients is the absence of central 
tolerance to FVIII127. Central tolerance is established during the ontogeny of the immune system to 
prevent the existence of circulating T and B cells, which recognize and react to endogenous proteins. 
These self-reactive T and B cells are deleted or rendered anergic in the thymus and in the bone 
 Introduction  7 
marrow128. Patients with severe Hemophilia A produce only fragments or no endogenous FVIII and even 
patients with moderate and mild Hemophilia A might have endogenous FVIII with large differences in 
the amino acid sequence compared to normal FVIII. This absence of FVIII or the existence of an altered 
FVIII leads to the problem that T and B cells are not deleted during ontogeny and central tolerance can 
not be established129,130. In these cases, therapeutically applied FVIII can be recognized as a foreign 
molecule by B and T cells. This initiates an immune response, which leads to the production of antibodies. 
Due to this, mutations leading to the total absence of FVIII or to large alterations in the amino acid 
sequence result in a much higher inhibitor risk compared to other mutations131. 
Nevertheless, not all patients without endogenous FVIII develop antibodies and antibody 
formation also occurs in patients with endogenous FVIII. Due to that, there is the possibility that not 
only the discrimination between self and non-self proteins influences antibody production but that also 
the general immune status and the presence of danger signals might influence the immune system132. 
These danger signals can be infections, vaccinations or probably even a bleeding event itself114. 
Regarding other risk factors, some could be proven to have an influence on inhibitor development, 
whereas others are still under investigation. An important risk factor is the treatment. Especially the first 
20 exposure days to FVIII seem to be crucial for inhibitor development11,131. Afterwards, the risk lowers 
until it is decreased to below 1 % at exposure day 50133. Due to this, PUPs have a higher risk to develop 
inhibitors compared to previously treated patients (PTPs). However, also in the cohort of PTPs with more 
than 50 exposure days, inhibitors can be detected134,135. The genetic background, apart from the FVIII 
gene, is also important, as some patients also have mutations in some immune-modulating genes, like 
Interleukin (IL)-10, tumor necrosis factor α (TNF-α) and cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4)136–138. Additionally, the blood group might be a risk factor, as it was revealed that patients with 
blood group 0 have a twofold lower risk to develop antibodies compared to non-0 blood group patients. 
This might be due to different glycosylation patterns of vWF in patients with different blood groups. The 
glycosylation in the 0 blood group leads to vWF, which is cleared faster from circulation. Consequently, 
the bound FVIII is also cleared faster and the time of potential contact with immune cells is reduced139. 
Furthermore, ethnicity is discussed as a genetic risk factor, as it was shown that antibody development 
is more frequent in Africans and Hispanics than in Caucasians140,141. The reason for that is not yet fully 
understood142. 
 
 
1.2.2. Treatment of patients with inhibitory antibodies 
 
The ITI therapy for Hemophilia A patients with inhibitors is initiated after the detection of the 
inhibitor. The first ITI protocol was applied in Bonn in the 1970s143. Different protocols are available 
today, differing in length and dosage. All protocols share the application of a very high FVIII dose, in 
order to induce tolerance, due to exhaustion of the immune system. This increases the costs for therapy 
1.5-3 fold, compared to non-inhibitor treatment144–146, and lowers the standard of life24. The most 
common ITI protocols range between an application of 50 IU of FVIII per kg body weight three times per 
week and daily applications of up to 200 IU/kg147. Despite the huge differences in the applied FVIII 
amounts, the rates of ITI success are similar for the distinct protocols148. Main differences were observed 
regarding the bleeding incidences and the time needed to achieve a tolerance induction. Fewer bleedings 
and a shorter time to achieve ITI were detected when higher amounts of FVIII were applied147,149. An ITI 
therapy is considered to be successful when the inhibitors are no longer detectable (< 0.6 BU/ml), the 
FVIII recovery is over 66 % and the half-life of FVIII is longer than 6 hours147. 
Different predictors for a successful ITI were investigated, revealing that a low inhibitor titer 
(<10 BU/ml) before starting an ITI therapy and a historical peak inhibitor below 200 BU/ml were the 
best indicators for success150–152. Due to this, it is recommended for patients with titers above 10 BU/ml 
to wait until the titer drops148. The influence of the age at the beginning of the therapy and the time 
between the first detection of an inhibitor and start of the ITI therapy are controversial and seen as very 
unlikely predictors of ITI success150. Further evidence is needed regarding the FVIII mutations and the 
type of FVIII product. Recent studies point to a greater ITI success for patients with a non-null FVIII 
mutation whereas no significant differences regarding FVIII products were observed until now150,153. 
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The molecular mechanisms of the tolerance induction are not yet fully understood. Inactivation or 
depletion of memory B and T cells, development of anti-idiotypic antibodies and development of 
regulatory T cells might be possible mechanisms112,154–156. The ITI therapy is successful in 60-80 % of the 
patients with inhibitory antibodies99. In the case of an ITI failure a rescue ITI therapy is started. During 
this therapy, the amount of applied FVIII is further increased up to 200 IU/kg/day and 
immunosuppressive drugs are additionally applied. Apart from that, a rescue ITI therapy is performed 
with a pFVIII product containing vWF, in the case that the first ITI therapy was performed with a rFVIII 
product157. When the rescue ITI is not successful, the further therapy depends on bypassing agents like 
coagulation FVIIa and activated prothrombin complex concentrates (aPCC)149. 
 
 
1.2.3. Subclasses of inhibitory antibodies and the involvement of T cells 
 
It was revealed that the inhibitory antibodies produced by the patients’ B cells have a high affinity 
to FVIII and belong to the subclasses of Immunoglobulin G (IgG) 1 and IgG4158–160. These subclasses 
develop after affinity-maturation and class-switching, which only occurs when B cells mature in a T cell-
dependent manner, indicating that cluster of differentiation (CD) 4+ helper T cells are involved in the 
development of inhibitory antibodies against FVIII113,114. 
Interacting B and T cells have to recognize the same protein but not the same epitope. Whereas 
B cells recognize their epitope extracellular by surface-bound antibodies, T cells recognize their epitope 
presented on the surface of APCs161. As long as the CD4+ T cells are still naïve and have never been in 
contact with their epitope, the first important signal for maturation is the recognition of their epitope 
with their T cell receptor (TCR). Additionally, they are depended on co-stimulation and cytokines 
provided by the APCs162. Naïve CD4+ T cells mainly mature upon contact with Dendritic cells (DCs), a 
subtype of APCs. These cells take up extracellular proteins80, process them intracellular and bind them 
to the major histocompatibility complex (MHC) class II132. This peptide-MHC class II complex is then 
presented on the surface of DCs130. A naïve T cell binds with its TCR to this complex, followed by binding 
to the co-stimulatory DC receptors CD40 and CD80/CD86163. Additionally, the T cell takes up the 
cytokines secreted by the DC (Figure 1-4)162. Depending on the cytokines secreted, the naïve T cell 
differentiates into one of the many T helper cell (Th) subclasses. 
 
 
Figure 1-4: Interaction between DC and T cell. The DC takes up extracellular proteins and processes them intracellular. Resulting 
peptides are bound to the MHC class II and presented on the surface. A naïve T cell can be activated by the DC when the TCR 
recognizes the peptide-MHC class II complex. Co-stimulation occurs via interaction between CD40-CD40L and CD80/CD86-CD28. 
Additionally, the T cell takes up the cytokines secreted by the DC. 
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Most T cells develop into the Th1 or Th2 subclass of T helper cells. Both types are capable of 
stimulating B cells130,160. Th1 cells favor the synthesis of IgG1 and IgG2 and Th2 cells favor the synthesis 
of IgG4160. Nevertheless, B cell stimulation by Th1 or Th2 cells only occurs when the T cells recognize 
the epitope specific for their TCR on the B cells. Antigen uptake by B cells occurs via binding of the 
protein by surface-bound immunoglobulins followed by receptor-mediated endocytosis. Afterwards, the 
protein is processed into peptides, which are bound to the MHC class II and presented on the cell surface. 
In addition to the interaction via the TCR, T and B cells also interact via CD40L-CD40 binding. The 
binding of CD40L to CD40 on the B cells and the uptake of cytokines, secreted by the T cells, are the 
main maturation signals for the B cells. After the interaction with the T cells, B cells differentiate into 
antibody-secreting plasma B cells and memory B cells (Figure 1-5)162. 
 
 
Figure 1-5: T cell-dependent activation of B cells. In the first step, naïve T cells have to differentiate into T helper cells upon 
detection of their antigen presented by DCs. In the second step, T helper cells detect their antigen presented by naïve B cells. 
Upon receptor interaction and cytokine secretion by T helper cells, the naïve B cells start to differentiate. The activated B cells 
differentiate into memory B cells and antibody-secreting plasma B cells. 
 
The MHC class II is the most important complex during the activation of T cells, as it binds and 
presents the antigen. The extracellular compartment of the complex consists of two alpha helices, 
building a peptide binding cleft164. As the cleft is open at both ends, the length of the bound peptides 
varies between 10 and 25 amino acids, whereas peptides between 13 and 16 amino acids are most 
frequent165–167. The loading of the peptides occurs intracellularly in the endosomes, where all ingested 
proteins are digested. In these endosomes reducing conditions and a low pH contribute to the enzymatic 
degradation of the protein by cathepsins168. Not every peptide resulting from enzymatic degradation of 
the protein can be bound to the MHC class II. Only peptides, which bind with a certain stability to the 
cleft are presented on the surface169,170. On the one hand binding occurs via hydrogen bonds between 
side-chains of the MHC class II molecule and the peptide backbone, on the other hand amino acid side 
chains of the peptide bind to defined pockets in the MHC class II binding cleft164. 
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The research in the field of MHCs revealed the positions in the MHC class II binding groove (P1, 
P4, P6 and P9) and the amino acids in the peptides, which are important for the binding of the peptide 
to the MHC class II. This provides the possibility to predict which peptides of a protein can be bound and 
presented on the surface of APCs. Nevertheless, this prediction is very extensive, as the genetic diversity 
of the MHC class II is very high. More than 800 different human leukocyte antigen (HLA)-DR alleles, 
coding for the MHC class II, are known until today, leading to a vast diversity of MHC class II variants109. 
Fortunately, many of these alleles only differ in minor parts. Over 90 % of the binding clefts can be 
predicted using eight different HLA-DR supertypes, clustering HLA-DR alleles with similar binding 
patterns166,171–173. 
In addition to the HLA alleles of a person, also the expression of intracellular enzymes degrading 
the protein as well as the naïve T cell pool itself influence the development of antibodies. Due to this, 
two patients with the same HLA alleles do not have to present the same peptides and do not have to 
possess the same reactive T cells needed to activate the naïve B cells174. 
Until today, it is not known where the applied FVIII is internalized by APCs. In mice accumulation 
in the liver and the spleen could be proven, although the FVIII levels were only stable in the spleen and 
the levels in the liver decreased within 30 minutes175. In addition, the uptake of FVIII by APCs in the 
circulation176 or at the bleeding site115 is possible. From these sites it might be transported to secondary 
lymphoid organs, to be presented to CD4+ T cells177.  
 
 
 
1.3. Deimmunization of therapeutic proteins 
 
Antibodies against therapeutic proteins, neutralizing their activity, are widely known and not only 
limited to FVIII178. Due to this, many immunoinformatic tools evolved, in order to predict T and B cell 
epitopes. Whereas many T cell epitope prediction tools are available, only a few B cell epitope tools were 
developed. This is due to the fact that B cell epitopes are mostly three-dimensional, compared to the 
linear T cell epitopes179, rendering the prediction highly complicated172. Apart from that, the 
development of anti-drug antibodies (ADA) is mostly T cell-dependent, which led to the focus on T cell 
epitope prediction tools. Whereas some tools only indicate potential immunogenic peptides of a protein 
by calculating peptide-binding affinities to the MHC, others are also able to indicate amino acid 
substitutions, in order to deimmunize a protein. Due to this, in silico analyses of recombinant proteins 
became an important method during the development of new therapeutics. 
Although the in silico tools are constantly improved, the predictions have to be determined in vitro 
and in vivo180. Regarding in vitro analyses, mainly HLA-binding assays as well as T cell stimulation assays 
are performed. The in vivo models focus on HLA-transgenic mice and knockout mice for the protein of 
interest. However, the analytical methods in vitro as well as in vivo are constantly improved and refined. 
The reduction of the immunogenicity of the FVIII molecule is a major need in FVIII therapy, next 
to the prolongation of half-life. Due to this, a deimmunized FVIII molecule would be promising, in order 
to decrease the probability of an antibody response128,179, and would be an improvement for PUPs as 
well as PTPs. For PUPs and PTPs without inhibitors, this FVIII would reduce their risk of an initial 
immune response. For PTPs, who already developed inhibitors, the deimmunized FVIII might be an 
alternative therapeutic product. Therefore, a FVIII product with a reduced immunogenicity could 
improve the way of life of the patients and their caregivers as well as reduce the costs for the health 
system. One approach to deimmunize FVIII is to utilize the available T cell epitope prediction tools, in 
order to mutate the FVIII amino acid sequence, leading to a reduced binding of FVIII peptides to the 
MHC class II. Based on this modification, the production of high-affinity antibodies could be prevented 
at the stage of T cells (Figure 1-6). 
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Figure 1-6: Deimmunization prevents B cell activation. Due to deimmunization of the protein, no immunogenic peptides shall 
be presented on the surface of DCs. This prevents the activation of naïve T cells. As a result of this missing first step, naïve B cells 
are not activated and cannot differentiate into antibody-secreting plasma and memory B cells. 
 
 
1.3.1. In silico T cell epitope-modelling tools 
 
Using in silico modelling tools, a protein can be analyzed regarding the peptides most likely to be 
presented on the surface of APCs. The first modelling tool was developed in 1995, calculating T cell 
epitopes for one MHC class II allele181. Nowadays, many different tools are available for the calculation 
of peptide-binding to MHC class I and class II109. Many tools calculate the contribution of each amino 
acid of a peptide to the overall binding affinity. The calculation is matrix-based and utilizes binding data 
of HLA alleles collected over the years. Further improvement of the prediction tools includes the 
prediction of binding to HLA alleles without available binding data182. Most of the public tools are 
available from the Immune Epitope Database and Analysis Resource (IEDB)183. In addition, commercial 
T cell epitope-mapping tools are provided. With these tools, the results are further analyzed, epitopes 
are clustered and even amino acid exchanges for the reduction of peptide-binding are predicted. 
In order to deimmunize FVIII, the EpiMatrix tools, commercially provided by EpiVax, were chosen 
in this thesis. The analysis comprises several steps and tools, starting with the identification of binding 
peptides, clustering the results, comparing the clusters to other endogenous proteins and finally 
predicting amino acid exchanges. The provided analysis is optimal, in order to determine which regions 
of FVIII are most immunogenic regarding MHC class II presentation and provide insight into mutation 
possibilities and their benefit. The EpiMatrix system was widely proven to deimmunize various 
proteins184,185 and even the C2 domain of FVIII has already been analyzed and deimmunized173.  
 
 
1.3.2. In vitro tools for the determination of a deimmunization 
 
In order to determine whether predicted peptides really bind to the MHC and elicit an immune 
response, the in silico results have to be confirmed in vitro and in vivo. The analytical in vitro methods 
provide the possibility to compare immunogenic and non-immunogenic peptides or modified and non-
modified peptides. Depending on the method, either peptides or whole proteins can be used. 
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HLA binding assays are performed, in order to determine whether peptides bind to the MHC 
class II. One possibility is to use MHC class II loaded with fluorescence-labeled peptides and add the 
peptides of interest. The amount of the released labeled peptides correlate with the bound peptides of 
interest109. Alternatively, the peptides of interest can be added to empty MHC class II. After incubation 
the amount of bound peptide can be determined via a fluorescence-labeled antibody or the peptide-MHC 
class II complexes can be purified186. When required, the peptides can be removed and analyzed, in order 
to reveal which peptides of a mixture of peptides were bound by the MHC class II. The strength of binding 
of a peptide-MHC class II complex can be determined by surface plasmon resonance109. However, 
peptides always have the disadvantage of being artificially designed. In order to circumvent this, the 
protein of interest can be added to APCs. The MHC class II is isolated afterwards and the bound peptides 
are analyzed. This ensures a natural processing of the protein. Unfortunately, this method requires a 
huge amount of protein, which might not be available in every approach. 
Another method to test the detected peptides is to perform an in vitro T cell assay. Diverse setups 
and readouts for these assays are possible109. Peptides or proteins can be added to either PBMCs or 
purified T cells and APCs. The cells can be derived from healthy donors or, in the case of testing the 
deimmunization of a therapeutic protein already used in the clinic, derived from patients180. The 
response of T cells can be detected by flow cytometry, using specific markers or proliferation dyes, or by 
Enzyme-linked Immunosorbent Assays (ELISA) or Enzyme-linked Immunospot Assays (ELISpot), 
detecting the secreted cytokines172. Due to this, T cell assays are a good tool to evaluate the in silico 
predictions and to test deimmunized proteins in comparison to their wild-type protein. 
In order to compare the immunogenicity of a deimmunized and a non-deimmunized FVIII in this 
thesis, an in vitro T cell assay is most promising. Due to the large size of FVIII, the production of 
overlapping peptides for an HLA assay would be too extensive. However, a huge limitation in the 
development of an in vitro assay for FVIII is the availability of blood samples from Hemophilia A patients. 
The best approach to prove a deimmunization would be an assay, which reveals a reduced amount of 
activated T cells derived from PUPs in response to the deimmunized FVIII. Unfortunately, theses patients 
are babies or toddlers and the amount of available blood is far too low. In addition to that, patient 
samples are rare, even in the cohort of PTPs, leading to an assay development based on cells from healthy 
donors. However, the amount of naïve T cells against FVIII in healthy donors is low. Though, 
restimulation of CD4+ T cells from healthy donors with FVIII is published124,187. This is due to the fact 
that thymic deletion of self-reactive T cells is not complete and self-reactive T cells are known to leave 
the thymus188. These T cells are controlled by natural and induced regulatory T cells in the 
periphery115,177,189. In order to circumvent this suppression of self-reactive T cells by regulatory T cells, 
the assay is based on regulatory T cell-depleted CD4+ T cells. Using this approach, it was already proven 
that CD4+ T cells of healthy donors can be restimulated with FVIII190. In order to keep the influences of 
different cell types on each other as predictable as possible, only DCs are chosen as APCs. DCs are able 
to activate naïve T cells as well as to restimulate mature T cells. This setup makes it feasible to test a 
deimmunized FVIII in a setup with T cells derived from healthy donors and Hemophilia A patients. 
 
 
1.3.3. In vivo tools for the determination of a deimmunization 
 
Although in vitro tools give an impression, regarding the immunogenicity of peptides and proteins, 
only in vivo experiments provide a full immune system with all interacting cells. Nevertheless, mouse 
models have disadvantages, especially regarding immune response to human proteins. In a normal 
mouse model a given human protein is differently processed, presented on a murine MHC class II and 
detected by murine T cells, as a human protein is always foreign to the murine immune system109. 
Additionally, mice mostly express their own endogenous version of the protein of interest and might 
already have established tolerance towards this protein. Due to that, a normal mouse model cannot be 
used to draw conclusions regarding the immunogenicity of a protein. In order to circumvent these 
problems, HLA transgenic mice191, humanized mice and knockout mouse models were developed. 
The T cell response in HLA transgenic mice was proven to correlate with the T cell response in 
humans192,193. However, one mouse strain can only be transgenic for one HLA type. As the in silico 
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analysis covers many HLA types, various HLA transgenic mice strains have to be used, in order to receive 
a complete analysis. In addition to this, a deimmunization does not result in the total absence of 
presented peptides. This may influence the results from HLA transgenic mice, as the presented human 
peptides might be foreign to the murine immune system and due to this might elicit an immune response. 
A possibility to circumvent this is to use a humanized mouse model. Humanized mice are transplanted 
with human CD34+ stem cells and develop an immune system with human immune cells. This provides 
human MHC molecules and human DCs, B and T cells194,195. However, as for the HLA transgenic mice, 
the experiments have to be performed in various mice, transplanted with stem cells from different 
donors, in order to cover different HLA alleles. 
In the case of evaluating the immunogenicity of a deimmunized protein, which is also present in 
mice, the response might be influenced by central tolerance of the murine immune system to the 
endogenous protein. Murine T cells, which might react against the human protein, might have been 
elicited during the ontogeny of the murine immune system. In order to circumvent this possibility, mice 
with a knockout for the protein of interest were developed180.  
Both types of mice, HLA transgenic or humanized mice as well as knockout mice, provide an 
important characteristic for the determination of the immunogenicity of a protein and to compare a 
deimmunized to a non-deimmunized variant. Due to this, a combination of both would be the most 
promising model. 
In order to determine the immunogenicity of a deimmunized FVIII variant in vivo, a FVIII-knockout 
mouse model and a humanized mouse model is applied in this thesis. Unfortunately, a humanized FVIII 
knockout model was not available. In the E16 FVIII knockout model, the mice will reveal a naïve response 
to FVIII. Although the deimmunization is predicted based on human HLA alleles, it might also be 
detectable to a lesser extent in mice, as the MHC class II alleles share several homologies. The humanized 
mouse model on the other hand provides the largest possible similarity to the human immune system. 
In the highly developed humanized BRGSF mice the FVIII is processed by human APCs, presented bound 
to a human MHC class II and detected by human T cells196. Due to this, the model provides the possibility 
to detect in vivo whether a deimmunized protein is less frequently presented by APCs and elicits a 
reduced immune response compared to a wild-type BDD-FVIII molecule.  
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1.4. Aim of the thesis 
 
The aim of this thesis was the development of a less immunogenic recombinant BDD-FVIII 
molecule. This deimmunized FVIII shall reduce the risk of inhibitory antibody formation in Hemophilia 
A patients and via this, improving the life of the patients as well as decreasing the costs for therapy. The 
modified FVIII should be presented to a much lesser extent on the surface of APCs and therefore have a 
reduced capacity to activate T cells. Due to this absence of helper T cells, B cells should not be able to 
differentiate and produce high-affinity inhibitory antibodies against FVIII113. 
In order to deimmunize the FVIII, in silico analyses, predicting MHC class II presentation of FVIII 
peptides, were utilized. Recommended amino acid exchanges were incorporated into the FVIII sequence 
with the aim to decrease the amount of FVIII peptides displayed on the surface of APCs. However, it was 
important that the mutated FVIII variant was still produced in the same amount as a non-modified FVIII 
and remained unchanged regarding its structure, activity in the coagulation cascade and interaction with 
other proteins. This specific combination of mutations had to be revealed in various rounds of screening, 
as modelling of the mutated FVIII was not possible41,52. 
The mutated FVIII variants were produced in two human cell lines, in order to reduce the influence 
of the production cell line on the post-translational modifications and by this on the immunogenicity of 
FVIII. HEK293-F cells and Cevec's Amniocyte Production (CAP-T) cells were chosen. Both cell lines grew 
in suspension and the produced FVIII was purified from the cell culture supernatant197,198. As both cells 
were derived from a human origin, a similar post-translational modification of rFVIII compared to pFVIII 
was highly likely. Consequently, the selected cell lines would circumvent one major drawback of the first 
to third generation rFVIII products. 
In order to determine in vitro whether the incorporated mutations led to a less immunogenic FVIII 
molecule, an assay with human DCs and T cells was developed. This was required, as the 
deimmunization focused on the presentation of human FVIII peptides on human MHC class II. The 
artificial approach of an in vitro assay containing only DCs and regulatory T cell-depleted CD4+ T cells 
was chosen, in order to guarantee that enough DCs were present to activate naïve T cells in addition to 
the recall response induced in already mature T cells. Using this assay, differences in T cell proliferation 
in response to different FVIII variants and control proteins could be detected. 
However, the complex interactions of an immune response to a given protein could only be 
determined in vivo. Due to this, the deimmunized FVIII was also tested in two mouse models. In order 
to circumvent most of the limitations of a normal mouse model, a humanized mouse model was chosen 
for this thesis. The mice were transplanted with human stem cells, developing human APCs, B, T and 
NK cells. This provided the best available pre-clinical in vivo model to determine the immunogenicity of 
the mutated FVIII molecule. In addition to this, a FVIII knockout mouse model was applied, in order to 
detect a naïve T cell response to the deimmunized FVIII in comparison to a FVIII reference molecule. 
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2. Material 
 
 
2.1. Cell culture reagents  
 
Product Manufacturer Order number 
2-Mercaptoethanol (50 mM) life technologies 31350-010 
Blasticidin life technologies R210-01 
CAP-CDM medium Merck Millipore/ 
Cevec 
Customized 
CD293 medium life technologies 11913019 
DMSO for cell culture AppliChem A3672,0250 
EDTA Solution Sigma-Aldrich E7889-100ML 
GlutaMAX (100 x) life technologies 35050-30 
Heat Inactivated FBS life technologies 10100-147 
HEK293-F cells life technologies 11625-019 
HEPES Buffer Solution (1 M) life technologies 15630-056 
HyClone Cell Boost 5 Supplement Thermo Scientific SH30865.01 
LONG R3 IGF-I Sigma-Aldrich 91590C 
Lymphoflot Bio-Rad 824012 
MEM NEAA (100 x) life technologies 11140-035 
Plasmids life technologies Customized 
ProFreeze-CDM NAO (2 x) Lonza 12-769E 
Protein Expression Medium (PEM) life technologies 12661013 
RPMI 1640 Medium life technologies 11875093 
Sodium Pyruvate 100 mM (100 x) life technologies 11360-039 
X-VIVO 15 w/o Gentamicin or Phenol Red Lonza 04-744Q 
 
 
2.2. Chemicals and Reagents 
 
Product Manufacturer Order number 
0.4 % Trypane Blue Solution Corning 25-900-CI 
1 M Tris-HCl pH 7.5 life technologies 15567-027 
1 M Tris-HCl pH 8.0 life technologies 15568-025 
10 x Deglycosylation Mix Buffer 2 New England BioLabs B6045S 
20 x Modified Dulbecco’s PBS Tween 20 Buffer Thermo Scientific 28346 
2-Propanol Merck Millipore 1.09634.2511 
3,3’,5,5’-Tetramethylbenzidine Sigma-Aldrich T0440-100ML 
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7-AAD BioLegend 420404 
AccuGENE 10 x PBS Lonza 51226 
Agarose low EEO AppliChem A2114,0100 
Anhydrous DMSO life technologies D12345 
Aqua dest. B. Braun 0082479E 
BD CompBeads BD 552843 
Bovine Serum Albumin Sigma-Aldrich A7906-100G 
CaCl2 Solution Siemens ORHO37 
Calcium Chloride AppliChem A1428,0500 
CFSE BioLegend 422701 
CHAPS Merck Millipore 220201-25MG 
Coagulation Factor VIII Deficient Plasma Siemens OTXW17 
Control Plasma N Siemens 10484201 
CS&T Research Beads BD 650622 
Dade Actin FSL Activated PTT Reagent Siemens 10284499 
DY-680-Ester Dyomics 680-01 
DY-780-Ester Dyomics 780-01 
EndoGrade Ovalbumin hyglos 321002 
Ethylene glycol Merck Millipore 1.09621.2500 
FcR Blocking Reagent, human Miltenyi Biotec 130-059-901 
FcR Blocking Reagent, mouse Miltenyi Biotec 130-092-575 
Human Alpha Thrombin Enzyme Research HT 1002a 
Human Coagulation Factor VIII Concentrate BRP Council of Europe H0920000 
Hydrochloric acid Merck Millipore 1.09057.1000 
Imperial Protein Stain Thermo Scientific 24615 
in-tem TEM 503-02 
Iodoacetamide GE Healthcare RPN6302 
IPG Buffer pH 4-7 GE Healthcare 17-6000-86 
L-Histidine Merck Millipore 1.04351.0100 
Methanol Merck Millipore 1.06009.1011 
NaCl 0.9 % B. Braun 357 0160 
N-Glycosidase F Roche 11365185001 
Nonidet P-40 Substitute amresco M158-50ML 
NuPage Antioxidant life technologies NP0005 
NuPage LDS Sample Buffer (4 x) life technologies NP0008 
NuPage MOPS SDS Running Buffer (20 x) life technologies NP0001 
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NuPage Sample Reducing Agent (10 x) life technologies NP0009 
NuPage Transfer Buffer (20 x) life technologies NP0006-1 
Odyssey Blocking Buffer Li-Cor 927-40000 
PBS Dulbecco w/o Ca2+ w/o Mg2+ Biochrom L1825 
Pierce DTT No-Weigh Thermo Scientific 20291 
PlusOne Bromophenol Blue GE Healthcare 17-1329-01 
PlusOne DryStrip Cover Fluid GE Healthcare 17-1335-01 
PlusOne Urea GE Healthcare 17-1319-01 
Precision Plus Protein All Blue Standards Bio-Rad 161-0373 
SDS 20 % Solution Ambion AM9820 
Sodium Bicarbonate pH 9.4 (1 M) Alfa Aesar J62808 
Sodium chloride Merck Millipore 1.06404.1000 
Sodium chloride (5 M) Applichem A7006,1000 
Sodium hydrogen carbonate Merck Millipore 1.06329.0500 
Sodium hydroxide solution (0.5 N) Merck Millipore 1.09138.1000 
star-tem Tem 503-10 
Sucrose Merck Millipore 1.07687.0250 
Sulfuric acid 98 % Merck Millipore 1.12080.1000 
Technothrombin TGA Calibrator Set Technoclone 5006345 
Technothrombin TGA Reagent C Low Technoclone 5006213 
Technothrombin TGA Substrate Technoclone 5006230 
Thiourea GE Healthcare RPN6301 
Tris pH 7.5 (1 M) life technologies 15567-027 
Tris-HCl Serva 39794.01 
Tween 20 Solution 10 % AppliChem A1284,0100 
Tween 80 Solution 10 % Merck Millipore 655207-50ML 
vWF, purified from plasma Biotest AG Technical batch 
Zombie Aqua BioLegend 423102 
Zombie Violet BioLegend 423114 
 
 
2.3. Kits 
 
Product Manufacturer Order number 
2-D Clean-Up Kit GE Healthcare 80-6484-51 
Asserachrom VIII:Ag ELISA Diagnostica Stago 00280 
CD14 MicroBeads Miltenyi Biotec 130-050-201 
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CD4+CD25+ Regulatory T Cell Isolation Kit Miltenyi Biotec 130-091-301 
Cell Line Optimization 4D-Nucleofector X Kit Lonza V4XC-9064 
Coatest SP Factor VIII Chromogenix 82 4086 63 
CyDye DIGE Fluor (minimal dye) labeling kit GE Healthcare 25-8010-65 
Human Th1/Th2/Th17 Antibody Array abcam ab169809 
SE Cell Line 4D-Nucleofector X Kit L Lonza V4XC-1024 
SF Cell Line 4D-Nucleofector X Kit L Lonza V4XC-2024 
SG Cell Line 4D-Nucleofector X Kit L Lonza V4XC-3024 
 
 
2.4. FVIII products 
 
Product Manufacturer PZN 
Nuwiq 2000 I.E. Octapharma AG 10538172 
ReFacto AF 3000 I.E. Pfizer Inc. 7773372 
 
 
2.5. Cytokines 
 
Product Manufacturer Order number 
GM-CSF PeproTech AF-300-03 
IL-1β Miltenyi Biotec 130-093-897 
IL-2 PeproTech AF-200-02 
IL-4 PeproTech AF-200-04 
IL-6 Miltenyi Biotec 130-095-352 
IL-8 Miltenyi Biotec 130-093-942 
TNF-α Miltenyi Biotec 130-094-014 
 
 
2.6. Antibodies 
 
Product Manufacturer Order number 
Anti-HLA-DR FITC Miltenyi Biotec 130-095-295 
Anti-HLA-DR PE Miltenyi Biotec 130-095-298 
Anti-Sulfotyrosine Antibody  Merck Millipore 05-1100 
CD14 PerCP Miltenyi Biotec 130-094-969 
CD16 APC-Vio770 Miltenyi Biotec 130-096-655 
CD206 APC-Cy7 BioLegend 321120 
CD209 PE Miltenyi Biotec 130-092-869 
CD209 VioBlue Miltenyi Biotec 130-099-985 
 Material  19 
CD25 APC Miltenyi Biotec 130-101-435 
CD28 PerCP-Cy5.5 BioLegend 302922 
CD3 APC-Vio770 Miltenyi Biotec 130-096-610 
CD3 PE Miltenyi Biotec 130-091-374 
CD4 FITC Miltenyi Biotec 130-080-501 
CD4 PE-Vio770 Miltenyi Biotec 130-113-255 
CD4 VioBlue Miltenyi Biotec 130-097-333 
CD40 BV510 BioLegend 334330 
CD45 BV421, mouse BioLegend 103134 
CD45RA PerCP-Vio700 Miltenyi Biotec 130-097-693 
CD45RO VioBlue Miltenyi Biotec 130-099-044 
CD71 VioBlue Miltenyi Biotec 130-101-627 
CD8 APC Miltenyi Biotec 130-091-076 
CD80 APC Miltenyi Biotec 130-097-204 
CD86 PerCP-Vio700 Miltenyi Biotec 130-097-918 
Donkey anti-mouse IgG IRDye 680RD Li-Cor 926-68072 
Donkey anti-rabbit IgG IRDye 800CW Li-Cor 926-32213 
Donkey anti-sheep IgG CF488A Biotium 20024-1 
Donkey anti-sheep IgG CF680 Biotium 20062 
Donkey anti-sheep IgG IRDye 800CW Abm SI046 
Mouse anti-human Factor VIII Antibody, LC Merck Millipore MAB038 
Mouse anti-human IgG-Fc-HRPO Cedarlane CL6017HP 
Mouse anti-human IgM-HRP abcam ab99744 
Rabbit anti-human Factor VIII Antibody, HC Sino Biological Inc.  13909-R226 
Sheep anti-human Factor VIII:C Cedarlane CL20035AP 
Streptavidin IRDye 680RD Li-Cor 926-68079 
 
 
2.7. Consumables 
 
Product Manufacturer Order number 
15 ml Conical Tube Falcon 352096 
5 ml Round-Bottom Tube Falcon 352052 
50 ml Conical Tube Falcon 352070 
50 ml Mini Bioreactor Corning 421720 
Amicon Ultra-15 Centrifugal Filters, 10 kDa Merck Millipore UFC901024 
Cedex Sample Cups Roche 05 650 623 001 
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Cell Scraper Falcon 353086 
Combitips advanced 0.5 ml Eppendorf 0030 089.421 
Combitips advanced 10 ml Eppendorf 0030 089.464 
Combitips advanced 2.5 ml Eppendorf 0030 089.448 
Combitips advanced 5 ml Eppendorf 0030 089.456 
Cryotube vials, 1.8 ml Thermo Scientific 377267 
Cup & Pin pro Tem 200011 
Dualfilter epTIPS, 0.2-5 ml Eppendorf 0030 077.725 
Dualfilter epTIPS, 0.1-10 µl Eppendorf 0030 077.512 
Dualfilter epTIPS, 2-200 µl Eppendorf 0030 077.555 
Dualfilter epTIPS, 50-1000 µl Eppendorf 0030 077.571 
epTIPS, 0.1-20 µl Eppendorf 0030 073.380 
epTIPS, 2-200 µl Eppendorf 0030 073.428 
epTIPS, 50-1000 µl Eppendorf 0030 073.460 
Erlenmeyer Flask, 125 ml Corning 431143 
Erlenmeyer Flask, 250 ml Corning 431144 
Erlenmeyer Flask, 500 ml Corning 431145 
FACSClean BD 340345 
FACSFlow BD 342003 
Immobiline DryStrip pH 4-7, 7 cm GE Healthcare 17-6001-10 
LD columns Miltenyi Biotec 130-042-901 
Leucosep tube, 50 ml Greiner 227290 
LS columns Miltenyi Biotec 130-042-401 
Microplate, 96-well, PS, F-Bottom Greiner 655001 
Microplate, 96-well, PS, F-Bottom, black Greiner 655906 
MS columns Miltenyi Biotec 130-042-201 
NuPage 4-12 % Bis-Tris Gel, 1.0 mm x 10 well Invitrogen NP0321BOX 
NuPage 4-12 % Bis-Tris Gel, 1.0 mm x 12 well Invitrogen NP0322BOX 
NuPage 4-12 % Bis-Tris ZOOM Gel, 1.0 mm x IPG 
well 
Invitrogen NP0330BOX 
Odyssey Nitrocellulose Membrane Li-Cor 926-31090 
Sample cups 0.5 ml, safe-lock Eppendorf 0030 121.708 
Sample cups 1.5 ml, safe-lock Eppendorf 0030 123.328 
Sample cups 2.0 ml, safe-lock Eppendorf 0030 120.094 
Serological pipette, 5 ml VWR 612-1248 
Serological pipette, 10 ml VWR 612-4952 
Serological pipette, 25 ml VWR 612-1245 
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Serological pipette, 50 ml VWR 612-4953 
Sterling Nitrile-Xtra Gloves Kimtech 98343 
Tissue Culture Testplate, 12-well TPP 92012 
Tissue Culture Testplate, 24-well TPP 92024 
Tissue Culture Testplate, 48-well TPP 92048 
Tissue Culture Testplate, 96-well TPP 92096 
Tissue Culture Testplate, 96-well, U-bottom TPP 92197 
Western Blotting Filter Paper, 7 cm x 8.4 cm Thermo Scientific 84783 
 
 
2.8. Equipment and Software 
 
Product Manufacturer 
4D-Nucleofector Lonza 
ÄKTA start GE Healthcare 
Amershan Typhoon Imager GE Healthcare 
BCS XP Siemens 
Cedex HiRes Innovatis 
Climo-Shaker ISF1-X Kuhner 
Electrophoresis Power Supply GEPS 200/2000 Elchrom Scientific 
Eppendorf Centrifuge 5427 R Eppendorf 
Ettan IPGphor3 GE Healthcare 
Ettan IPGphor3 Control Software GE Healthcare 
FACSuite BD 
FACSVerse BD 
FlowJo X Tree Star 
GraphPad Prism GraphPad Software 
HERACell 150i CO2 Incubator Thermo Scientific 
HERACell 240i CO2 Incubator Thermo Scientific 
HERASafe KS  Thermo Scientific 
ImageStudio Li-Cor 
Integra Vacusafe Integra 
IPG Box GE Healthcare 
MACS magnet Miltenyi Biotec 
MARS BMG Labtech 
Megastar 3.0 R Centrifuge VWR 
Multipette Eppendorf 
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Nalgene Freezing Container Nalgene 
Neubauer chamber Labor Optik 
Novex Mini-Cell life technologies 
Odyssey CLx Li-Cor 
Olympus IX53 microscope Olympus 
pHmeter SevenCompact Mettler Toledo 
Pipetus Hirschmann 
PLA 3.0 Stegmann Systems 
POLARstar Omega BMG Labtech 
Research pipette, 30-300 µl, 12-channel Eppendorf 
Research plus pipette 0.1-2.5 µl Eppendorf 
Research plus pipette 0.5-10 µl Eppendorf 
Research plus pipette 100-1000 µl Eppendorf 
Research plus pipette 10-100 µl Eppendorf 
Research plus pipette 1-20 µl Eppendorf 
Research plus pipette 20-200 µl Eppendorf 
Research plus pipette 500-5000 µl Eppendorf 
Rocking shaker Rocker 25 Labnet 
Shaking Platform Sea Star 
Shaking platform THERMOstar BMG Labtech 
ThermoMixer C Eppendorf 
Unicorn start 1.0 GE Healthcare 
VectorNTI Express life technologies 
Water bath GFL 
XCell II Blot Module life technologies 
XCell SureLock life technologies 
 
 
2.9. Buffer protocols 
 
FVIII Formulation Buffer pH 7.0 
205 mM NaCl 
5.3 mM CaCl2 
6.7 mM L-Histidine 
1.3 % Sucrose 
0.013 % Tween 20 
In distilled water 
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Lysis Buffer pH 8.5 
30 mM Tris 
7 M Urea 
2 M Thiourea 
4 % CHAPS 
In distilled water 
 
MACS Buffer 
2 mM EDTA 
0.5 % BSA 
In PBS 
 
SAEx Elution Buffer pH 6.0 
1 M NaCl 
20 mM CaCl2 
20 mM L-Histidine 
0.02 % Tween 80 
In distilled water 
 
SAEx Equilibration Buffer pH 7.5 
100 mM NaCl 
20 mM CaCl2 
20 mM L-Histidine 
0.02 % Tween 80 
In distilled water 
 
Sample Rehydration Buffer  
7 M Urea 
2 M Thiourea 
2 % CHAPS 
20 mM DTT 
1 % IPG pH 4-7 
Bromophenol blue 
In distilled water 
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TBSA Buffer pH 7.4 
25 mM Tris 
150 mM NaCl 
1 % BSA 
In distilled water 
 
Thrombin-activation Buffer pH 7.5 
20 mM Tris 
150 mM NaCl 
In distilled water 
 
VIIISelect Elution Buffer pH 6.5 
1.5 M NaCl 
20 mM CaCl2 
20 mM L-Histidine 
0.02 % Tween 80 
50 % Ethylene glycol 
In distilled water 
 
VIIISelect Equilibration Buffer pH 7.0 
300 mM NaCl 
20 mM CaCl2 
10 mM L-Histidine 
0.02 % Tween 80 
In distilled water 
 
VIIISelect Wash Buffer pH 6.5 
1 M NaCl 
20 mM CaCl2 
20 mM L-Histidine 
0.02 % Tween 80 
In distilled water 
 
Western Blot Buffer 
10 % Methanol 
0.1 % Antioxidant 
In Transfer Buffer 
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2.10. Vector 
 
The FVIII vector (Figure 2-1) contained the sequence of the different FVIII variants within the 
unique restriction sites HindIII and XbaI. An additional unique restriction site, BamHI, occurred naturally 
in the middle of the FVIII sequence. The unique restriction sites KpnI, XmaI and EcoRI were inserted, in 
order to be able to exchange smaller parts of the FVIII sequence. The human elongation factor-1 alpha 
(EF-1α) initiated the transcription of the FVIII gene. Additionally, the vector coded for an ampicillin 
resistance and a dihydrofolate reductase (dhfr), serving as pro- and eukaryotic selection markers. The 
simian vacuolating virus 40 (SV40) origin indicates the origin of replication in eukaryotes, whereas the 
pBR322 origin indicates the origin of replication in prokaryotes. 
 
 
Figure 2-1: FVIII vector card. The arrow indicates the functional orientation of the genes. FVIII signal sequence, FVIII heavy chain 
and FVIII light chain comprise the coding regions for the whole FVIII molecule. HindIII, KpnI, XmaI, BamHI, EcoRI and XbaI are 
the unique restriction sites used for cloning. EF-1α is the promotor for the FVIII gene. The ampicillin resistance is the prokaryotic 
selection marker and dhfr is the eukaryotic selection marker. The SV40 origin provides the origin of replication for eukaryotes 
and the pBR322 origin provides the origin of replication for prokaryotes.  
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3. Methods 
 
 
3.1. In silico analyses 
 
The modelling tools used for the in silico analyses are commercially available and were performed 
by EpiVax. The tools analyze protein sequences, in order to detect peptides potentially binding to the 
MHC class II. These peptides are further analyzed regarding potential amino acid exchanges, in order to 
reduce the strength of the binding. The functionality of these tools was already proven for FVIII, 
deimmunizing peptides of the C2 domain173. 
The modelling process, in order to deimmunize a BDD-FVIII, comprised four steps. In the first step, 
the EpiMatrix tool split the protein into peptides, consisting of nine amino acids, so-called 9-mers. This 
was due to the fact that the core binding region of the MHC class II comprises nine amino acids199. The 
sequence of a 9-mer and its following 9-mer overlapped by eight amino acids179. By building these highly 
overlapping 9-mers, no potential binding peptides were lost. The binding capacity of all 9-mers was 
calculated for eight common HLA class II supertype alleles (DRB1*0101, DRB1*0301, DRB1*0401, 
DRB1*0701, DRB1*0801, DRB1*1101, DRB1*1301, DRB1*1501), covering over 90 % of the human 
population172,173. The potential of each 9-mer to bind a HLA allele was indicated by a “Z score”. This 
score indicated the strength of binding, normalized to the frequency of the given allele in the 
population172,200. A 9-mer with a high Z-score for at least four HLA alleles was regarded as highly 
immunogenic and a called EpiBar (Figure 3-1)179. 
 
 
Figure 3-1: EpiMatrix results200. Example for an analysis of EpiBars in the Class II-associated invariant chain peptide (CLIP) region, 
a part of the invariant chain, which is bound to the MHC class II groove before peptide loading. 
 
In the following step, overlapping EpiBars were clustered using the program ClustiMer173. This 
analysis led to EpiBar clusters of up to 25 amino acids, binding to class II MHCs derived from multiple 
HLA alleles179. Before the optimization of these clusters, an analysis regarding similarity with other 
endogenous proteins was performed using the program JanusMatrix. A sequence overlap with at least 
two other endogenous proteins led to the exclusion of the cluster from further modification. This was 
because central tolerance has very likely been established to common endogenous peptides. In addition 
to that, clusters comprising cleavage sites, activation sites or other sites important for the activity of FVIII 
were set aside and were not altered. 
In the last step, amino acid exchanges were calculated using OptiMatrix. This tool evaluated the 
contribution of each amino acid of a cluster to the MHC class II-binding173. Afterwards, OptiMatrix 
calculated which amino acid substitutions reduced this binding affinity (Figure 3-2)180. These 
optimizations were based on the principles that the amino acid exchanges had to be conservative, 
preferably occurred in other species and were not registered in the database comprising all known FVIII 
mutations leading to Hemophilia A6. 
 
 
Figure 3-2: OptiMatrix report201. Example for an analysis, which reveals the contribution of each amino acid to binding, indicated 
by the OptiMatrix score. Color and size of the letters visualize their strength of contribution. 
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Based on the in silico results, the most promising mutations were selected and inserted into the 
DNA sequence of a BDD-FVIII as single mutations and in combination. The plasmid design was 
performed using Vector NTI Express. The synthesis of the plasmids was performed by life technologies. 
HEK293-F and CAP-T cells were transfected with these different plasmids, as described in 3.2.2.3 and 
3.2.3.3. 
 
 
 
3.2. Cell culture techniques 
 
 
3.2.1. General techniques 
 
 
3.2.1.1. Determination of cell numbers 
 
All cells were either counted manually, using a Neubauer chamber, or automatically, using the 
Cedex HiRes Analyzer. In both cases a trypane blue staining was applied to distinguish viable and dead 
cells. 
The Neubauer chamber comprises nine big squares. The square in the center is used to count 
platelets and red blood cells, whereas the four squares in the corners are used to count white blood cells 
and most cell line-derived cells. Each of the four corner squares are subdivided into 4 x 4 small squares 
and comprise a volume of 0.0001 ml.  
In order to determine a cell number, a sample of the cell suspension was diluted at least 1:2 with 
0.2 % trypane blue solution. In the case of high cell densities, the sample was pre-diluted in phosphate-
buffered saline (PBS) so that each big square contained at least 15 cells and did not exceed 200 cells. 
10 µl sample were applied between the chamber and the glass cover. The cells were counted using a 
microscope. Bright cells were counted as viable cells, whereas dark blue cells, which had taken up the 
trypane blue solution, were counted as dead cells. Afterwards, the following formulas were applied to 
calculate the cell concentration of the suspension, the absolute cell number and the viability. 
 
 
Cell concentration (cells/ml) = 
Number of viable cells ⋅ Dilution factor 
Number of squares ⋅ 0.0001 ml
 
 
 
Absolute cell number = Cell concentration ⋅ Total volume 
 
 
Viability (%) = 
Number of viable cells 
Number of total cells
⋅100 
 
 
The Cedex HiRes Analyzer stains and counts the cells fully automated. The applied cell suspension 
is mixed internally with the 0.2 % trypane blue solution and analyzed by a scanner unit. Cell 
concentrations are calculated by the Cedex HiRes software. 300 µl of the cell suspension were transferred 
to a Cedex Sample Cup and set into the sample rack of the Analyzer. In the case of high cell densities, 
the sample was pre-diluted in PBS. The concentration and viability values were taken directly from the 
software. 
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3.2.2. HEK293-F cells 
 
The HEK293-F cell line is derived from the original HEK293 cell line202 and was adapted to 
suspension growth in serum-free medium197. HEK293-F cells are already used in the production of 
recombinant proteins, even rFVIII94. The cells were used for the small-scale production of various 
mutated FVIII variants. 
 
 
3.2.2.1. Cryopreservation of HEK293-F cells 
 
HEK293-F cells for cryopreservation were taken from cultures with a low passage number in mid-
log phase of growth. The required amount of cells was harvested by centrifugation at 200 x g for 
5 minutes. The cells were resuspended in 4 °C chilled cryopreservation medium, consisting of 7.5 % 
Dimethyl sulfoxide (DMSO) and 92.5 % growth medium, whereas the growth medium consisted of 50 % 
conditioned and 50 % fresh CD293 medium. The suspension was adjusted to a concentration of 
5·106 cells/ml in cryopreservation medium. Aliquots of 1 ml were generated and stored in freezing 
containers at -80 °C, in order to ensure a temperature decrease of 1 °C per minute. The frozen cells were 
transferred to -150 °C for long-term cryopreservation. 
 
 
3.2.2.2. Cultivation of HEK293-F cells 
 
HEK293-F cells were cultured in chemically defined CD293 medium supplemented with 4 mM 
GlutaMAX. In order to thaw the cells, the required amount of frozen vials were transferred to a 37 °C 
water bath. After thawing, each cryovial was transferred to a 125 ml shake flask, containing 30 ml of 
warmed, supplemented CD293 medium. The cells were incubated at 37 °C in a humidified incubator 
with an atmosphere, containing 5 % Carbon dioxide (CO2). The flasks were set on a shaking platform, 
rotating at 120 rpm with an orbit of 25 mm. 
The cells were subcultured every 3 to 4 days. The fresh cultures were set to 0.3·106 cells/ml by 
transferring the required amount of cell suspension to a new flask and adding supplemented CD293 
medium to reach the seeding density of 0.3·106 cells/ml. In the case that the transferred cell suspension 
exceeded 20 % of the total volume, the suspension was centrifuged at 200 x g for 5 minutes and the 
pellet was resuspended in medium, consisting of 80 % fresh medium and 20 % conditioned medium. 
The volume of cell suspension per shaking flask was 20 % of the total flask volume. 
A minimum of three subcultures were performed after thawing before the first transfection 
experiments were performed. In addition to that, the cell line was only used until passage 25. 
 
 
3.2.2.3. Transfection of HEK293-F cells 
 
The HEK293-F cells were transfected using the 4D-Nucleofector. The 4D-Nucleofector is suitable 
for performing 16 transfections in a 20 µl scale or two transfections in a 100 µl scale in parallel. The 
Nucleocuvettes are single-use and supplied together with Transfection Buffer SE, SF or SG plus buffer 
supplements in the respective kits. The 16-well format was used for screening, in order to reveal the 
appropriate transfection program and buffer for maximal transfection efficacy and viability. The larger 
transfection format was used for all further experiments. The plasmids were provided in Tris-EDTA (TE)-
buffer. The transfected HEK293-F cells were in mid-log growth phase and had a viability above 90 %. 
The 16 transfections were performed in Nucleocuvette strips, consisting of 16 separated cuvettes. 
Each transfection was prepared in a single 15 ml conical tube, containing 0.3·106 HEK293-F cells. The 
cell suspension was centrifuged at 200 x g for 5 minutes. The cells were resuspended in 20 µl of the SE, 
SF or SG Buffer and 0.4 µg plasmid were added. The cell suspension was transferred to the cuvettes and 
they were inserted into the 4D-Nucleofector. As each cuvette was pulsed separately, different buffers 
and transfection programs could be tested within the same strip. For each cuvette, buffer and 
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transfection program were defined in the software of the 4D-Nucleofector. After the transfection, the 
strip was taken from the 4D-Nucleofector and 80 µl of warmed RPMI 1640 medium were added to each 
transfected well. The strip was incubated for 10 minutes at 37 °C. Afterwards, the cell suspensions were 
transferred to supplemented CD293 medium and incubated as described in 3.2.2.2. 
The transfections in the 100 µl Nucleocuvettes were adapted regarding the amount of cells and 
plasmid, in order to achieve maximal protein production. The transfection of 7·106 HEK293-F cells with 
7 µg FVIII plasmid was found to be the optimal approach for maximal protein production. This setup 
was used in all 100 µl transfections. The cells were centrifuged at 200 x g for 5 minutes in 15 ml conical 
tubes and resuspended in 80 µl of supplemented SG Buffer, taking into account the volume of the pellet 
and the volume of the plasmid solution. The cell solution was transferred to the Nucleocuvettes. Up to 
eight Nucleocuvettes were prepared in parallel and transfected successively in pairs of two. The applied 
transfection program was DU-100. After the transfection, 400 µl of warmed RPMI 1640 were added to 
each Nucleocuvette and the suspension was incubated for 10 minutes at 37 °C. Afterwards, the cells from 
one Nucleocuvette were transferred to 50 ml cell culture tubes, containing 2.2 ml supplemented CD293 
medium and 0.3 ml HyClone Cell Boost 5. The cells were cultivated for 4 days as described in 3.2.2.2. 
At day 4 the cells were harvested by centrifugation at 200 x g for 5 minutes. Afterwards, the FVIII activity 
in the supernatant was determined as described in 3.4.1 and 3.4.2. The pellet and the remaining 
supernatant were frozen separately at -20 °C for further analyzes. 
 
 
3.2.3. CAP-T cells 
 
CAP-T cells are derived from amniocytes and optimized for transient transfection. The cell line was 
developed to produce high amounts of large proteins198. As FVIII is a very large and complex protein, 
the large-scale production of the final deimmunized FVIII molecule was performed in CAP-T cells. 
 
 
3.2.3.1. Cryopreservation of CAP-T cells 
 
In order to freeze and cryopreserve CAP-T cells, the required amount of cells was harvested by 
centrifugation at 150 x g for 5 minutes. The pellet was resuspended in chilled CAP-CDM medium to a 
concentration of 1.7·107 cells/ml. This suspension was further diluted 1:2 with chilled ProFreeze-CDM 
NAO medium, containing 15 % DMSO. Aliquots of 1.8 ml were generated and stored in freezing 
containers at -80 °C, in order to ensure a temperature decrease of 1 °C per minute. The frozen cells were 
transferred to -150 °C for long-term cryopreservation. 
 
 
3.2.3.2. Cultivation of CAP-T cells 
 
CAP-T cells were cultured in CAP-CDM medium supplemented with 50 µg/ml LONG R3 IGF-I and 
6 mM GlutaMAX. In order to thaw the cells, the required amount of frozen vials were transferred to a 
37 °C water bath. After thawing, each vial was transferred to 10 ml of chilled, supplemented CAP-CDM 
medium. The cell suspension was centrifuged at 150 x g for 5 minutes. During this washing step the 
DMSO was removed. The pellet was resuspended in 15 ml warm, supplemented CAP-CDM medium and 
transferred to a 125 ml shaker flask. The cells were incubated at 37 °C in a humidified incubator with an 
atmosphere containing 5 % CO2. The flasks were set on a shaking platform, rotating at 185 rpm with an 
orbit of 50 mm. 
Subculturing of the cells was performed every 3 to 4 days. The fresh culture was set to 
1·106 cells/ml by transferring the required amount of cultured cell suspension to a new flask and adding 
supplemented CAP-CDM medium. In the case that the transferred cell suspension exceeded 20 % of the 
total volume, the suspension was centrifuged at 150 x g for 5 minutes and the pellet was resuspended in 
fresh supplemented CAP-CDM medium. The volume of cell suspension per shaking flask was 20 % of the 
total flask volume. 
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In order to use CAP-T cells for high yield protein production, the cells were cultivated in PEM 
medium supplemented with 4 mM GlutaMAX and 5 µg/ml blasticidin. The handling and cultivation 
conditions remained the same as for the cultivation in CAP-CDM medium. 
A minimum of three subcultures were performed after thawing before the first transfection 
experiments were performed. In addition to that, the cells were only used until passage 25. 
 
 
3.2.3.3. Transfection of CAP-T cells 
 
The CAP-T cells were transfected using the 4D-Nucleofector as described in 3.2.2.3 for HEK293-F 
cells. The appropriate transfection program was determined from four possible transfection programs in 
SE Buffer. In all experiments the CAP-T cells were transfected in the 100 µl Nucleocuvettes. For each 
transfection 10·106 CAP-T cells were centrifuged at 150 x g for 5 minutes in 15 ml conical tubes. The 
cells were resuspended in 80 µl supplemented SE Buffer, taking into account the volume of the pellet 
and the volume of the plasmid solution. Afterwards, 5 µg of FVIII-plasmid were added to the cell 
suspension. The solution was transferred to the Nucleocuvettes. Up to eight Nucleocuvettes were 
prepared in parallel and transfected successively in pairs of two. The used transfection program was ED-
100. After the transfection, the cells from one Nucleocuvette were transferred to 125 ml shaker flasks, 
containing 12.5 ml supplemented PEM medium. The cells were cultivated for 4 days as described in 
3.2.3.2. At day 4 the cells were harvested by centrifugation at 150 x g for 5 minutes. Afterwards, the FVIII 
activity in the supernatant was determined as described in 3.4.1 and 3.4.2. The pellet and the remaining 
supernatant were frozen separately at -20 °C for further analyzes. 
In order to gain larger amounts of transfected CAP-T cells, multiple transfections were performed 
and the transfected cells were pooled afterwards. The final culture volume was dependent on the number 
of transfections, comprising 12.5 ml medium per transfection. As for the small volume transfections, the 
FVIII activity was determined at day 4 (3.4.1 and 3.4.2). Afterwards, the FVIII was either purified directly 
from the supernatant as described in 3.5.1 or stored at -20 °C until purification. 
 
 
3.2.4. Primary cells 
 
 
3.2.4.1. Purification of PBMCs 
 
Peripheral blood mononuclear cells (PBMCs) are purified from blood via density gradient 
centrifugation. Particles with a higher density than the separation medium pass through the medium 
during centrifugation, whereas particles with a lower density stay above. Red blood cells (RBCs), which 
would not pass the separation medium, due to their low density, aggregate upon contact with the 
medium. The aggregates have a higher density and can pass the medium. Granulocytes are also able to 
pass, as they naturally have a higher density than the separation medium. All other cell types stay above 
the separation medium. 
PBMCs were either purified from whole blood or leukapheresis products. In both cases the products 
were diluted 1:2 with PBS. In the case of a cell suspension derived from a leukapheresis, 25 ml of the 
suspension were applied to a 50 ml conical tube. Afterwards, 20 ml of the density gradient medium 
Lymphoflot were slowly pipetted beneath the cell suspension. In the case of whole blood, the 20 ml 
Lymphoflot were first applied to a 50 ml conical tube and the 25 ml blood were carefully pipetted on top 
of the Lymphoflot. Both preparations were not allowed to be mingled. The tubes were centrifuged at 
1000 x g for 20 minutes, in order to accelerate the separation. The break of the centrifuge was switched 
off, in order to prevent a mixing of the separated layers at the end of the centrifugation. After the 
centrifugation, erythrocytes and granulocytes were pelletized at the bottom of the tube. Above that pellet 
the Lymphoflot was visible, layered by an opaque yellow band of PBMCs. The layer above the PBMCs 
was the plasma (Figure 3-3). As the minimum purified volume per donor was 400 ml, the sample was 
split to various tubes. The tubes were filled successively and centrifuged together. 
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Figure 3-3: Purification of PBMCs. Prior to centrifugation the blood is layered above the Lymphoflot. After centrifugation, four 
layers were formed. The upper layer is plasma, followed by the PBMC layer. The lower layers are the Lymphoflot and the RBCs. 
 
Using a 10 ml serological pipette, the PBMC layers derived from the same donor were pooled in 
50 ml conical tubes. In order to pelletize the cells and to remove the transferred plasma, the cells were 
centrifuged at 500 x g for 10 minutes. Afterwards, the pellets were resolved in warm X-VIVO 15 medium 
and pooled in up to ten 50 ml conical tubes, depending on the amount of cells. In an additional washing 
step, the cells were centrifuged at the same conditions as before. If the cells were pooled in more than 
one tube, the resolving, pooling and centrifugation was repeated, in order to receive one 50 ml conical 
tube, containing all PBMCs. The cells were then resuspended in a defined volume of X-VIVO 15 and 
counted using a Neubauer chamber as described in 3.2.1.1. The PBMCs were cryopreserved as described 
in 3.2.4.2 and were stored at -150 °C until further purification (3.2.4.3 and 3.2.4.4). 
In order to simplify the procedure, Leucosep tubes were used for the purification of whole blood. 
These 50 ml conical tubes contain a porous barrier, which prevents the mixing of Lymphoflot and blood. 
15 ml Lymphoflot were applied to the barrier and the tubes were centrifuged at 1000 x g for 30 seconds, 
in order to force the Lymphoflot below the barrier. Afterwards, 30 ml of 1:2 diluted blood were applied 
onto the barrier. The centrifugation was performed at 1000 x g without brake for 10 minutes. After the 
separation, PBMCs and plasma laid above the barrier and were directly poured to fresh 50 ml conical 
tubes. The further procedure was performed as described above. 
 
 
3.2.4.2. Cryopreservation of PBMCs 
 
The PBMCs were cryopreserved immediately after the purification. After the determination of the 
cell number, the cells were harvested by centrifugation at 300 x g for 10 minutes. The pellet was 
resuspended in chilled freezing medium, consisting of 90 % fetal bovine serum (FBS) and 10 % DMSO. 
The final concentration varied between 0.7-6.7·107 cells/ml, depending on the required amount per vial. 
Aliquots of 1.5 ml were generated resulting in 1-10·107 cells/vial. The vials were stored in freezing 
containers at -80 °C, in order to ensure a temperature decrease of 1 °C per minute. The frozen cells were 
transferred to -150 °C for long-term cryopreservation. 
 
 
3.2.4.3. Purification of Monocytes 
 
Monocytes were purified from PBMCs with CD14 MicroBeads, using the Magnetic Activated Cell 
Sorting (MACS) technology. The CD14 MicroBeads consist of monoclonal anti-human CD14 antibodies 
conjugated to MicroBeads. These antibodies bind to the CD14+ cells and label them. All cells are applied 
to columns, which are filled with a matrix able to generate a strong magnetic field when attached to a 
magnet. Due to this magnetic field, the MicroBead-labeled cells are retained inside the column. After the 
elution of all unbound cells, the column is removed from the magnet and the purified, labeled cells are 
eluted (Figure 3-4). 
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Figure 3-4: Positive selection of CD14+ cells, using MACS. All CD14+ cells in the cell suspension are labeled with MicroBead-coupled 
anti-CD14 antibodies. The unlabeled cells pass through the column and only labeled cells remain in the column. After removal 
of the column from the magnetic field, the labeled CD14+ cells can be eluted from the column. 
 
At least one vial of PBMCs was thawed in a 37 °C water bath and transferred to chilled X-VIVO 15. 
Up to 5·107 PBMCs were transferred to 10 ml X-VIVO 15, higher cell numbers were transferred to 40 ml 
X-VIVO 15. The PBMCs were centrifuged at 300 x g for 10 minutes. The pellet was resuspended in 12 ml 
X-VIVO 15 for lower cell numbers and 45 ml X-VIVO 15 for higher cell numbers. Afterwards, the total 
cell number was determined using a Neubauer chamber (3.2.1.1). The cells were again centrifuged using 
the same settings as before. At first the pellet was resuspended in 80 µl of MACS Buffer per 1·107 cells. 
Afterwards, 20 µl of CD14 MicroBeads per 1·107 cells were added. The antibody was incubated for 
15 minutes at 4 °C. Afterwards, the tube was filled with MACS Buffer and centrifuged at 300 x g for 
10 minutes, in order to remove unbound CD14 MicroBeads. During labeling, MS columns, for up to 2·108 
total cells, or LS columns, for up to 2·109 total cells, were attached to a strong magnet and rinsed with 
500 µl or 3 ml of MACS Buffer, respectively. After centrifugation the pellet was resuspended in 500 µl 
MACS Buffer per 1·108 cells and applied to the appropriate column. Three washing steps were performed 
using 3 x 500 µl MACS Buffer for the MS column or 3 x 3 ml MACS Buffer for the LS column. Afterwards, 
the column was taken from the magnet and transferred to a 15 ml conical tube. In order to elute the 
bound cells, 1 ml or 5 ml MACS Buffer were applied to the MS column or LS column. Using a plunger, 
the cells were flushed out of the column. The suspension contained enriched CD14+ monocytes. The 
cells were counted using a Neubauer chamber (3.2.1.1) and plated as described in 3.2.4.6. 
In order to determine the viability, the composition of the PBMCs and the purity of the monocytes, 
the cells were analyzed by flow cytometry (3.3.1), using the PBMCs & Monocytes stain (Table 3-1). A 
sample was taken from the PBMCs prior to purification and from the monocytes after purification. 
 
 
3.2.4.4. Purification of regulatory T cell-depleted CD4+ T cells 
 
Regulatory T cell-depleted CD4+ T cells were purified from PBMCs, using the MACS technology. 
In comparison to the monocyte purification (3.2.4.3), during which the cells of interest are labelled with 
MicroBeads, the CD4+CD25+ Regulatory T Cell Isolation Kit labels all cells except the cells of interest. 
The kit contains a CD4+ T Cell Biotin-Antibody Cocktail and corresponding Anti-Biotin MicroBeads, as 
well as CD25 MicroBeads. The CD4+ T Cell Biotin-Antibody Cocktail contains antibodies against CD8, 
CD14, CD15, CD16, CD19, CD36, CD56, CD123, TCRγ/δ, and CD235a. These antibodies bind to all cell 
types existing in the PBMCs except CD4+ T cells. The addition of the CD25 MicroBeads specifically labels 
CD4+CD25+ regulatory T cells. The cells are applied to a column, which is attached to a magnet. All 
labelled cells remain in the column, whereas the cells of interest pass through the column (Figure 3-5). 
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Figure 3-5: Negative selection of CD25- CD4+ cells, using MACS. All cells in the cell suspension except CD25- CD4+ cells are labeled 
with antibodies and MicroBeads. The cells of interest pass through the column and the labeled cells remain in the column. 
 
The PBMCs were thawed, washed and counted, as for the purification of monocytes (3.2.4.3). 
After the determination of the cell number, the cells were centrifuged at 300 x g for 10 minutes. The 
pellet was labeled using the CD4+CD25+ Regulatory T Cell Isolation Kit. The manufacturer’s protocol 
was modified, in order reduce the amount of cell loss, resulting in a combined labeling step and the use 
of only one column. At first the pellet was resuspended in 80 µl of MACS Buffer per 1·107 cells. 
Afterwards, 10 µl of CD4+ T Cell Biotin-Antibody Cocktail and 10 µl of CD25 MicroBeads per 1·107 cells 
were added. The antibodies were incubated for 5 minutes at 4 °C. Afterwards, 20 µl of Anti-Biotin 
MicroBeads were added per 1·107 cells, in order to magnetically label the biotin-coupled antibodies. The 
beads were incubated for 10 minutes at 4 °C. During labeling, a LD column, for up to 1·108 labeled cells, 
was attached to a strong magnet and rinsed with 2 ml of MACS Buffer. The labeled cells were applied 
directly to the column without an additional washing step. Two column washing steps were performed 
using 2 x 1 ml MACS Buffer. The total effluent was collected containing the regulatory T cell-depleted 
CD4+ T cells. The column was discarded without elution of the cells. The purified CD4+CD25- T cells 
were labeled with carboxyfluorescein succinimidyl ester (CFSE) directly after purification, as described 
in 3.2.4.5. 
In order to determine the viability and the purity of the regulatory T cell-depleted CD4+ T cells, 
they were analyzed by flow cytometry (3.3.1), using the T cell stain 1 and 2 (Table 3-3 and Table 3-4). 
A sample was taken after purification and prior to CFSE-labeling. 
 
 
3.2.4.5. CFSE labeling of regulatory T cell-depleted CD4+ T cells 
 
Immediately after the purification of the CD4+CD25- T cells, the cells were labeled with CFSE, in 
order to track their proliferation in cell culture. Carboxyfluorescein diacetate succinimidyl ester (CFDA-
SE) is able to pass the plasma membrane of cells, due to two acetate groups. Inside the cells, the acetate 
groups are removed by esterases, leading to the highly fluorescent CFSE, which has a very low membrane 
permeability and remains inside the cells. Due to the succinimidyl group, CFSE covalently binds to amino 
groups. These conjugates are able to persist in the cells and are split between daughter cells at each cell 
division. Due to that, cell proliferation can be tracked via the dilution of the fluorescent CFSE. However, 
not every CFSE molecule is bound intracellularly. All unbound CFSE molecules are degraded or exit the 
cell within the first 24 to 48 hours after labeling. 
The labeling of the CD4+CD25- T cells occurred according to the protocol of Quah et al.203. The 
purified T cells were harvested by centrifugation at 300 x g for 10 minutes. Afterwards, the pellet was 
resuspended in 1 ml warmed PBS, containing 5 % FBS and transferred to a fresh 15 ml conical tube. The 
tube was laid nearly horizontally and 110 µl PBS were applied to the tube wall, not touching the cell 
suspension. 1.1 µl of a 5 mM CFSE solution were diluted in the PBS. The tube was capped and the CFSE 
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solution was mixed with the cell suspension. In order to reduce bleaching, the tube was wrapped in 
aluminum foil and incubated at room temperature for 5 minutes. Afterwards, the cells were washed by 
adding ten volumes of warmed PBS, containing 5 % FBS and centrifuged at 300 x g for 10 minutes. The 
washing step was repeated twice. Afterwards, the cells were cultured for 48 hours as described in 3.2.4.7, 
in order to cure the cells and to ensure that only steadily bound CFSE remained inside the cells. 
The protocol was used for cell numbers between 5·106 and 60·106 cells. No differences were 
detected regarding labeling intensity. At cell numbers below 5·106 cells the washing steps were decreased 
from three to two steps, in order to reduce cell loss.  
 
 
3.2.4.6. Cultivation of monocytes and DCs 
 
Monocytes were cultivated in the chemically defined and serum-free medium X-VIVO 15, in order 
to keep influences of non-human proteins on the cells as low as possible and to circumvent lot-to-lot 
variabilities. Monocytes were cultivated in 24-, 48- or 96-well flat-bottom plates, depending on the 
amount of cells. The concentration of monocytes was 1·106 cells/ml and the seeding volume was 
0.6 ml/well for 24-well plates, 0.3 ml/well for 48-well plates and 0.1 ml/well for 96-well plates. 
Immediately after the purification and determination of the cell number (3.2.4.3), the monocytes 
were harvested by centrifugation at 300 x g for 10 minutes. Afterwards, the cells were resuspended in 
the appropriate amount of X-VIVO 15 to reach a final concentration of 1·106 cells/ml204. This cell 
suspension was transferred to the wells of a cell culture plate. In order to differentiate the monocytes to 
immature DCs (iDCs), a final concentration of 4000 U/ml Granulocyte-macrophage colony-stimulating 
factor (GM-CSF) and 1250 U/ml IL-4 were added to each well. The amount of interleukins was 
determined in a preceding master thesis205. The plates were incubated at 37 °C in a humidified 
atmosphere, containing 5 % CO2. After 5 days the monocytes were differentiated to iDCs. In order to 
obtain mature DCs (mDCs), which present peptides, 0.05 µg/ml Lipopolysaccharide (LPS) or an IL-Mix 
and an antigen of interest were added to each well. The IL-Mix contained a final concentration of 
10 ng/ml IL-1β, 10 ng/ml IL-6 and 10 ng/ml TNF-α and is widely published206–208. The antigens of 
interest were various FVIII products in concentrations of 5 U/ml to 15 U/ml. The control antigen was 
Ovalbumin (OVA) at a final concentration of 1 mg/ml. The cells were incubated for another 24 hours at 
the same conditions, in order to maturate. Afterwards, the mDCs were co-cultivated with CD4+CD25- 
T cells as described in 3.2.4.8. 
 
 
3.2.4.7. Cultivation of regulatory T cell-depleted CD4+ T cells 
 
CFSE-labeled CD4+CD25- T cells were cultivated in chemically defined and serum-free X-VIVO 15 
medium. The cells were cultivated in 12-, 24-, 48- or 96-well flat-bottom plates, depending on the 
amount of purified T cells. The concentration of the CD4+CD25- T cells was 2·106 cells/ml and the 
seeding volume was 1.3 ml/well for 12-well plates, 0.6 ml/well for 24-well plates, 0.3 ml/well for 48-
well plates and 0.1 ml/well for 96-well plates. In order to provide optimal conditions, 20 U/ml IL-2 were 
added to each well209,210. 
Immediately after the CFSE labeling (3.2.4.5) and the determination of the cell number (3.2.4.4), 
the T cells were harvested by centrifugation at 300 x g for 10 minutes. Afterwards, the cells were 
resuspended in the appropriate amount of X-VIVO 15, in order to reach a final concentration of 
2·106 cells/ml. IL-2 was added to the cell suspension to reach the final concentrations of 20 U/ml. In the 
last step, the cells were transferred to the wells of the cell culture plate. The plates were incubated at 
37 °C in a humidified atmosphere, containing 5 % CO2 for 48 hours. Afterwards, the cells were co-
cultivated with mature DCs as described in 3.2.4.8. 
 
 
 
 36  Methods 
3.2.4.8. Co-cultivation of mature DCs and regulatory T cell-depleted CD4+ T cells 
 
The co-cultivation of DCs and CD4+CD25- T cells occurred after the maturation of the DCs and the 
CFSE-labeling and curing of the T cells. Due to the different cultivation durations, the T cells had to be 
purified 24 hours prior to the maturation stimulation of the DCs. 
After two days of cultivation, the CFSE-labeled T cells were harvested and pooled. Afterwards, the 
total cell number was determined (3.2.1.1) and a sample was taken, in order to analyze the T cells by 
flow cytometry (3.3.1), using the T cell proliferation stain (Table 3-5). The cells were co-cultivated at a 
ratio of at least 1:10 DCs to T cells210,211. The T cells were centrifuged at 300 x g for 10 minutes and 
resuspended in warmed X-VIVO 15 to a final concentration of 2·106 cells/ml. The supernatant of the 
T cell culture was cryopreserved at -20 °C for potential further analyses. The supernatant of the DCs was 
carefully aspirated, in order not to harm the DCs, which were tightly attached to the bottom of the wells. 
Immediately after the aspiration, the T cell suspension was added to the wells containing the DCs. 
Depending on the plates in which the DCs were seeded, the applied T cell suspension was 0.6 ml/well 
for 24-well plates, 0.3 ml/well for 48-well plates and 0.1 ml/well for 96-well plates. An exact 
determination of the DC:T cell ratio was not possible, due to the fact that the mDCs were not harvested. 
However, preceding experiments, counting the mDCs in the wells, revealed that the DC:T cell ratio was 
at least 1:10. No additional cytokines were applied to the co-cultivation. The plates were incubated at 
37 °C for 9 days in a humidified atmosphere, containing 5 % CO2. After 9 days, the T cells were harvested 
and centrifuged at 300 x g for 10 minutes. The T cells were further analyzed using a flow cytometer 
(3.3.1 and Table 3-5), whereas the supernatant was cryopreserved at -20 °C and analyzed later regarding 
cytokine secretion, using a cytokine array (3.3.2). 
 
 
 
3.3. Cellular assays 
 
 
3.3.1. Flow cytometry 
 
In order to analyze different cell types and their activation status, flow cytometric analyses were 
performed. Using a flow cytometer, previously fluorescent-labeled cells can be analyzed one by one, due 
to single-cell dilution inside the instrument. The cells are labeled with fluorochrome-coupled antibodies 
against various proteins on their cell surface or against intracellular proteins. In addition to that, viability 
stains and proliferation stains can be applied. Viability stains are based on the permeabilized membrane 
of dead cells. Due to this, viability dyes can pass the membrane and stain the DNA or amine-groups 
inside the cell. In contrast to that, proliferation dyes are incorporated into viable cells and are diluted 
due to cell division. Therefore, highly proliferating cells can be detected by a low signal of the 
proliferation dye. 
Inside the instrument each cell is excited by one or more lasers and the emitted fluorescence is 
guided via various filters and mirrors inside the instrument until it reaches the specific sensor for the 
given wavelength. These sensors are photomultiplier tubes (PMTs), which convert the signal of the 
photon into a voltage pulse, which is depicted as an event in the software. In addition to the detection 
of the fluorescent dye signal, the forward- and the sideward-scattered light is measured by two detectors. 
The forward-scattered (FSC) light indicates the size of a cell and the sideward-scattered (SSC) light the 
granularity (Figure 3-6). 
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Figure 3-6: Setup of a flow cytometer. Each cell is excited by the laser and the emitted light is detected by the FSC and SSC 
detectors and the sensors specific for the emitted wavelengths. The different wavelengths are separated by various mirrors and 
filters. 
 
The applied flow cytometer was a FACSVerse with a blue (488 nm), red (640 nm) and violet 
(405 nm) laser. Due to the integrated filters, the fluorescent dyes fluorescein isothiocyanate (FITC), 
phycoerythrin (PE), peridinin-chlorophyll-protein complex (PerCP), PE-cyanine (Cy) 7, allophycocyanin 
(APC), APC-Cy7, Brilliant Violet V450 and Brilliant Violet V500 could be detected. Apart from these 
fluorescent dyes, forward and sideward scatter were analyzed. In total, the simultaneous detection of 10 
parameters was possible. However, some fluorescent dyes influenced each other and especially the DCs 
were highly auto-fluorescent. Considering this, the following stains were designed. They were applied, 
in order to determine the composition of the PBMCs and the purity of the monocytes (Table 3-1), the 
differentiation and maturation state of the DCs (Table 3-2), the purity of the CD4+CD25- T cells before 
CFSE-labeling (Table 3-3 and Table 3-4) and the proliferation of T cells in the DC-T cell Assay (Table 
3-5) or in the humanized mouse cell assay (Table 3-6). 
 
Table 3-1: Antibodies and volumes required for the PBMCs & Monocytes stain. 
PBMCs & Monocytes stain 
Excitation laser Fluorescence Channel Antibodies Volume per tube 
Blue laser 
(488 nm) 
FITC CD4 FITC 10 µl 
PE CD3 PE 10 µl 
PerCP CD14 PerCP 10 µl 
PE-Cy7 - - 
Red laser 
(640 nm) 
APC CD8 APC 10 µl 
APC-Cy7 CD16 APC-Vio770 10 µl 
Violet laser 
(405 nm) 
BV450 CD209 VioBlue 10 µl 
BV510 Zombie Aqua 0.5 µl 
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Table 3-2: Antibodies and volumes required for the DC stain. 
DC stain 
Excitation laser Fluorescence Channel Antibodies Volume per tube 
Blue laser 
(488 nm) 
FITC HLA-DR FITC 10 µl 
PE CD209 PE 10 µl 
PerCP CD86 PerCP-Vio700 10 µl 
PE-Cy7 - - 
Red laser 
(640 nm) 
APC CD80 APC 10 µl 
APC-Cy7 CD206 APC-Cy7 5 µl 
Violet laser 
(405 nm) 
BV450 Zombie Violet 0.5 µl 
BV510 CD40 BV510 5 µl 
 
Table 3-3: Antibodies and volumes required for the T cell stain 1. 
T cell stain 1 
Excitation laser Fluorescence Channel Antibodies Volume per tube 
Blue laser 
(488 nm) 
FITC CD4 FITC 10 µl 
PE CD3 PE 10 µl 
PerCP CD45RA PerCP-Vio700 10 µl 
PE-Cy7 - - 
Red laser 
(640 nm) 
APC CD25 APC 10 µl 
APC-Cy7 - - 
Violet laser 
(405 nm) 
BV450 CD45RO VioBlue 10 µl 
BV510 Zombie Aqua 0.5 µl 
 
Table 3-4: Antibodies and volumes required for the T cell stain 2. 
T cell stain 2 
Excitation laser Fluorescence Channel Antibodies Volume per tube 
Blue laser 
(488 nm) 
FITC CD4 FITC 10 µl 
PE CD3 PE 10 µl 
PerCP CD28 PerCP-Cy7 5 µl 
PE-Cy7 - - 
Red laser 
(640 nm) 
APC CD25 APC 10 µl 
APC-Cy7 - - 
Violet laser 
(405 nm) 
BV450 CD71 VioBlue 10 µl 
BV510 Zombie Aqua 0.5 µl 
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Table 3-5: Antibodies and volumes required for the T cell proliferation stain. 
T cell proliferation stain 
Excitation laser Fluorescence Channel Antibodies Volume per tube 
Blue laser 
(488 nm) 
FITC CFSE Pre-stained 
PE - - 
PerCP 7-AAD 5 µl 
PE-Cy7 - - 
Red laser 
(640 nm) 
APC CD25 APC 10 µl 
APC-Cy7 - - 
Violet laser 
(405 nm) 
BV450 CD4 VioBlue 10 µl 
BV510 - - 
 
Table 3-6: Antibodies and volumes required for the T cell proliferation stain for humanized mouse splenocytes. 
Mouse T cell proliferation stain 
Excitation laser Fluorescence Channel Antibodies Volume per tube 
Blue laser 
(488 nm) 
FITC CFSE Pre-stained 
PE - - 
PerCP 7-AAD 5 µl 
PE-Cy7 CD4 PE-Vio770 2 µl 
Red laser 
(640 nm) 
APC CD25 APC 10 µl 
APC-Cy7 CD3 APC-Vio770 10 µl 
Violet laser 
(405 nm) 
BV450 Murine CD45 BV421 5 µl 
BV510 - - 
 
For staining, the cells were harvested in individual 1.5 ml reaction tubes and centrifuged at 300 x g 
for 5 minutes. The pellets were resuspended in 40 µl MACS Buffer and 5 µl FcR Blocking Reagent per 
tube. This step blocked all available Fc receptors on the surface of the cells, in order to prevent unspecific 
binding of the detection antibodies. During the incubation time of 10 minutes at 4 °C, FACS tubes were 
prepared. Each tube contained the antibodies for the given stain and was filled to 100 µl with PBS. After 
the incubation of the FcR Blocking reagent, 10 µl – 30 µl of each cell suspension were added to one of 
the prepared FACS tubes. The cells and antibodies were incubated for 10 minutes at 4 °C. Afterwards, 
the cells were washed with 1 ml PBS and centrifuged at 300 x g for 5 minutes. The supernatant was 
aspirated and the pellet was resuspended in 300 µl PBS. The cell suspension was analyzed using the 
FACSVerse. 
The FACSVerse was controlled by the software FACSuite. Using this software, an assay for each 
stain was designed, which contained the PMT voltages, flow rate and gating strategy. In addition to that, 
each assay contained the information for the compensation of the given antibodies in one stain. This 
ensured that the same parameters were applied to each analysis. All stains were automatically 
compensated by the software, except the T cell proliferation stain, which was not compensated. 
Automatic compensation was applied every 4 weeks or when a new batch of a tandem dye was used. 
The final data were evaluated using the software FlowJo X. 
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3.3.2. Cytokine array 
 
The human Th1/Th2/Th17 Antibody Array allows the simultaneous detection of 34 cytokines from 
cell culture supernatant. Antibodies against these cytokines are spotted to a membrane in duplicates 
(Figure 3-7). Upon sample application to the membrane, the cytokines are bound by these antibodies. 
The detection of the bound cytokines occurs via biotinylated detection antibodies for each cytokine, 
which are visualized via fluorescence labeled streptavidin. The membrane is analyzed using an Odyssey 
CLx imager. The imager excites the flurochromes and the emitted light is detected by photodiodes, which 
convert the light to an electrical signal. Using this system, a detection of secreted cytokines as well as a 
comparative quantification of the amount of the secreted cytokines is feasible. 
 
 A B C D E F G H I J K L 
1 Pos Pos Neg Neg CD30 CD40L CD40 GCSF GITR GM-CSF IFN-γ IL-1 sRI 
2 Pos Pos Neg Neg CD30 CD40L CD40 GCSF GITR GM-CSF IFN-γ IL-1 sRI 
3 IL-1 sRII IL-10 IL-12 p40 IL-12 p70 IL-13 IL-17 IL-17F IL-17R IL-1β IL-2 IL-21 IL-21R 
4 IL-1 sRII IL-10 IL-12 p40 IL-12 p70 IL-13 IL-17 IL-17F IL-17R IL-1β IL-2 IL-21 IL-21R 
5 IL-22 IL-23 p19 IL-28A IL-4 IL-5 IL-6 IL-6 sR MIP-3α sgp 130 TGF-β1 TGF-β3 TNF- α 
6 IL-22 IL-23 p19 IL-28A IL-4 IL-5 IL-6 IL-6 sR MIP-3α sgp 130 TGF-β1 TGF-β3 TNF- α 
7 TNF-β TRANCE Neg Neg Neg Neg Neg Neg Neg Neg Neg Pos 
8 TNF-β TRANCE Neg Neg Neg Neg Neg Neg Neg Neg Neg Pos 
Figure 3-7: Map of the spotted cytokines on the membrane of the human Th1/Th2/Th17 Antibody Array. 
 
The cytokine arrays were performed after all DC-T cell Assays were finished. Due to this a control 
was generated, in order to be able to compare the cytokine secretion of the T cells derived from different 
co-cultivations (3.2.4.8). The control was a mixture of all of the analyzed supernatants. This control was 
applied to every membrane in addition to the sample. Due to this, it was possible to normalize each 
sample to a given background. In order to be able to separate sample and control, the samples were 
labeled with streptavidin conjugated to the fluorochrome IRDye 800 whereas the control was labeled 
with streptavidin conjugated to the fluorochrome IRDye 680. 
At first each membrane was prepared by cutting off the edge with the dash mark and transferring 
the membrane to the provided tray. All membranes were handled with care, not touching the membrane 
directly, only by using forceps. 2 ml of Odyssey Blocking Buffer, containing 0.05 % Tween 20 were 
applied to each membrane. The membranes were incubated overnight at 4 °C on a shaking platform at 
50 rpm. The next day the biotin-conjugated anti-cytokine antibodies were reconstituted by adding 
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1460 µl of Odyssey Blocking Buffer, containing 0.05 % Tween 20 to one vial. Per two membranes one 
vial of anti-cytokine antibodies was reconstituted. Both Streptavidin-IRDye conjugates were diluted 
1:200 in Odyssey Blocking Buffer, containing 0.05 % Tween 20. Per two membranes a total of 100 µl of 
each conjugate was required. All supernatants were thawed at 37 °C. Afterwards, 100 µl of each sample 
were removed and pooled, in order to build the control. For each membrane 100 µl sample were mixed 
with 350 µl biotin-conjugated anti-cytokine antibodies and 50 µl streptavidin-IRDye 800. In parallel, 
100 µl control were mixed with 350 µl biotin-conjugated anti-cytokine antibodies and 50 µl streptavidin-
IRDye 680 for one membrane. As several samples were analyzed at once, the staining of the control 
occurred in a master mix staining the total volume of control needed in one vial. The staining of the 
samples occurred for 1 hour at room temperature. After the blocking, the buffer was aspirated from the 
membranes and 500 µl of the labeled sample and 500 µl of the labeled control were applied per 
membrane. The membranes were incubated for 45 minutes at room temperature on a shaking platform. 
Meanwhile the Wash Buffers I and II were diluted 1:20 with distilled water. After the incubation, the 
samples were decanted and the membranes were washed four times for 5 minutes with 2 ml of 1 x Wash 
Buffer I and two times for 5 minutes with 2 ml of Wash Buffer II. The membranes stayed in Wash Buffer II 
until they were scanned using the Odyssey CLx imager. Each scan had a resolution of 84 µm and no 
focus offset. Afterwards, the membranes were analyzed using the software ImageStudio.  
 
 
 
3.4. Coagulation-related assays 
 
 
3.4.1. Chromogenic FVIII activity assay 
 
The activity of FVIII was determined by a chromogenic assay. In this two-step assay, FIXa and 
FVIIIa activate FX in the first step. In the second step, the activated FX hydrolyses a chromogenic 
substrate, resulting in a color change, which can be measured at 405 nm. Due to the fact that calcium 
and phospholipids are present in optimal amounts and an excess of FIXa and FX is available, the 
activation rate of FX is only dependent on the amount of active FVIII in the sample.  
The reagents for this chromogenic FVIII activity assay were taken from the Coatest SP FVIII Kit. 
The kit contained phospholipids, calcium chloride (CaCl2), trace amounts of thrombin, the substrate S-
2765, a mixture of FIXa and FX and the thrombin inhibitor I-2581. The inhibitor was added, in order to 
prevent hydrolysis of the substrate by thrombin, which was build during the reaction. All dilutions were 
performed in distilled water or Tris-BSA (TBSA) Buffer, containing 25 mM Tris, 150 mM sodium chloride 
(NaCl) and 1 % Bovine serum albumin (BSA), set to pH 7.4. Each sample was diluted at least 1:2 with 
FVIII-depleted plasma. Further dilutions were performed using the TBSA Buffer. 
The assay was performed by the BCS XP, a fully automated hemostasis analyzer. All reagents 
including water, TBSA Buffer and the samples were inserted into the analyzer. For each sample the 
analyzer mixed 34 µl calcium chloride, 20 µl TBSA Buffer, 10 µl sample, 40 µl water, 11 µl phospholipids 
and 56 µl FIXa-FX-mixture. This mixture was incubated for 300 seconds. Afterwards, 50 µl of S-2765 + 
I-2581 were added to the reaction. Upon addition of the substrate, the absorption at 405 nm was 
measured for 200 seconds. Each sample was measured in duplicate. 
In order to calculate the amount of active FVIII, the software of the analyzer evaluated the slope 
of the measured kinetic between 30 seconds and 190 seconds after starting the reaction. This result was 
correlated to a calibration curve, generated with a biological reference preparation (BRP) of FVIII. The 
activity of the BRP is indicated in IU/ml. However, IU/ml can be assumed equivalent to U/ml. The results 
were indicated as “% of normal”. These results were converted to U/ml, as 100 % of normal FVIII activity 
are equivalent to 1 U FVIII activity per ml. 
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3.4.2. Clotting FVIII activity assay 
 
In addition to the two-stage chromogenic assay (3.4.1), a one-stage clotting assay was performed, 
in order to determine the amount of active FVIII. During this assay, FVIII-depleted plasma, CaCl2, the 
activator Actin FSL and the FVIII-containing sample are mixed in one step. The activator leads to the 
generation of FXIa, which activates FIX. FVIIIa, FIXa and FX built the tenase complex and FX becomes 
activated. Further activation of prothrombin and fibrinogen finally lead to the formation of a fibrin clot. 
The time needed to form the clot, the activated partial thromboplastin time (aPTT), is measured. The 
aPTT varies, depending on the amount of FVIII.  
The clotting assay was performed by the BCS XP. TBSA Buffer, FVIII-depleted plasma, Actin FSL, 
CaCl2 and the sample were inserted into the analyzer. The sample was diluted at least 1:2 with FVIII-
depleted plasma. Further dilutions were performed using the TBSA Buffer. For each sample the analyzer 
mixed 45 µl TBSA Buffer, 5 µl sample, 50 µl FVIII-depleted plasma and 50 µl Actin FSL. The reaction was 
started by the addition of 50 µl CaCl2. The analyzer measured the time needed for clot formation.  
In order to calculate the amount of active FVIII, the software of the analyzer evaluated a baseline 
extinction at 405 nm at the beginning of the reaction. All of the following extinction values, within a 
time of 200 seconds, were analyzed regarding their difference to the baseline extinction. The first time 
point exceeding a defined threshold was determined as the clotting time. This result was correlated to a 
calibration curve, generated with a BRP of FVIII. 
 
 
3.4.3. FVIII antigen ELISA 
 
The amount of FVIII antigen was determined using the Asserachrom VIII:Ag ELISA. In this 
sandwich ELISA, the applied FVIII is bound by mouse monoclonal anti-human FVIII F(ab’)2 fragments, 
which are coated to the plate by the manufacturer. The detection of the bound FVIII occurs via mouse 
monoclonal anti-human FVIII antibodies, which are coupled to a peroxidase. In the case that FVIII is 
present, the peroxidase-coupled antibody binds to FVIII and can be detected by the addition of a 
tetramethylbenzidine (TMB) solution. TMB turns from a clear to a blue-green solution upon reaction 
with peroxidase. After a short time, this reaction is stopped by the addition of sulfuric acid (H2SO4), 
which turns the solution yellow (Figure 3-8). The amount of bound FVIII correlates with the intensity of 
the yellow color, which can be measured at 450 nm. The final amounts of FVIII are calculated using a 
calibration curve generated by the measurement of at least five serial dilutions of a calibrator with a 
known antigen concentration. 
 
 
Figure 3-8: FVIII antigen ELISA. The applied FVIII is bound by the coated anti-FVIII F(ab‘)2 fragments. Bound FVIII is detected by 
peroxidase-coupled anti-FVIII IgGs. The added TMB solution turns blue-green upon reaction with the peroxidase. The addition 
of sulfuric acid stops the reaction and turns the solution yellow. 
 
The supplied calibrator and control were reconstituted with 500 µl of distilled water, 30 minutes 
before starting the ELISA. After this incubation time, the calibrator was diluted 1:10 in the supplied 
phosphate buffer. This represented the starting concentration. The calibrator was further serially diluted 
1:2 up to a dilution of 1:64. As the concentration of the calibrator contained approximately 1 U/ml FVIII, 
depending on the batch, the starting concentration was equivalent to 0.1 U/ml FVIII whereas the last 
dilution contained approximately 0.0016 U/ml FVIII. The control was diluted 1:10 and 1:20 with the 
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phosphate buffer. All samples were diluted with the phosphate buffer, depending on their previously 
determined activity (3.4.1) with the aim to be in the middle of the calibration curve. After the dilution 
of FVIII samples, control and calibrator, 200 µl of each solution were applied per well in duplicates. In 
addition to that, two wells were filled with 200 µl of phosphate buffer as a blank control. The plate was 
incubated for 2 hours at room temperature covered with a film. During this time, the peroxidase-coupled 
anti-human FVIII antibodies were reconstituted with 8 ml phosphate buffer and incubated 30 minutes at 
room temperature. After the antigen immobilization, the wells were washed five times with the supplied 
washing solution, which was previously diluted 1:20 with distilled water. Immediately after the washing, 
200 µl of the peroxidase-coupled anti-human FVIII antibodies were added to each well and incubated 
for 2 hours at room temperature covered by a film. Afterwards, the plate was washed five times as before. 
In order to reveal the amount of bound FVIII, 200 µl of TMB solution were added to each well and 
incubated for exact 5 minutes at room temperature. This reaction was stopped by the addition of 50 µl 
1 M H2SO4 to each well. After an incubation time of 15 minutes at room temperature, the absorbance of 
each well was measured at 450 nm using the POLARstar Omega plate reader. 
The results of the ELISA were calculated using the MARS software. In a first step, all wells were 
blank corrected and the mean of the duplicates was calculated. Afterwards, a 4-parameter fit was 
applied, in order to calculate the concentrations from the calibration curve. According to this calibration 
curve the amount of FVIII antigen in each well was determined. In the last step, the values were corrected 
by the dilution factor, resulting in the FVIII antigen amount of each sample. 
 
 
3.4.4. vWF-binding ELISA 
 
In order to determine the binding of a FVIII sample to vWF, a vWF-FVIII ELISA was performed. In 
this ELISA, vWF is coated to the wells of a 96-well plate. FVIII samples are added to this plate in serial 
dilutions. As a control an authorized FVIII product known to bind to vWF is additionally applied. The 
bound FVIII is detected using the Coatest SP Factor VIII Kit, which is also used for the chromogenic 
determination of FVIII activity (3.4.1). The absorbance is measured at 405 nm and relative vWF binding 
is calculated using a Parallel-Line-Assay (PLA) software. 
In the first step, the vWF was diluted to a concentration of 0.1 U/ml with a 0.9 % sodium chloride 
solution. 100 µl were applied to each well of the plate. The plate was incubated at 37 °C and 400 rpm 
for 2 hours covered by a film. Meanwhile the Wash Buffer was prepared by dilution of the 20 x PBS 
Tween 20 Buffer to a 1 x solution with distilled water. Additionally, a Dilution Buffer, containing 25 mM 
Tris and 150 mM NaCl, was prepared in distilled water and adjusted to pH 7.4. The samples and the 
control ReFacto AF were diluted to 0.25 U/ml with this Dilution Buffer, depending on their previously 
determined or indicated chromogenic activity (3.4.1). After the coating, the plate was washed three 
times with 300 µl Wash Buffer per well. Immediately after the washing, the samples were applied to the 
plate. 200 µl of sample were applied per well and each sample was analyzed in duplicate. The samples 
were only applied to the first row of the plate. All remaining wells were filled with 100 µl of the Tris-
NaCl Buffer. Afterwards, 100 µl of each well of the upper row were transferred to the well below, 
generating a 1:2 dilution. This serial dilution was continued to the second last row, resulting in seven 
serial 1:2 dilutions. From the wells of the seventh row 100 µl of sample were discarded, in order to have 
the same volume in each well. The last row contained only 100 µl of Dilution Buffer. The plate was 
incubated at 37 °C and 400 rpm for 1 hour covered with a film. During the incubation, the Coatest SP 
FVIII Kit was reconstituted. 10 ml distilled water were added to the FIXa + FX mixture, whereas 12 ml 
distilled water were added to the substrate-inhibitor mixture S-2765 + I-2581. The POLARstar Omega 
plate reader was set to 37 °C. After the incubation, the plate was washed three times as described before. 
Not until the last washing step, 5 ml of the FIXa + FX solution were mixed with 1 ml of phospholipids. 
50 µl of this mixture were applied to each well. The incubation time was 5 minutes at 37 °C and 400 rpm 
covered by a film. Afterwards, 25 µl CaCl2 were added to each well and the plate was incubated at the 
same conditions for 5 minutes. In the last step 50 µl of S-2765 + I-2581 were added to each well and the 
absorbance at 405 nm was measured immediately in the plate reader for a total of 490 seconds. 
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The analysis of the data was performed using the PLA software. This software performed a 4-
parameter fit, resulting in a sigmoidal dose-response correlation curve for each measured FVIII product. 
The different curves were compared to the curve representing the standard. In order to compare only 
parallel graphs, the highest and the lowest value for each curve were not taken into the analysis. Based 
on this, a vWF-binding potency of the FVIII products in relation to the standard was calculated. 
 
 
3.4.5. Thrombin Generation Assay 
 
The Thrombin Generation Assay (TGA) determines the amount of generated thrombin over time 
in plasma samples. The clotting cascade in the sample is initiated by the addition of phospholipids, 
calcium chloride and tissue factor. The generated thrombin finally cleaves an artificial substrate, which 
emits light at 460 nm upon cleavage. Due to this, the amount of generated thrombin can be correlated 
to the fluorescence intensity based on a standard curve. As nearly the complete clotting cascade takes 
place in the TGA, the assay is utilized, in order to determine various coagulation deficiencies and to 
monitor coagulation-related therapies. 
The assay was performed using the Technotrombin TGA reagents comprising the TGA calibrator 
set, containing buffer and thrombin calibrator, the fluorogenic TGA substrate and the TGA reagent C 
low. The TGA substrate contained calcium chloride and the fluorogenic substrate, whereas the TGA 
reagent C low contained low concentrations of phospholipid micelles with TF. In order to generate a 
calibration curve, the calibrator was diluted 1:2, 1:2.5, 1:3, 1:6, 1:10, 1:20 and 1:200 in the provided 
buffer. The FVIII samples were diluted to 0.25 U/ml, 0.063 U/ml and 0.016 U/ml in FVIII-deficient 
plasma, based on their previously determined activity (3.4.1). The samples were pipetted into black 96-
well plates with transparent bottom. 40 µl of either the different calibrator dilutions or the FVIII samples 
were applied per well. The calibrator dilutions were measured in duplicates and the FVIII samples were 
measured in triplicates. The substrate and the reagent C low were mixed in a ratio of 5:1 immediately 
prior to starting the reaction. The substrate-reagent-mixture and the plate were placed into the 
POLARstar Omega plate reader. The reader was set to pipet 60 µl of substrate-reagent mixture to each 
well. Afterwards the plate was incubated for 5 minutes. Then the generated fluorescence was measured 
for 75 cycles every 90 seconds at 460 nm. 
Due to the known amount of thrombin in the calibrator, a calibration curve was generated with 
the MARS software after the measurement. A 4-parameter fit was applied, in order to calculate the 
concentrations from the calibration curve. Based on this the amount of generated thrombin was 
calculated for each sample. In order to calculate the area under the curve and the time to maximum 
thrombin generation, the first deviation of the measured curve was calculated using GraphPad Prism. 
 
 
3.4.6. Thromboelastometry 
 
Thromboelastometry (TEM) is a method for hemostasis testing, revealing various parameters like 
clotting time, clot formation time and maximum clot firmness. The sample is applied to a cup and a pin 
is set into the middle of the cup. The sample lies in the space between cup and pin. The pin rotates and 
its rotation is monitored by a light beam, which is reflected from the pin onto a detector. Upon the onset 
of coagulation, the generated clot restricts the movement of the pin up to a maximum when the final 
clot is formed. When performing the experiment over a longer time also lysis parameters can be 
determined, as the movement of the pin starts to increase again when the clot is lysed. Due to this 
detected pin movements, the different parameters can be calculated and displayed in a curve. 
In order to determine the clotting time for the different FVIII variants, the TEM was performed 
using the rotation TEM (ROTEM) system. The clotting was initiated using the in-tem and star-tem 
reagents, which mimic an intrinsic activation. In-tem contained the partial thromboplastin phospholipid 
whereas the star-tem contained the calcium chloride needed for activation. The FVIII samples were 
diluted to 1 U/ml, 0.2 U/ml, 0.1 U/ml, 0.05 U/ml and 0.01 U/ml in FVIII-deficient plasma, based on 
their previously determined chromogenic activity (3.4.1). Each concentration was measured in 
 Methods  45 
duplicate. All reagents and samples were set to 37 °C prior to starting the experiment. The reagents were 
mixed directly in the cup by pipetting 20 µl star-tem reagent and 20 µl in-tem reagent. Afterwards 300 µl 
of FVIII sample were added. The regents were mixed by pipetting. The mixture was set into the ROTEM 
system and the measurement was started immediately. Four reactions were measured in parallel. The 
analysis was performed for 30 minutes and stopped afterwards, as only clotting parameters were 
required. The determined clotting times for the different samples and dilutions were directly taken from 
the ROTEM system. 
 
 
 
3.5. Protein analytics 
 
 
3.5.1. Fast protein liquid chromatography 
 
Fast protein liquid chromatography (FPLC) was used to purify FVIII from cell culture supernatant. 
Liquid chromatography is based on the principle of a mobile phase passing through a stationary phase. 
The mobile phase is the buffer and the stationary phase consists of chromatography beads, which build 
the resin of the chromatography column. Different kinds of chromatography, like ion exchange 
chromatography (IEX) or affinity chromatography (AC), can be performed. However, all 
chromatographic methods utilize the different protein properties between required and contaminating 
proteins for purification. 
In order to purify FVIII, a combination of chromatographic methods was applied. The first step 
was an IEX, using the strong anion exchange columns HiTrap Capto Q. This strong anion exchange 
chromatography (SAEx) separates proteins due to their surface charge. Negatively charged proteins bind 
to the positively charged linkers, which are coupled to the agarose matrix of the column (Figure 3-9). 
Elution of the bound proteins occurs using either a buffer with increased salt concentrations or a change 
in the pH of the buffer. IEX is suitable for high volumes and leads to a concentration of the sample. 
 
 
Figure 3-9: Anion exchange chromatography. Negatively charged proteins bind to the positively charged resin. Positively 
charged proteins flow through. 
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During FVIII purification, SAEx was used, in order to remove host cell proteins and to concentrate 
the sample. The cell culture supernatant was adjusted to pH 7.2 prior to purification. By combining five 
HiTrap Capto Q columns, leading to a total column volume (CV) of 25 ml, up to 375 ml of supernatant 
were purified, corresponding to 15 x CV. Prior to the application of the supernatant, the column was 
washed with 5 CV of SAEx Equilibration Buffer, containing 100 mM NaCl, 20 mM CaCl2, 20 mM L-
Histidine and 0.02 % Tween 80 at pH 7.5. The supernatant was applied to the column at a flow rate of 
5 ml/min. Afterwards, the column was washed with 3 CV SAEx Equilibration Buffer, in order to wash 
out unbound proteins. The elution of bound proteins occurred by switching to the SAEx Elution Buffer, 
containing 1 M NaCl, 20 mM CaCl2, 20 mM L-Histidine and 0.02 % Tween 80 at pH 6.0. A total of 6 CV 
SAEx Elution Buffer were applied to the column at 5 ml/min and the flow through was fractionated in 
12.5 ml. Depending on the chromatogram, the fractions containing the eluted proteins were pooled. In 
the case of starting volumes larger than 375 ml, the columns were equilibrated again and the process 
was repeated. All elutions were combined and further purified using a second chromatography. 
The second step was an AC, using a column packed with VIIISelect resin. During AC, the protein 
of interest is specifically and reversibly bound to a ligand, which is coupled to the matrix of the column 
(Figure 3-10). The bound protein is eluted using a buffer, which either contains a competitive ligand or 
which leads to conditions that impair binding, like variations in the pH. 
 
 
Figure 3-10: Affinity chromatography. The protein of interest is specifically bound by antibodies coupled to the resin. Proteins 
not bound by the antibody flow through. 
 
During the AC, FVIII was specifically bound by Camelidae-derived, single domain antibody 
fragments, which were coupled to an agarose matrix. This AC was applied, in order to specifically purify 
FVIII and to further concentrate the protein. The VIIISelect column comprised 0.94 ml of column volume 
and was run with a maximum flow rate of 2.5 ml/min. The column was equilibrated with 5 CV of 
VIIISelect Equilibration Buffer, containing 300 mM NaCl, 20 mM CaCl2, 10 mM L-Histidine and 0.02 % 
Tween 80 at pH 7.0. The eluted sample from the SAEx chromatography was diluted 1:2 with VIIISelect 
Equilibration Buffer and adjusted to pH 7.0. The sample was loaded to the column at a flow rate of 
2.5 ml/min. In order to remove unbound proteins, the column was washed after the sample application 
with 5 CV VIIISelect Wash Buffer, containing 1 M NaCl, 20 mM CaCl2, 20 mM L-Histidine and 0.02 % 
Tween 80 at pH 6.5. The bound FVIII was eluted from the column by 17.5 CV of VIIISelect Elution Buffer, 
containing 1.5 M NaCl, 20 mM CaCl2, 20 mM L-Histidine, 50 % ethylene glycol and 0.02 % Tween 80 at 
pH 6.5. The eluted protein was collected in fractions of 5 ml. As for the SAEx chromatography, the 
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fractions revealing a protein elution in the chromatogram were pooled. This sample, containing purified 
FVIII, was either directly applied to the last column or stored at -80 °C until further processing. 
The last step during FVIII purification was a buffer exchange by size exclusion chromatography 
(SEC), using the HiTrap Desalting columns. During SEC no binding of the applied proteins occurs. The 
chromatography is based on the different sizes of the applied substances. Whereas large proteins can 
migrate alongside the dextran beads of the matrix, small molecules, like salts, enter the beads, leading 
to a longer retention time in the column (Figure 3-11). In the case of a buffer exchange, the column is 
equilibrated with the new buffer and the old buffer with the protein is applied to the column. Due to 
their large size, proteins pass the column quickly and are eluted together with the new buffer, whereas 
the components of the old buffer reside in the column. 
 
 
Figure 3-11: Size exclusion chromatography. Larger proteins pass alongside the particles of the resin and elute earlier compared 
to smaller molecules, which enter the particles, leading to a longer retention time in the column. 
 
This step was applied during FVIII purification, in order to transfer the FVIII from the AC Elution 
Buffer into the FVIII Formulation Buffer, containing 205 mM NaCl, 5.3 mM CaCl2, 6.7 mM L-Histidine, 
1.3 % Sucrose and 0.013 % Tween 20 at pH 7.0. Four HiTrap Desalting columns were combined resulting 
in a total column volume of 20 ml, in order to exchange the buffer of 6 ml purified FVIII. The column 
was equilibrated with 5 CV FVIII Formulation Buffer at a flow rate of 5 ml/min. Afterwards, 6 ml of the 
FVIII sample were applied to the column. The elution occurred with 0.5 CV FVIII Formulation Buffer. 
The flow through of the column was fractionated in 2 ml fractions. The fractions revealing a high 
ultraviolet (UV) peak and a stable conductivity peak in the chromatogram were pooled. In the case of 
more than 6 ml initial volume, the column was equilibrated again with FVIII Formulation Buffer and the 
process was repeated until the whole FVIII sample was transferred to FVIII Formulation Buffer. 
In the case of a low FVIII concentration after the buffer exchange, the sample was concentrated 
using Amicon Centrifugal Filters with a molecular weight cut-off of 10 kDa. These filters are placed into 
a 50 ml conical tube and, due to centrifugation, all molecules smaller than 10 kDa pass the membrane. 
Depending on the length of centrifugation, the sample can be concentrated up to 80-fold. In order to 
concentrate the purified FVIII sample, 15 ml were applied to one column and centrifuged at 4000 x g for 
20 minutes. In the case of sample volumes larger than 15 ml, the column was refilled with sample 
solution after the first centrifugation and the process was repeated. When the preferred FVIII 
concentration was reached, the sample was transferred from the filter to cryovials and stored at -80 °C. 
In order to monitor the purification process, samples were taken from every step, including wash 
and flow through of each column. The amount of active FVIII was determined for every sample in parallel 
to the purification (3.4.1). After the purification, all samples were also applied to a sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and a Western Blot (3.5.2 and 3.5.3), in order 
to visualize the increasing grade of purity and possible changes in the structure of the protein. 
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3.5.2. SDS-PAGE 
 
Proteins can be separated depending on their size in a SDS-PAGE. During sample preparation, the 
proteins are mixed with dithiothreitol (DTT) and sodium dodecyl sulfate (SDS). DTT reduces disulfide 
bonds and destroys the tertiary structure of the protein, whereas SDS binds to the proteins. Due to the 
negative charge of SDS, the binding results in negatively charged, denatured proteins. The prepared 
proteins are applied to a Bis-Tris polyacrylamide gel, consisting of a stacking gel and a separating gel. 
Upon voltage application, the negatively charged proteins move towards the anode. In the stacking gel 
the proteins travel between chloride (Cl-) leading ions from the gel buffer and 3-(N-morpholino) propane 
sulfonic acid (MOPS) trailing ions from the running buffer. This step concentrates all proteins to a small 
region until they reach the separating gel. In this separating gel the former leading and trailing ions 
quickly move to the anode, due to their small size, and the proteins are separated depending on their 
size. Smaller proteins can move faster than larger proteins, resulting in various bands, each representing 
proteins of a specific size. After the SDS-PAGE, the proteins are either visualized by staining with 
Coomassie solution or blotted to a membrane and specifically labeled with antibodies (3.5.3). 
All SDS-PAGE were performed using the NuPage system with pre-cast 4-12 % Bis-Tris gels. Each 
sample was diluted 1:2 with 2 x Loading Buffer, consisting of lithium dodecyl sulfate (LDS) Sample 
Buffer, Reducing Agent, containing DTT, and distilled water. In the case of further dilution of the sample, 
this was performed using 1 x Loading Buffer. The samples were incubated at 70 °C for 10 minutes. The 
pre-cast gels were set into the XCell SureLock Mini-Cell electrophoresis chamber. The upper and lower 
buffer chambers were filled with 1 x MOPS SDS Running Buffer. Additionally, 500 µl Antioxidant were 
added to the upper chamber. The samples were applied to the wells of the gel, 10 µl per well. In addition 
to the samples, 4 µl of Precision Plus Protein All Blue Standard was applied to at least one well. The 
standard was diluted 1:10 with 1 x Loading Buffer. The chamber containing the gel was connected to 
the power supply and run at 200 V for 50 minutes. Afterwards, the gel was taken from its plastic cover 
and either stained with Coomassie or transferred to a membrane (3.5.3). 
 In the case of Coomassie staining, the gel was rinsed in water and transferred to Imperial Protein 
Stain Solution, containing Coomassie Brilliant Blue R-250. The gel was incubated overnight at room 
temperature on a shaking platform. Coomassie Brilliant Blue R-250 bound to the basic amino acids of 
the proteins in the gel. Excessive Coomassie was washed away by incubation of the gel in distilled water 
for 1 hour on a shaking platform. The washing step was performed twice. In the last step, the stained 
gel was scanned using the Odyssey CLx imager at a resolution of 86 µm and a focus offset of 0.5 mm. 
 
 
3.5.2.1. Thrombin-activation of FVIII for SDS-PAGE 
 
In order to determine whether the FVIII variants can be activated, the samples were incubated 
with thrombin prior to a SDS-PAGE. The FVIII samples were diluted to 20 U/ml in Thrombin-activation 
Buffer, containing 20 mM Tris and 150 mM NaCl at pH 7.5. The thrombin solution was diluted from 
1000 U/ml to 10 U/ml in the same buffer and warmed to 37 °C. Afterwards, 50 µl of FVIII were 
transferred to 1.5 ml tubes, placed in a 37 °C ThermoMixer. 50 µl thrombin solution were added to each 
tube and incubated for 8 minutes at 37 °C. In order to stop the reaction, 100 µl 2x Loading Buffer were 
added to each reaction and incubated for 10 minutes at 70 °C, as described for sample preparation in 
3.5.2. The non-activated control samples were treated in the same way, except that no thrombin was 
added. The samples were further processed as described in 3.5.2. 
 
 
3.5.2.2. Deglycosylation of FVIII for SDS-PAGE 
 
In order to determine whether the produced FVIII was glycosylated, a SDS-PAGE was performed 
containing every sample in its original form and in a deglycosylated form. For deglycosylation 40 µl of a 
20 U/ml FVIII sample were incubated with 5 µl of Deglycosylation Mix Buffer 2 and incubated for 
10 minutes at 75 °C. After the reaction was cooled to room temperature, 0.1 µl Nonidet P-40 and 5 µl N-
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Glycosidase F were added. N-Glycosidase F removes all asparagine-bound glycosylations. The reaction 
was at first incubated at room temperature for 25 minutes and afterwards for 1 hour at 37 °C. In the last 
step 30 µl 20 % SDS were added. The original samples were treated in the same way, except that no N-
Glycosidase F was added. The samples were further processed as described in 3.5.2. 
 
 
3.5.3. Western Blot 
 
During Western Blotting, proteins separated by SDS-PAGE (3.5.2) are transferred to a 
nitrocellulose membrane, in order to detect them with specific antibodies. The proteins are transferred 
from the gel to the membrane by an electric field. As in the PAGE, the negatively charged proteins 
migrate towards the anode. The membrane is a barrier for further migration and the proteins bind to 
the membrane. After blotting, the membrane is blocked to prevent unspecific binding of the detection 
antibodies. These antibodies are applied, in order to bind to the blotted proteins. The primary antibody 
specifically binds the protein of interest, whereas the secondary antibody is coupled to a fluorochrome 
and binds to the primary antibody. The bound antibodies can be detected by an imager. 
Western Blots were performed using the XCell II Blot Module. A nitrocellulose membrane was 
activated by incubation in distilled water followed by incubation in 1 x Western Blot Buffer, consisting 
of the commercially available Transfer Buffer, 10 % methanol, 0.1 % Antioxidant and distilled water. 
Filter papers and sponges were also soaked in Western Blot Buffer. The gel from the SDS-PAGE (3.5.2) 
was transferred to a filter paper. The membrane was applied to the other side of the gel and covered 
with a filter paper. This was placed between soaked sponges and into the Blot Module. Western Blot 
Buffer was applied to the upper chamber and water for cooling to the lower chamber. The Blot Module 
was connected to the power supply and run at 30 V for 1 hour. Afterwards, the membrane was rinsed in 
distilled water and transferred to Blocking Buffer. Blocking was performed overnight at 4 °C. The next 
day the Blocking Buffer was decanted and 15 ml Blocking Buffer, containing 0.05 % Tween 20 and the 
primary antibody, were added to the membrane (Table 3-7). The primary antibody was incubated for 1 
hour on an orbital shaking platform at room temperature.  
 
Table 3-7: Primary and corresponding secondary antibodies used for Western Blot. 
Primary antibody Secondary antibody 
Antibody Dilution Antibody Dilution 
Sheep anti-human Factor VIII:C 
Antibody 
1:5000 
Donkey anti-sheep IgG IRDye 800CW 
or 
Donkey anti-sheep IgG CF680 
1:15 000 
 
1:15 000 
Rabbit anti-human Factor VIII 
Antibody, heavy chain 
1:1000 Donkey anti-rabbit IgG IRDye 800CW 1:15 000 
Mouse anti-human Factor VIII 
Antibody, light chain 
1:2500 Donkey anti-mouse IgG IRDye 680RD  1:15 000 
Mouse anti-human Sulfotyrosine 
Antibody 
1:1000 Donkey anti-mouse IgG IRDye 800CW 1:15 000 
 
Afterwards, the membrane was washed four times 5 minutes with PBS, containing 0.1 % 
Tween 20, on a shaking platform. The secondary antibody was also applied diluted in 15 ml Blocking 
Buffer, containing 0.05 % Tween 20, and incubated for 1 hour on an orbital shaking platform (Table 
3-7). The four washing steps were performed as before. Afterwards, two additional washing steps with 
PBS were performed for 5 minutes each. In the last step, the membrane was washed in distilled water 
and afterwards dried between filter paper. The dried membrane was scanned with the Odyssey CLx 
imager at a resolution of 86 µm and a focus offset of 0.02 mm. 
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3.5.4. 2D-DIGE 
 
In order to gain a more detailed insight into the differences of distinct rFVIII proteins, a two-
dimensional difference gel electrophoresis (2D-DIGE) was performed. The 2D gel electrophoresis (2D-
GE) separates proteins not only by their molecular weight but also by their isoelectric point (pI). The 
first dimension of separation is the isoelectric focusing (IEF) along an immobilized pH gradient. The 
second dimension is a SDS-PAGE as described in 3.5.2. In addition to that, for a 2D-DIGE the proteins 
were previously labeled with different fluorescent CyDye DIGE Fluor minimal dyes. This allows 
multiplexing of up to three proteins on one gel. Using this method, similarities and differences in diverse 
FVIII products can be directly detected by overlapping and not overlapping fluorescence signals. 
The proteins used for 2D-DIGE were precipitated in the first step, using the 2-D Clean-Up Kit, in 
order to concentrate the proteins and to remove detergents, salts and other impurities. For one 2D-DIGE 
5-10 µg of each FVIII product were precipitated. The different FVIII products were kept separate during 
precipitation. In the case that the required volume of a FVIII product exceeded 100 µl, the sample was 
split into 100 µl aliquots in sterile 1.5 ml reaction tubes. In the first step 300 µl of precipitant solution 
were added to each tube, vortexed and incubated on ice for 15 minutes. Afterwards, 300 µl of a co-
precipitant solution were added to each tube, mixed and centrifuged at 30 000 x g for 5 minutes at 4 °C. 
The supernatant was carefully removed and the tubes were centrifuged again briefly to bring down the 
remaining supernatant. When the whole supernatant was removed, 40 µl of co-precipitant solution were 
added to each pellet without disturbing the pellet and incubated on ice for 5 minutes. Subsequently the 
tubes were centrifuged at 30 000 x g for 5 minutes at 4 °C. The supernatant was carefully removed and 
25 µl of distilled water were added to each pellet. The tubes were vortexed for at least 10 seconds and 
afterwards 1 ml of chilled Wash Buffer plus 5 µl of wash additive were added to each tube. The tubes 
were incubated at -80 °C overnight and vortexed after 30 minutes and 2 hours of incubation. After the 
precipitation, the tubes were centrifuged at 30 000 x g for 5 minutes. The supernatant was removed and 
the pellets were dried. 
The precipitated proteins were immediately labeled, using the CyDye DIGE Fluor Minimal Labeling 
Kit when combining three proteins per DIGE or DY-680-Ester and DY-780-Ester when combining two 
proteins per DIGE. The flurochromes covalently bind to the amino group of lysine. Due to the limiting 
amount of dye only 1-2 % of all lysines are labeled. This ensures that only one lysine per protein is 
labeled and the molecular weight of the protein is only altered by 500 Da, which does not alter the 
protein pattern in the SDS-PAGE. Additionally, each dye carries a +1 charge, in order to replace the +1 
charge of the bound lysine. This ensures no alteration in the pI of the protein. The pellets were 
resuspended in Lysis Buffer, containing 30 mM Tris, 7 M Urea, 2 M Thiourea and 4 % CHAPS at pH 8.5. 
Each FVIII was resuspended in a final volume of 25 µl Lysis Buffer when combining two proteins per 
DIGE or 17 µl Lysis Buffer when combining three proteins per DIGE. If one FVIII product was precipitated 
in more than one tube, the resuspended FVIII was pooled by transferring the Lysis Buffer from one tube 
to the next. In order to label the proteins, the dye stock solutions were diluted to a final concentration 
of 400 pM, by adding 1 volume of dye stock solution to 1.5 volumes anhydrous DMSO. The amount of 
added dye was calculated for each protein, as 1 µl of 400 pM dye solution was added to 50 µg of protein. 
After the addition of the dyes, the FVIII samples were incubated on ice for 30 minutes. In order to stop 
the labeling reaction, an equal amount of lysine was added and the samples were incubated on ice for 
20 minutes. The differently labeled FVIII samples were pooled afterwards, leading to a total volume of 
75 µl. 
In order to prepare the sample for isoelectric focusing, 75 µl of Sample Rehydration Buffer were 
added. This buffer contained 7 M Urea, 2 M Thiourea, 2 % CHAPS, bromophenol blue and freshly added 
20 mM DTT and 1 % IPG Buffer pH 4-7. Afterwards, the sample was applied to one lane in the IPGbox 
and an Immobiline DryStrip pH 4-7, was laid on top, with the gel side facing towards the sample. The 
DryStrip was rehydrated overnight. The next day the rehydrated strip was transferred to the Ettan 
IPGphor 3 system and isoelectric focusing was started. The program began with a holding step at 50 V 
for 15 hours, in order to perform the IEF overnight. In the second step, the voltage was set to 300 V and 
kept for 50 minutes. This was followed by the first gradual increase of voltage from 300 V to 1000 V in 
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50 minutes. The second gradual increase was from 1000 V to 5000 V in 2 hours and 20 minutes. In the 
last step the 5000 V were kept for 5200 Vh. Afterwards, the program was automatically stopped. 
After the first dimension of IEF, the strip was prepared for the transfer to a NuPage 4-12 % Bis-
Tris ZOOM Gel. The strip was taken from the IPGphor and transferred to a 15 ml conical tube. 5 ml of 
reducing SDS-PAGE Sample Buffer were added, consisting of 1 x LDS Sample Buffer, 1 x reducing agent 
and distilled water. After 15 minutes of incubation on a rocking platform, the SDS-PAGE Sample Buffer 
was removed and 5 ml of 125 mM iodoacetamide in 1 x LDS Sample Buffer were added to the strip and 
incubated for 15 minutes on a rocking platform. Prior to the transfer of the IEF strip to the gel, the strip 
was carefully washed in distilled water to remove remaining buffer. The strip was transferred to the gel 
and fixed by the addition of a 0.5 % agarose solution. Afterwards, the SDS-PAGE was performed as 
described in 3.5.2, using MOPS Buffer. The gels were scanned after the SDS-PAGE, using the Typhoon 
Imager. 
In the case that only two samples were applied to the 2D-DIGE and only two colors were used for 
labeling, the gel was blotted after scanning, as described in 3.5.3. The blotted proteins were stained 
afterwards, using a polyclonal anti-FVIII primary antibody and a secondary antibody coupled to the 
fluorochrome CF488 A (Table 3-8). The Blot was scanned using the Typhoon imager.  
 
Table 3-8: Primary and corresponding secondary antibody used for Western Blot of a 2D-GE. 
Primary antibody Secondary antibody 
Antibody Dilution Antibody Dilution 
Sheep anti-human Factor VIII:C 
Antibody 
1:5000 Donkey anti-sheep IgG CF488A 1:15 000 
 
 
 
3.6. Mouse studies 
 
 
3.6.1. In vivo experiments  
 
 
3.6.1.1. Immunization of humanized mice 
 
The generation of human immune system (HIS) mice and the immunization of the mice with FVIII 
was performed by Axenis. The utilized mice were BRGSF-A2 (BALB/c Rag2-/- IL-2RγC-/- SIRPαNOD Flk2-/-
TgHLA-A2) mice. Due to genetic modifications this mouse strain is transgenic for HLA-A2212 and supports 
the development of a human immune system. Knockouts of the recombination activating gene 2 (Rag2) 
and the IL-2 receptor gamma chain (IL-2Rγc) gene prevent the generation of murine T, B and natural 
killer (NK) cells213. An additional knockout of the fetal liver kinase-2 (Flk2) gene (also fms like tyrosine 
kinase 3 (Flt3)) reduces the amount of murine DCs196,214. The introduction of the signal regulatory 
protein α (SIRPα) gene from non-obese diabetic (NOD) mice (SIRPαNOD) results in murine macrophages 
tolerating human hematopoietic cells. This is due to a proper interaction between SIRPα on the murine 
macrophages and CD47 on human T and NK cells, inhibiting phagocytosis215. 
The newborn mice were sublethally irradiated and 24 hours after the irradiation intra-hepatically 
transplanted with 1·105 human hematopoietic progenitor cells (Figure 3-12). The transplanted 
progenitor cells were purified CD34+ cells derived from human umbilical cord blood196. Three different 
donors were used for the study. After the stem cell transplantation, the mice were treated with Flt3-
Ligand and plasmids coding for IL-4 and GM-CSF were delivered hydrodynamically to promote the 
generation of human monocytes, macrophages and DCs196,216. All the genetic variations, the treatment 
and the stem cell transplantation led to mice, which express human APCs, T, B and NK cells. After the 
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last treatment with Flt3-Ligand, the immunization with FVIII was started. FVIII was applied 
intravenously at 200 U/kg per mouse. The FVIII amounts were based on the chromogenic activity values 
of each variant. Four injections were administered within an interval of one week. On day 36, a final 
application of 400 U/kg FVIII was injected per mouse. Three days after the last FVIII injection the mice 
were euthanized and plasma and spleen were harvested and cryopreserved at -150 °C (Figure 3-12). The 
plasma was further analyzed in an ELISA detecting antibodies against the FVIII, as described in 3.6.2.3. 
The splenocytes were isolated and restimulated with FVIII, in order to detect whether CD4+ T cells 
against FVIII evolved during the immunization (3.6.2.1 and 3.6.2.2). 
 
 
Figure 3-12: Immunization scheme of humanized mice. The newborn mice were sublethally irradiated and intra-hepatically 
injected with CD34+ stem cells. The HIS mice were further treated with Flt3-L and plasmids coding for GM-CSF and IL-4. On day 
8, 15, 22 and 29 after the first Flt3-L treatment, 200 U/kg FVIII were injected. On day 36 400 U/kg FVIII were injected. The study 
ended at day 39. 
 
 
3.6.1.2. Immunization of FVIII-deficient mice 
 
The immunization and analysis of FVIII-deficient mice was performed by EpiVax. The mice were 
Exon 16 (E16) FVIII knockout (KO) mice. This mouse model is based on a C57BL/6 mice background. 
Blastocysts of these mice were injected with embryonic stem cells of 129S4/SvJae mice, containing the 
E16 disruption, leading to a knockout of the FVIII gene. Immunization occurred four times every 7 days 
with 4 U FVIII per mouse or FVIII Formulation Buffer via intravenous injection. The last FVIII injection 
was 8 U FVIII per mouse or FVIII Formulation Buffer. The amount of FVIII was calculated based on the 
FVIII antigen values. After five applications of FVIII Formulation Buffer or FVIII, the mice where 
euthanized at day 32. Blood and spleen of the mice were harvested (Figure 3-13). The plasma of the 
mice was analyzed in an ELISA, as described in 3.6.2.3, in order to detect an antibody response to the 
applied FVIII in the immunized mice. The splenocytes were purified from the spleen and cultured as 
described in 3.6.2.2., in order to determine whether T cells detecting the FVIII had evolved. 
 
 
Figure 3-13: Immunization scheme of FVIII-deficient mice. The mice were injected with 4 U FVIII or FVIII Formulation Buffer at 
day 1, 7, 14 and 21. At day 29 the mice were injected with FVIII Formulation Buffer or 8 U FVIII. The study ended at day 32.  
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3.6.2. In vitro experiments  
 
 
3.6.2.1. Thawing of mouse splenocytes 
 
The spleens derived from the humanized BRGSF mice immunized with FVIII (3.6.1.1) were further 
analyzed in vitro. The splenocytes were provided by Axenis, where the in vivo experiments were 
conducted. The spleens were extracted after the end of the experiment. The splenocytes were isolated 
and red blood cells were lysed. The cells were frozen in FBS containing 10 % DMSO and shipped on ice. 
The splenocytes were thawed in a 37 °C water bath and transferred to chilled complete RPMI 1640 
medium (cRPMI), containing 10 % FBS, 50 µM 2-Mercaptoethanol, 25 mM HEPES, 1 x Sodium Pyruvate 
and 1 x MEM Non-Essential Amino Acids Solution. The splenocytes were centrifuged at 500 x g for 
10 minutes. The pellet was resuspended in warm cRPMI and centrifuged as before. Afterwards, the cells 
were labeled with CFSE (3.2.4.5). After the last washing step, the cells were resuspended in 1 ml cRPMI 
and counted (3.2.1.1). The cells were immediately plated as described in 3.6.2.2. 
 
 
3.6.2.2. Cultivation and restimulation of mouse splenocytes 
 
The isolated splenocytes of the immunized mice (3.6.1.1 and 3.6.1.2) were cultivated, in order to 
determine whether a restimulation of the CD4+ T cells with FVIII was possible. In the case of a successful 
immunization of the mice with the applied FVIII product, CD4+ T cell would have evolved, recognizing 
different FVIII epitopes. A restimulation of these cells in vitro would lead to a detectable proliferation 
and activation of these cells.  
The cells were plated in 96-well U-bottom plates at a concentration of 1.5·106 cells/ml and 200 µl 
per well. Splenocytes were plated either in cRPMI or in cRPMI, containing 10 U/ml FVIII for 
restimulation. The FVIII product used for restimulation was the same as used for the immunization. The 
plates were incubated at 37 °C in a humidified atmosphere, containing 5 % CO2. On day 3, 100 µl of cell 
suspension were removed from every well and replaced by 100 µl fresh cRPMI with or without 10 U/ml 
FVIII, depending on the initial stimulation. On day 4 the cells were harvested and analyzed by flow 
cytometry (3.3.1), using the T cell proliferation stain for humanized mouse splenocytes (Table 3-6). 
 
 
3.6.2.3. Determination of anti-FVIII antibodies in mouse plasma 
 
In order to determine whether anti-FVIII-antibodies were generated during the immunization, an 
ELISA was performed. In this ELISA, FVIII is coated to the wells and the plasma samples are added in 
serial dilutions. The bound anti-FVIII antibodies are detected by a peroxidase-coupled secondary anti-
IgG or anti-Immunoglobulin M (IgM) antibody. The peroxidase cleaves the added TMB substrate and 
the absorbance is measured at 450 nm after stopping the reaction with sulfuric acid (Figure 3-14). 
 
 
Figure 3-14: Anti-FVIII antibody ELISA. FVIII is coated to the bottom of each well. Plasma samples are added and the anti-FVIII-
specific antibodies bind to the coated FVIII. Bound antibodies are detected by peroxidase-coupled anti-IgG or anti-IgM 
antibodies. The added TMB solution turns blue-green upon reaction with the peroxidase. The addition of sulfuric acid stops the 
reaction and turns the solution yellow. 
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A 96-well plate was coated with FVIII, either ReFacto AF, FVIII-19M or FVIII-6rs, depending on 
the product used for immunization. Each well was coated with 50 µl of a 10 U/ml FVIII solution. The 
dilutions were performed in 50 mM Sodium Bicarbonate Buffer pH 9.6 and the units FVIII referred to 
the antigen values, in order to receive comparable amounts of FVIII protein in each well for each product. 
In the case that mice were immunized with FVIII Formulation Buffer, the wells were coated with ReFacto 
AF. Coating was performed overnight at 4 °C. The next day the FVIII solution was removed and the wells 
were washed twice with 100 µl Blocking Buffer per well, consisting of 0.5 % FBS in PBS with 0.05 % 
Tween 20. Afterwards 100 µl Blocking Buffer were added to each well and incubated for 1 hour at 4 °C. 
After blocking, the plate was washed twice with 100 µl Washing Buffer per well, consisting of PBS with 
0.05 % Tween 20. The plasma of each E16 FVIII KO mouse was diluted 1:10 in Washing Buffer and 75 µl 
of each dilution were added to one well in the first row of the plate. Plasma of BRGSF mice was added 
undiluted to the first row of the plate. Commercially available human FVIII inhibitor plasma was used 
as a positive control for the ELISA with the anti-human detection antibodies. The plasma of the mice 
from both models were serially diluted 1:3 in each column. Therefore, 50 µl of Washing Buffer were 
applied to each well except for the wells in the first row. 25 µl of the plasma from the first row were then 
transferred to the well below and mixed. Again, 25 µl of this well were transferred to the well below. 
This was continued until seven serial dilutions were performed. From the well containing the last 
dilution, 25 µl were discarded. The plate was incubated at 4 °C for 2 hours. Afterwards the plate was 
washed thrice with 100 µl of Washing Buffer per well. Then 100 µl of secondary antibody were added 
per well. In the case of the E16 FVIII KO mice the secondary antibody was a goat anti-mouse IgG-
Peroxidase diluted 1:5000 in Washing Buffer. In the case of the BRGSF mice, a mouse anti-human IgG-
Horseradish Peroxidase (HRP) and a mouse anti-human IgM-HRP were used. The anti-IgG antibody was 
diluted 1:9000 in Washing Buffer, whereas the anti-IgM antibody was diluted 1:6000 in Washing Buffer. 
The secondary antibodies were incubated for 1 hour at 4 °C. The plate was then washed thrice with 
100 µl Washing Buffer per well. Afterwards 50 µl TMB were added to each well. After 5 minutes the 
reaction was stopped by adding 50 µl of 1 M sulfuric acid. After stopping the reaction, the absorbance at 
450 nm was measured, using the POLARStar Omega plate reader. 
In order to determine the antibody titer, the measured absorbance values were plotted against the 
corresponding dilutions. The first dilution leading to an absorbance value above 0.2 was considered to 
be the antibody titer. 
 
 
 
3.7. Statistical analyses 
 
All statistical analyses were performed using the software GraphPad Prism. Due to the low amount 
of replicates in the different assays, variabilities and outliners, all results were considered to be non-
parametric217,218 and the analyses were based on the median instead of the mean. The Wilcoxon test or 
the Mann-Whitney test were used in order to compare two groups, depending on whether the results 
were analyzed in pairs or groups. The Friedman test was applied when more than two groups were 
analyzed but the results were paired. In the case that the results were not paired, the Kruskal-Wallis test 
was applied. The results are indicated as not significant (ns) or marked with asterisks, depending on the 
significance. One asterisk corresponds to P value ≤ 0.05 and two asterisk correspond to a P value ≤ 0.01. 
P values > 0.05 were considered not significant.  
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4. Results 
 
 
4.1. In silico analysis of the BDD-FVIII variant 
 
The first step in the deimmunization of a BDD-FVIII was the in silico analysis performed by EpiVax. 
The EpiMatrix tools were used to identify which peptides of the FVIII sequence were most likely bound 
by the MHC class II. For the identified clusters, amino acid exchanges were suggested, in order to reduce 
the binding (3.1). The analysis was run for a FVIII sequence, comprising 1514 amino acids, excluding 
the 19 amino acids of the signal sequence and 818 amino acids of the B domain. The excluded amino 
acids of the B domain did not interfere with either the furin or the thrombin cleavage sites.  
The in silico tools revealed a total of 52 immunogenic peptide clusters, with cluster scores ranging 
between 4 and 34, indicating a very high binding affinity at high values and a lower affinity at low 
values. The clusters comprised between 14 and 22 amino acids and some clusters were overlapping by 
a few amino acids. For 12 of the 52 clusters no amino acid mutations were recommended, either due to 
interference with regions important for activity, binding or stability or due to the lack of possible 
exchanges. In order to deimmunize the remaining 40 clusters, 74 mutations were recommended. The 
exchanged amino acids were preferably based on natural occurring changes in other species. If no natural 
changes were available, amino acid exchanges were selected from point accepted mutation (PAM) 
matrices219, which contain mutations that occurred by natural selection (Table 4-1). 
 
Table 4-1: Accepted amino acid substitutions used for the deimmunization of FVIII. 
Original amino acid Potential amino acids for exchange 
Arginine Glutamine, Histidine (H), Serine 
Asparagine (N) Aspartic Acid (D), Histidine, Serine 
Glutamine (Q) Arginine, Aspartic Acid, Glutamic Acid (E), Histidine, Lysine 
Isoleucine (I) Threonine (T) 
Leucine (L) Asparagine, Glutamine 
Lysine (K) Asparagine, Aspartic Acid, Glutamic Acid, Glutamine, Serine, Threonine  
Methionine (M) Arginine, Glutamine, Lysine, Threonine 
Phenylalanine (F) Histidine, Serine 
Serine (S) Alanine (A), Asparagine, Glycine (G), Threonine 
Tryptophan (W) Arginine, Histidine, Serine 
Tyrosine (Y) Asparagine, Histidine 
Valine (V) Alanine, Threonine 
 
For some clusters up to three mutations were indicated, all leading to a strong reduction in the 
cluster score. In these cases, all mutations were selected for the incorporation. In the case that an 
additional mutation only led to a low reduction in the score, this mutation was set aside. Additionally, 
mutations in five clusters were completely set aside, as the total score of the cluster was already low and 
the predicted improvement by the mutations was marginal. These exclusion criteria led to the reduction 
from 74 to 57 mutations for the incorporation into the BDD-FVIII. 
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4.2. Incorporation of the mutations into the BDD-FVIII variant 
 
The incorporation of the mutations was performed in three rounds. Whereas in the first round only 
single mutations were incorporated, the second and third round comprised the combination of the 
successfully incorporated single mutations from the first round. For each round, the most important 
readout was the activity of the mutated FVIII variants in comparison to the non-mutated control FVIII. 
The DNA sequence for all FVIII variants was synthesized by life technologies and cloned into a 
provided vector backbone (2.10). In order to reduce the size of the synthesized fragments, three 
additional restriction sites were integrated into the FVIII sequence by silent mutations. The sequence 
already had a restriction site at the beginning (HindIII) and at the end (XbaI) of the FVIII sequence, for 
cloning into the backbone. One additional restriction site (BamHI) occurred naturally after the removal 
of the B domain sequence. This led, in combination with the additionally incorporated three restriction 
sites (KpnI, XmaI and EcoRI), to a FVIII molecule with six unique restriction sites, as shown in Figure 
4-1. As a result, not only the sequences to be synthesized were shortened but a modular system emerged 
which made the combination of mutations easier. The FVIII molecule, derived from the sequence with 
the six restriction sites, was the reference molecule for all the experiments and was called FVIII-6rs. 
 
  
Figure 4-1: Restriction sites in the BDD-FVIII sequence. The original insert contained three restriction sites (HindIII, BamHI and 
XbaI) located at the ends and in the middle of the FVIII sequence. Three additional sites (KpnI, XmaI and EcoRI) were inserted 
by silent mutations. This led to a FVIII sequence with six restriction sites. 
 
 
4.2.1. First screening round 
 
In the first round of screening, the 57 single mutations were inserted into the FVIII sequence. A 
scheme of the positions of the mutations in the FVIII molecule is shown in Figure 4-2. The selection of 
base triplets for the new amino acids was based on a human codon usage table220. The most frequently 
used base triplet for an amino acid was chosen. 
 
 
Figure 4-2: Mutations in the FVIII sequence. 57 single mutations were inserted into the FVIII sequence. The arrows indicate the 
positions of the mutations. 
 
The FVIII variants containing the single mutations were produced in small-scale HEK293-F culture. 
The HEK293-F cells were transfected in duplicates for each FVIII construct in the Nucleocuvettes, as 
described in 3.2.2.3. The transfected cells were cultured for 4 days (3.2.2.2). After the cultivation, the 
supernatant, containing the FVIII, was harvested by centrifugation. The FVIII activity in the supernatant 
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was analyzed with the chromogenic method in duplicates (3.4.1). The remaining supernatant was frozen 
until the FVIII antigen ELISA was performed (3.4.3). Per day HEK293-F cells were transfected with five 
different FVIII constructs in duplicate. In order to compare the activity results for different constructs 
from different transfection days, HEK293-F cells were additionally transfected with the reference vector, 
coding for the FVIII-6rs. The FVIII activity for each variant was therefore not indicated in U/ml but the 
relative activity was calculated, indicating the activity of the variant in relation to the FVIII-6rs of the 
same transfection day. 
In Figure 4-3 the relative activities of the single mutation variants are displayed, allocated to the 
domains of FVIII. The analyses revealed that only eight mutations led to a total loss of FVIII activity in 
the cell culture supernatant, whereof L1963Q was a control mutation, known to lead to severe 
Hemophilia A. Eleven mutations led to a FVIII activity in the supernatant, which was below 50 % of the 
activity of the control. Thus, in total 19 mutations were excluded from further experiments, due to low 
or absent FVIII activity. Nevertheless, although the 19 excluded mutations were spread over 16 
immunogenic clusters, only ten immunogenic clusters had to be excluded, as further mutations were 
successfully incorporated in the other six clusters. The remaining 38 mutations led to FVIII variants with 
activities, which were at least equivalent to half of the activity of the FVIII-6rs. 
In addition to the activity, the antigen values of the FVIII variants and the resulting specific 
activities were determined (Figure 4-4). As the specific activity is the relation of FVIII activity to FVIII 
antigen, 100 % indicated that the amount of FVIII activity was equivalent to the amount of FVIII antigen. 
However, most values were above 100 %. Values up to 150 % were assumed to be in the normal range 
and derived from inaccuracies in the measurement. Even higher values might indicate an improvement 
of the activity of the variants. Of the 38 active FVIII variants, 35 had specific activities of at least 100 %. 
The three remaining variants had specific activities below 100 % but above 70 %, indicating that a 
fraction of the produced FVIII was inactive. Five of the excluded FVIII variants revealed specific activities 
below 70 %, whereof three had values even below 25 %, indicating that most of the secreted FVIII was 
inactive. In contrast to that, six of the excluded variants had high specific activities above 100 %, hinting 
towards active FVIII but a reduced secretion. All eight variants with no FVIII activity, which led to a 
specific activity of 0 %, also revealed no FVIII antigen. This indicated that the incorporated mutations 
led either to no production or to no secretion of the FVIII variants. 
Although all of the 38 successfully incorporated single mutations had the characteristics to be 
transferred to the second round, only one mutation for each immunogenic cluster was chosen, in order 
to keep the combination of the single mutations feasible. Hence, the mutation resulting in a lower FVIII 
activity was excluded. Additionally, mutation S2030A was found not to be part of the cluster comprising 
S2037G and N2038D but of a preceding cluster. As the calculated score of this cluster was already very 
low without the mutation, S2030A was also excluded. This led to 25 mutations, which were transferred 
to the second round of screening. 
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Figure 4-3: Relative activities of FVIII variants with single mutations. The FVIII activity of each single-mutation variant was 
calculated in relation to the FVIII activity of the control FVIII-6rs. The brackets indicate mutations, which belong to one cluster. 
(A) FVIII variants with mutations in the A1 domain. (B) FVIII variants with mutations in the A2 domain. (C) FVIII variants with 
mutations in the A3 domain. (D) FVIII variants with mutations in the C1 domain. (E) FVIII variants with mutations in the C2 
domain. 
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Figure 4-4: Specific activities of FVIII variants with single mutations. The relation of FVIII activity to FVIII antigen was calculated 
for each single-mutation variant. The brackets indicate mutations, which belong to one cluster. (A) FVIII variants with mutations 
in the A1 domain. (B) FVIII variants with mutations in the A2 domain. (C) FVIII variants with mutations in the A3 domain. (D) 
FVIII variants with mutations in the C1 domain. (E) FVIII variants with mutations in the C2 domain. 
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Prior to starting the combination of the mutations, five additional single mutations were tested. 
These mutations were proposed for four of the immunogenic clusters, which had to be excluded in the 
first screening round, due to non-functional mutated variants. These five mutations were originally not 
tested, as they had a lower calculated influence on the reduction of immunogenicity. However, analyses 
of the variants revealed only low or no FVIII activity in the supernatant, although the specific activities 
were around 100 % for three of the variants (Figure 4-5). Nevertheless, the mutations were not 
transferred to the second round of screening, as the activities were quite low, only exceeding the 50 % 
limit by about 10 % for I658T and N2137H. 
 
 
Figure 4-5: Results of the additionally tested single-mutation variants. (A) Relative activities of the FVIII variants. The FVIII activity 
of each single-mutation variant was calculated in relation to the FVIII activity of the control FVIII-6rs. (B) Specific activities of the 
FVIII variants. The relation of FVIII activity to FVIII antigen was calculated for each single-mutation variant. 
 
Altogether, the first screening round led to a reduction from 57 mutations to 25 mutations (Figure 
4-6). Exclusions were mainly based on the activity results, setting aside the mutations, which led to a 
reduction in FVIII activity. Additionally, only one mutation per immunogenic cluster was transferred to 
the second round of screening, further reducing the amount of mutations. 
 
 
Figure 4-6: Summary of the first screening round. 57 single mutations were initially tested. 19 mutations were excluded due to 
low activities of the single-mutation variants and 13 mutations were excluded due to the decision that only one mutation per 
immunogenic cluster was transferred to the second round. 
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4.2.2. Second screening round 
 
In the second screening round, the 25 mutations, leading to active FVIII variants in the first round, 
were combined. As no modelling of the FVIII variants was possible, the combination occurred in sections. 
This kept the identification of mutations, which led to an inactive FVIII, feasible. The sections were 
defined by the restriction sites, leading to section A1, A1A2, A2 and A3C1C2. The names indicated the 
comprised FVIII domains. The section BA3, comprising the remaining parts of the B domain and parts of 
the A3 domain, was missing, as only one mutation in this section was left after the first screening round. 
For every section one vector was designed containing all mutations, which led to FVIII variants with 
relative activities above 50 %. Additionally, one vector was designed containing only the mutations, 
which led to relative activities above 80 % and reduced the immunogenicity score for the cluster by at 
least 15 points. For section A1A2 and A2 only one vector was constructed, as all mutations had relative 
activities above 80 % and reduced the score by more than 15 points. Based on this, the vectors shown in 
Table 4-2 were designed. 
 
Table 4-2: Mutations combined in the indicated sections of FVIII for the second screening round. 
Section 
Number of 
mutations 
Relative activities of 
the single mutations 
Incorporated mutations 
A1 4 > 80 % N79S, S112T, N233D, I265T 
A1 7 > 50 % 
N79S, S112T, L160S, L171Q, V184A, N233D, 
I265T 
A1A2 3 > 80 % N299D, Y426H, S507E 
A2 5 > 80 % F555H, N616E, I632T, L706N, Y748S 
A3C1C2 6 > 80 % 
N2038D, S2077G, S2125G, K2258Q, S2315T, 
V2333A 
A3C1C2 9 > 50 % 
R1936Q, N2038D, S2077G, S2125G, F2215H, 
K2226Q, K2258Q, S2315T, V2333A 
 
The production of the FVIII variants occurred as described for the first round. After four days of 
production, the FVIII activity in the cell culture supernatant was determined. Activities comparable to or 
even better than the control FVIII-6rs were achieved in the sections A1 and A1A2 (Figure 4-7 A, bar one 
to three). Especially the combination of the three mutations in section A1A2 seemed to have a positive 
effect on either production or secretion of the FVIII variant, leading to more than twice the amount of 
FVIII-6rs. Due to the good activities, the seven mutations in A1 and the three mutations in A1A2 were 
taken to the third round. In section A2 the activity of the FVIII variant was below 80 % (Figure 4-7 A, 
bar four) and the two variants of the A3C1C2 section revealed activities below 40 % (Figure 4-7 A, bar 
five and six). Due to these results, the mutations combined in A2 and A3C1C2 had to be further analyzed. 
The specific activities for all combinations were above 100 %, indicating that the produced FVIII variants 
were functional, except for the variant with nine mutations in the A3C1C2 section (Figure 4-7 B). The 
low specific activity of this variant indicated that mainly inactive FVIII was secreted. 
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Figure 4-7: Results for the FVIII variants with combined mutations in section A1, A1A2, A2 and A3C1C2. (A) Relative activities of 
the FVIII variants. The FVIII activity of each variant was calculated in relation to the FVIII activity of the control FVIII -6rs. (B) 
Specific activities of the FVIII variants. The relation of FVIII activity to FVIII antigen was calculated for each variant. 
 
In order to detect the mutations in the A2 and A3C1C2 section, which interfered with the activity 
of the FVIII variant, two design-of-experiment (DOE) matrices were generated. However, as full factorial 
designs, comprising every possible combination of the mutations, would have resulted in too many 
vectors, the five mutations in the A2 section were modelled in a half factorial design, whereas the six 
mutations in the A3C1C2 section were analyzed in an 8th fraction fractional design. Setting aside the 
variants which were already tested (single-mutant, full-mutant and naïve variant), ten additional vectors 
were designed for the A2 section and 14 additional vectors were designed for the A3C1C2 section. As 
before, the variants were produced in HEK293-F cells and the FVIII activity in the supernatant was 
determined. The analysis revealed that mutation I632T in the A2 section probably was responsible for 
the reduced activity, as it was incorporated in all variants with activities below 100 % (Figure 4-8 A). In 
the A3C1C2 section three mutations, N2038D, S2125G and K2258Q, seemed to decrease the FVIII 
activity (Figure 4-8 B). However, an obvious influence on a decreased activity was only detectable for 
mutation S2125G. For N2038D and K2258Q it was not clearly identifiable whether their influence on 
the activity only occurred in combination with each other or S2125G.  
The specific activities of all variants in the A2 and the A3C1C2 section were at least around 100 % 
(Figure 4-9). This revealed that the reduced FVIII activities compared to FVIII-6rs were probably due to 
production or secretion problems and not due to inactive FVIII. Based on the specific activity results no 
further mutations had to be excluded. 
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Figure 4-8: Relative activities of FVIII variants comprising different mutations based on DOE matrices. The FVIII activity of each 
variant was calculated in relation to the FVIII activity of the control FVIII-6rs. (A) Results for the FVIII variants with mutations in 
the A2 domain. (B) Results for the FVIII variants with mutations in the A3C1C2 domain. 
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Figure 4-9: Specific activities of FVIII variants comprising different mutations based on DOE matrices. The relation of FVIII activity 
to FVIII antigen was calculated for each variant. (A) Results for the FVIII variants with mutations in the A2 domain. (B) Results 
for the FVIII variants with mutations in the A3C1C2 domain. 
 
Based on the results from the DOE matrices, one vector for the A2 section and four vectors for the 
A3C1C2 section were designed. The four A3C1C2 vectors omitted either only mutation S2125G, or 
mutation S2125G in combination with K2258Q or N2038D, or all three mutations. The incorporated 
mutations in the five vectors are indicated in Table 4-3. 
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Table 4-3: Mutations combined in the sections A2 and A3C1C2 after testing different FVIII variants based on two DOE matrices. 
Section Number of mutations Incorporated mutations 
A2 4 F555H, N616E, L706N, Y748S 
A3C1C2 3 S2077G, S2315T, V2333A 
A3C1C2 4 N2038D, S2077G, S2315T, V2333A 
A3C1C2 4 S2077G, K2258Q, S2315T, V2333A 
A3C1C2 5 N2038D, S2077G, K2258Q, S2315T, V2333A 
 
The measurement of the FVIII activity in the supernatant of the HEK293-F cells, transfected with 
the different vectors, revealed that the activity of the variant with four mutations in the A2 section was 
comparable to the activity of FVIII-6rs (Figure 4-10 A, first bar). In contrast to that, although all four 
A3C1C2 variants were active, the activity of the variants comprising five mutations and four mutations 
without mutation N2038D revealed a reduced activity compared to FVIII-6rs (Figure 4-10 A, bar two to 
five). This indicated that the exclusion of mutation N2038D alone had no influence on the production 
or secretion of FVIII, as the relative activity remained low. In contrast to that, the exclusion of K2258Q 
led to an increase in FVIII activity. However, although not effective as a single deletion, removal of 
N2038D in combination with K2258Q had an additive effect and further improved the FVIII activity of 
the variant. Nevertheless, the combination of four mutations, still containing the N2038D, was 
transferred to the third round. This was due to the aim to incorporate as many mutations as possible. 
Additionally, the relative activity of this variant was around 100 % and similar to the results for 
combinations in other sections. The specific activities for all variants were at least 100 %, indicating that 
only active FVIII was present (Figure 4-10 B). 
 
 
Figure 4-10: Results for the FVIII variants with combined mutations in the sections A2 and A3C1C2 after the DOE matrices. (A) 
Relative activities of the FVIII variants. The FVIII activity of each variant was calculated in relation to the FVIII activity of the 
control FVIII-6rs. (B) Specific activities of the FVIII variants. The relation of FVIII activity to FVIII antigen was calculated for each 
variant. 
 
Finally, the second screening round revealed 19 mutations, which could be combined in five 
sections (Figure 4-11). For section A1 and A1A2, the combination of all mutations from the first round 
was feasible. This was not possible for the sections A2 and A3C1C2. Based on DOE matrices one mutation 
had to be excluded in the A2 section and five mutations had to be excluded in the A3C1C2 section. 
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Figure 4-11: Summary of the first a second screening round. Of the 25 mutations from the first round, 6 mutations had to be 
excluded in the second round, as they led to a reduction of the FVIII activity, when combined with other mutations. 
 
 
4.2.3. Third screening round 
 
In the third round all combined mutations, leading to functional FVIII variants in the second round, 
were incorporated into one vector. However, as the A3C1C2 section revealed to be mostly influenced by 
the incorporation of mutations, an additional vector was designed with no mutations in section A3C1C2, 
in order to compare the activities. This led to two vectors comprising in total 15 and 19 mutations. The 
analysis of the FVIII activity in the supernatant revealed activities, for both vectors, at least comparable 
to FVIII-6rs, whereas the variant with the 15 mutations revealed a higher concentration of active FVIII 
compared to the one with the 19 mutations (Figure 4-12 A). The specific activities were nearly 100 % 
for the FVIII-15M and above 100 % for FVIII-19M (Figure 4-12 B). 
 
 
Figure 4-12: Results from the third screening round of the FVIII variants comprising 15 or 19 mutations in the whole molecule. 
(A) Relative activities of the FVIII variants. The FVIII activity of each variant was calculated in relation to the FVIII activity of the 
control FVIII-6rs. (B) Specific activities of the FVIII variants. The relation of FVIII activity to FVIII antigen was calculated for each 
variant. 
 
Of the initially tested 57 mutations 19 mutations were finally incorporated into the FVIII sequence, 
leading to the new variant FVIII-19M. The FVIII-19M was preferred over the FVIII-15M, as the aim was 
to incorporate as many mutations as possible, in order to gain a maximal reduction in the 
immunogenicity score while conserving FVIII activity. Additionally, the activity of FVIII-19M was 
comparable to the control FVIII-6rs. The three screening rounds are summarized in Figure 4-13. 
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Figure 4-13: Summary of all three screening rounds. In the third round, all mutations from the second round were combined in 
one FVIII molecule. 
 
Due to the incorporation of the 19 mutations into the FVIII sequence, the initial immunogenicity 
score of the FVIII-6rs of 7.01 was reduced to -10.55 for the FVIII-19M. The immunogenicity score 
indicates the immunogenicity of the protein of interest in relation to a protein with a random sequence. 
The immunogenicity score of the random protein is set to 0. In order to be able to compare the scores 
for different proteins of different length, the score was given per 1000 of the 9-mers, to which a protein 
is split for in silico analysis (3.1). The scores for FVIII-6rs and FVIII-19M and scores of other proteins are 
illustrated in Figure 4-14.  
 
 
Figure 4-14: Immunogenicity scale. The score indicates the immunogenicity of a protein. For comparability, the immunogenicity 
score of a protein is indicated in relation to a protein with a randomized sequence. The immunogenicity score of the randomized 
protein is 0. The immunogenicity score for each protein is given per 1000 9-mers, in order to be able to compare proteins of 
different lengths. 
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4.3. Production and purification of FVIII-19M and FVIII-6rs 
 
The FVIII-19M and the reference molecule FVIII-6rs were produced and purified for further 
analyses. This production of higher amounts, compared to the screening rounds, occurred in CAP-T cells. 
Per 12.5 ml cell culture, 10·106 CAP-T cells were transfected with 5 µg of plasmid (3.2.3.3). The first 
production of FVIII-19M occurred in a total volume of 800 ml. Further productions were performed by 
Cevec under the same conditions, leading to a 400 ml FVIII-19M production and a 400 ml and a 800 ml 
FVIII-6rs production. The FVIII of all four productions was purified by FPLC. The purification began with 
a SAEx, followed by an AC and in the final step a SEC (3.5.1). In order to keep the required FVIII volumes 
for cell culture experiments as low as possible, the FVIII products were concentrated after purification 
(3.5.1). Each purification was performed during one day, except the last purification of FVIII-6rs. In this 
case, the elution from the AC was frozen at -80 °C and thawed the following day, proceeding with the 
SEC. An exemplarily chromatogram for each chromatography is depicted in Figure 4-15 (SAEx), Figure 
4-16 (AC) and Figure 4-17 (SEC). The fractions, containing FVIII, were taken according to the 
chromatogram and are indicated by green, dashed boxes. In every chromatogram, an UV peak was 
clearly detectable. This was the main indicator for fractions containing protein. The pooled fractions 9-
12 from the SAEx were diluted 1:2 in AC Equilibration Buffer and transferred to the AC column. The 
eluted fractions 21 and 22 from the AC, containing the purified FVIII, were pooled and the buffer was 
exchanged to FVIII Formulation Buffer by SEC. For the selection of the fractions from the SEC, a stable 
conductivity peak was important in addition to a high UV peak. Based on this, the fractions 6-9 were 
pooled, and finally concentrated. 
 
 
Figure 4-15: Chromatogram of the SAEx. The chromatography was performed according to the protocol. The UV peak indicated 
that fractions 9 to 12 contained the eluted proteins (green, dashed box). The fractions were pooled and taken to the AC. 
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Figure 4-16: Chromatogram of the FVIII AC. The chromatography was performed according to the protocol. The UV peak 
indicated that fractions 21 and 22 contained the eluted FVIII (green, dashed box). The fractions were pooled and taken to the 
SEC. 
 
 
Figure 4-17: Chromatogram of the FVIII buffer exchange by SEC. The chromatography was performed according to the protocol. 
The high UV peak and the stable conductivity indicated that fractions 6 to 9 contained the buffer-exchanged FVIII (green, 
dashed box). The fractions were pooled and concentrated. 
 
During all purification steps samples were taken, including wash and flow through samples, in 
order to determine the FVIII activity and antigen of each step. The activity was determined in parallel to 
the purification (3.4.1), whereas the antigen was determined afterwards from frozen samples (3.4.3). 
Figure 4-18 illustrates the FVIII activities and the specific activities for all purification steps of the two 
FVIII-19M and the two FVIII-6rs purifications. In the case of purification from 800 ml supernatant, the 
volume was split and the SAEx was performed twice. The indicated values are the mean of the results 
derived from both runs. The activity values illustrate the constant increase of the FVIII concentration in 
the eluates of the different chromatographic columns. The highest increase in concentration was 
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achieved in the last step by concentration. The decrease in active FVIII concentrations from the elution 
of the SAEx to the source of the AC was due to the 1:2 dilution of the elution volume with AC 
Equilibration Buffer. In addition to that, the decrease in FVIII concentration from the elution of the AC 
to the elution of the SEC was also due to an increase in total volume during the buffer exchange. The 
very low specific activities in the flow through and wash fraction of the AC column indicate that mainly 
inactive FVIII was lost during this step. All elution fractions and the concentrated, purified FVIII revealed 
specific activities of about 100 % and above, indicating that only active FVIII was present. 
 
 
Figure 4-18: Activities and specific activities of FVIII-19M and FVIII-6rs in different purification steps. The concentrations of active 
FVIII (left y-axis) and the specific activities (right y-axis) are indicated for every purification step. In the case that two SAEx were 
performed, the indicated values are the mean values of the two performed runs. (A) First purification of FVIII-19M from an 
800 ml batch. (B) Second purification of FVIII-19M from a 400 ml batch. (C) First purification of FVIII-6rs from a 400 ml batch. 
(D) Second purification of FVIII-6rs from an 800 ml batch. 
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The yield of the steps, compared to the total amount of FVIII activity in the source, is displayed in 
Figure 4-19 for every purification. The data revealed that the concentrating step was one of the steps, 
which led to the highest loss of FVIII. However, the loss seemed to be associated with manufacturing 
differences of the filters, as all samples were handled in the same way but different batches of filters 
were used. Another step associated with loss of FVIII was the SAEx, especially when FVIII-19M was 
purified. It was not clear why FVIII-19M was lost during SAEx, as the mutations even led to the 
introduction of five negatively charged amino acids. One reason might have been that the buffers for the 
different chromatographic methods were not especially adapted to FVIII-19M. In total, the yield of FVIII 
was between 40 % and 70 % after the FPLC and reduced to 40 % to 50 % after concentration. 
 
 
Figure 4-19: Yield of FVIII-19M and FVIII-6rs during the purification steps. The yield of each step was calculated in reference to 
the total amount of active FVIII in the source. (A) First purification of FVIII-19M from an 800 ml batch. (B) Second purification 
of FVIII-19M from a 400 ml batch. (C) First purification of FVIII-6rs from a 400 ml batch. (D) Second purification of FVIII-6rs from 
an 800 ml batch. 
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The purification steps were additionally monitored via SDS-PAGE (3.5.2) and Western Blot 
(3.5.3), in order to detect contaminations and degraded FVIII. For each purification a SDS-PAGE with a 
total protein stain and a Western Blot, specifically detecting FVIII, was performed. Figure 4-20 displays 
the SDS-PAGE of the first purification of FVIII-19M and FVIII-6rs. The SDS-PAGE of the other 
purifications can be found in the Appendix (Figure A-1 and Figure A-2). The total protein stain of the 
SDS-PAGE revealed that the SAEx mainly led to concentration of the proteins, as only low amounts of 
protein were lost during flow and wash. The purification of FVIII from other proteins occurred during 
the AC, as most of the contaminating proteins were detectable in this flow through. The lower intensity 
of these bands compared to the bands of the SAEx elution was due to the 1:2 dilution of the SAEx elution 
sample prior to the application onto the AC column. No proteins were visible in the SEC elution, as 
contaminating proteins were lost during AC and the FVIII concentrations were too low to be visualized. 
 
 
Figure 4-20: SDS-PAGE of the first FVIII-19M and FVIII-6rs purification developed with Imperial Protein Stain. The samples from 
the purification were not pre-diluted, except for the FVIII concentrates and the reference ReFacto AF, which were set to 5 U/ml 
FVIII. 
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As the FVIII amounts were too low to be visualized on the SDS-PAGE, due to the high amounts of 
contaminating proteins, Western Blots were performed (Figure 4-21, Figure A-3 and Figure A-4). FVIII 
was specifically detected with a polyclonal anti-FVIII antibody and revealed to be present in all source 
and elution fractions. As already detected in the chromogenic FVIII assay, some FVIII was also present 
in the flow through and wash fractions of the AC. Although the FVIII in these fractions was not degraded, 
specific activity values revealed that this FVIII was mainly inactive (Figure 4-18). Some degraded FVIII 
was visible in the elution of the SAEx but was removed during AC. However, concentrating FVIII seemed 
to have led to the degradation of a small amount of FVIII.  
 
 
Figure 4-21: Western Blot of the first FVIII-19M and FVIII-6rs purification. The samples were not pre-diluted, except for the 
elutions from the AC and the SEC, which were pre-diluted 1:5. The FVIII concentrates and the reference ReFacto AF were set to 
5 U/ml FVIII. The upper band (≈ 200 kDa) represents single-chain FVIII, not processed by furin. The second band (≈ 110 kDa) 
represents the heavy chain and the following set of bands (≈ 80-90 kDa) are differently glycosylated forms of the light chain. 
The bands around 50 kDa represent degraded FVIII. FVIII was detected with the primary polyclonal sheep anti-human Factor 
VIII antibody and the secondary donkey anti-sheep IgG IRDye 800CW. 
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Due to the fact that high amounts of FVIII-19M and FVIII-6rs were needed for the analysis of the 
proteins themselves as well as for the DC-T cell Assay and the in vivo studies, more protein had to be 
produced. These productions and purifications were performed by Cevec, the provider of the CAP-T cell 
line. The cultivation, transfection and production protocols were similar to the ones described in 3.2.3. 
Differences only occurred during purification. Although the main purification step, the AC with the 
VIIISelect medium, was the same, Cevec performed a tangential flow filtration (TFF) prior to the AC 
instead of a SAEx. The TFF led to a concentration of the cell culture supernatant and the buffer was 
exchanged to the AC Equilibration Buffer. After the AC, the buffer exchange to FVIII Formulation Buffer 
occurred also via SEC. A Western Blot of the differently purified FVIII molecules revealed that no 
variations were detectable between the four previously described purifications and the purifications 
performed by Cevec (Figure 4-22). 
 
 
Figure 4-22: Western Blot of the different FVIII purifications. All samples were diluted to 5 U/ml FVIII. The FVIII-19M and FVIII-
6rs purifications show similar band patterns for the single chain (≈ 200 kDa), heavy chain (≈ 110 kDa) and light chain (≈ 80-
90 kDa). FVIII was detected with the primary polyclonal sheep anti-human Factor VIII antibody and the secondary donkey anti-
sheep IgG IRDye 800CW. 
 
The SDS-PAGE and Western Blots revealed that the productions and purifications of FVIII-19M 
and FVIII-6rs were successful. The purification yield was similar for both products, although the total 
amount of active FVIII-6rs was lower, due to lower initial concentrations in the cell culture supernatant. 
Additionally, the purified products derived from the different productions did not reveal differences on 
a Western Blot. 
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4.4. Analyses of FVIII-19M and FVIII-6rs 
 
The produced FVIII-19M and FVIII-6rs were at first analyzed regarding their chromogenic and 
clotting activity in comparison to the determined antigen values. In further analyses, post-translational 
modifications and functionality of FVIII-19M were compared to FVIII-6rs and the two clinically used 
rFVIII products ReFacto AF and Nuwiq. Both commercial products are also B-domain deleted. ReFacto 
AF is produced in CHO cells, whereas Nuwiq is produced in HEK cells. The analyses comprised Western 
Blots detecting FVIII heavy and light chain, thrombin cleavage, glycosylation and sulfation, 2D-DIGE and 
the functional assays ROTEM, TGA and a vWF-FVIII ELISA. 
 
 
4.4.1. Activities and specific activities 
 
The first analysis was the comparison of the activity and antigen values of the FVIII-19M and FVIII-
6rs from the different productions, in order to ensure similarity for the following experiments. For each 
production the relation of the amount of active FVIII to the amount of FVIII antigen, the specific activity, 
was calculated. The FVIII activity was either determined with the chromogenic or the clotting method 
(3.4.1 and 3.4.2), whereas the antigen value was measured via ELISA (3.4.3). This led to two different 
specific activities, one based on the chromogenic activity and the other based on the clotting activity. 
The results are illustrated in Figure 4-23. The specific activities based on the chromogenic activities 
(Figure 4-23 A), revealed similar results when comparing each of the four productions of the FVIII-6rs 
and FVIII-19M. Additionally, the median of the four productions was not significantly different between 
FVIII-6rs and FVIII-19M (Figure 4-23 A and Table A-1). The specific activities based on the clotting 
activities were lower compared to the specific activities based on the chromogenic activities (Figure 4-23 
B). Generally, this is a known phenomenon for rFVIII products in the clotting assay. The reason for this 
is not yet elucidated221. However, this did not explain the reduced specific activity of FVIII-19M 
compared to FVIII-6rs. Although the difference was not significant (Table A-2), the result hinted towards 
a slight impairment of the clotting cascade with FVIII-19M, which was not detectable with the 
chromogenic activity test. Nevertheless, when comparing the specific activities for the four productions 
of each product, the results were similar. Based on this, all productions were used for further 
experiments. However, the different productions were not mixed within one block of experiments. The 
protein analyses were performed with the FVIII-6rs and FVIII-19M from the first Cevec purification, the 
in vitro assays were performed with the material from the two purifications shown in chapter 4.3 and 
the in vivo studies were performed with the material of the second production and purification by Cevec.  
 
 
Figure 4-23: Specific activities of the four independent productions of FVIII-6rs and FVIII-19M. (A) Specific activities based on the 
chromogenic FVIII activity measurement. The line indicates the median of the four measurements. (B) Specific activities based 
on the clotting FVIII activity measurement. The line indicates the median of the four measurements. 
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4.4.2. Western Blots and 2D-DIGE 
 
The Western Blot (3.5.3), detecting light chain and heavy chain of FVIII, revealed that the 
constructs FVIII-19M and FVIII-6rs were secreted nearly in equal parts as double-chain FVIII, comprising 
heavy (red band) and light chain (green bands), and as single-chain FVIII (yellow band) (Figure 4-24). 
In contrast to that, the commercially available FVIII products ReFacto AF and Nuwiq were mainly present 
in the double-chain form. The different molecular weights of the heavy chains of the four FVIII products 
were due to the deletion of a larger B domain fraction in ReFacto AF and Nuwiq, compared to FVIII-19M 
and FVIII-6rs, leading to a lower molecular weight. The slight differences in the molecular weight of the 
light chain were probably due to differences in processing and post-translational modification. The 
detected variations in the ratios of double-chain to single-chain FVIII as well as the differences in post-
translational modification were probably due to the different cell lines (CHO, HEK and CAP-T) used for 
the production of the FVIII variants.  
 
 
Figure 4-24: Western Blot specifically detecting the FVIII heavy and light chain. The different FVIII products were applied at a 
concentration of 5 U/ml. The heavy chains (≈ 95-110 kDa) are indicated in red and the light chains (≈ 80-90 kDa) are indicated 
in green. Single-chain FVIII (≈ 200 kDa), consisting of heavy and light chain, is indicated in yellow, due to the overlay of green 
and red. The heavy chains were detected with the primary rabbit anti-human Factor VIII antibody and the secondary donkey 
anti-rabbit IgG IRDye 800CW. The light chains were detected with the primary mouse anti-human Factor VIII antibody and the 
secondary donkey anti-mouse IgG IRDye 680RD. 
 
In order to detect whether the FVIII variants 19M and 6rs were glycosylated, another Western Blot 
was performed (3.5.3). Each sample was applied in its original form and in a deglycosylated form to a 
SDS-PAGE (3.5.2). Deglycosylation was performed with N-Glycosidase F, which specifically removed N-
linked glycosylations (3.5.2.2). O-glycosylations were not expected to be present, as these glycosylation 
sites lay in the B domain regions which were deleted in all four products. The original samples were 
treated as the deglycosylated ones, except that no N-Glycosidase F was added. In the Western Blot the 
FVIII was detected with a polyclonal anti-FVIII antibody. As shown in Figure 4-25, the deglycosylation 
of FVIII-19M and FVIII-6rs as well as of the controls ReFacto AF and Nuwiq led to a band shift, due to 
the removal of the glycosylations. The shift appeared to be very similar for all variants. Unfortunately, 
various light chains were still detectable indicating that the deglycosylation was incomplete. In addition 
to that, it was not possible to determine whether all four N-glycosylation sites, which were still present 
 Results  77 
in the B-domain deleted variants, were originally glycosylated. In order to obtain detailed information 
on the glycosylation, mass spectrometric analyses would have been necessary. Using this method, a 
defined determination of the sugar types would be possible. However, the amounts of available FVIII-
19M and FVIII-6rs were too low for a detailed analysis of the glycosylation pattern. 
 
 
Figure 4-25: Western Blot with glycosylated and deglycosylated FVIII variants. Glycosylated and deglycosylated FVIII products 
were applied at a concentration of 5 U/ml. FVIII was detected with the primary polyclonal sheep anti-human Factor VIII antibody 
and the secondary donkey anti-sheep IgG IRDye 800CW. 
 
The sulfation of FVIII-19M and FVIII-6rs was also analyzed with a Western Blot (3.5.3). FVIII was 
specifically detected by a polyclonal FVIII antibody, revealing heavy, light and single chain of FVIII. A 
second antibody specifically detected sulfotyrosines. Sulfation was expected at four sites in the heavy 
chain (Y365, Y737, Y738 and Y742) and at two sites in the light chain (Y1683 and Y1699). In the 
Western Blot the sulfation was detectable as a yellow band, resulting from the overlay of the green 
signal, representing the FVIII, and the red signal, representing the sulfotyrosine (Figure 4-26 A). The 
commercially available product Nuwiq revealed a positive sulfation signal especially in the heavy chain, 
whereas ReFacto AF showed nearly no sulfation. The two variants FVIII-6rs and FVIII-19M revealed 
sulfation mainly in their single-chain form and nearly no sulfation was detectable in the heavy and light 
chain. In order to show the sulfotyrosine signal in more detail, Figure 4-26 B presents only the signal 
from the secondary antibody donkey anti-mouse IgG IRDye 800CW, which bound to the mouse anti-
human sulfotyrosine antibody. This figure revealed that at least a small amount of ReFacto AF was 
sulfated and that the light chains of Nuwiq, and the light and heavy chain of FVIII-19M and FVIII-6rs 
were also sulfated. This indicated that sulfation was not generally defective in the double-chain form of 
FVIII-19M and FVIII-6rs. In general, the Western Blot revealed the expected results with the highest 
sulfation signal for the single chain, containing all six sulfation sites, less signal for the heavy chain and 
the lowest signal for the light chain, containing only two sulfation sites. The variations between the 
products might have occurred, due to the different cell lines used for the production. 
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Figure 4-26: Western Blot detecting FVIII and sulfotyrosines. The FVIII products were applied at a concentration of 10 U/ml. FVIII 
was detected with the primary polyclonal sheep anti-human Factor VIII antibody and the secondary donkey anti-sheep IgG 
CF680. Sulfotyrosines were detected with the primary mouse anti-human sulfotyrosine antibody and the secondary donkey anti-
mouse IgG IRDye 800CW (A) FVIII is indicated in green and sulfotyrosines in red. The overlay of red and green results in a yellow 
signal. (B) Only the signal of the sulfotyrosine antibody is displayed. 
 
In order to compare the FVIII variants 19M and 6rs in more detail, 2D-DIGE was performed (3.5.4). 
Two DIGEs were specifically detecting FVIII, whereof one DIGE contained FVIII-19M and FVIII-6rs and 
the other contained ReFacto AF and Nuwiq. For these electrophoreses the proteins were labelled with 
different fluorochromes. As these fluorochromes labelled all proteins in the solution, also contaminating 
proteins were labelled. In order to distinguish FVIII from contaminating proteins, the gel was blotted 
and the polyclonal anti-FVIII antibody was applied to the Blot, followed by a secondary antibody labelled 
with a third fluorochrome. The overlay of the different fluorochromes revealed which protein spots were 
FVIII. In a third DIGE, FVIII-19M, FVIII-6rs and ReFacto AF were labelled with three different 
fluorochromes and compared on one gel, which was not blotted but scanned after the electrophresis, 
taking into consideration which spots were representing FVIII. 
Figure 4-27 shows the Western Blot of the 2D-DIGE with ReFacto AF and Nuwiq. In all three 
pictures only two of the three colours were overlayed. Unfortunately, the light chain was not completely 
focussed as the IEF strips were focussing from pH 4 to pH 7 and the light chain needed pH 8 for optimal 
focusing. Also the single chain was not optimally focussed, probably due to its size. Figure 4-27 A and B 
show the FVIII products (ReFacto AF in green, Nuwiq in red) together with the polyclonal anti-FVIII 
antibody (yellow). For both products, all spots were overlayed with the signal of the FVIII antibody, 
indicating that no contaminating proteins were detectable. However, more yellow FVIII bands than green 
or red bands were visible. This was due to the fact, that the anti-FVIII antibody, together with the 
secondary antibody, was more sensitive than the labeling of the proteins. The spots indicate that FVIII 
was present in these areas but it was not identifiable which product was bound by the antibody, as the 
green and red signals were too low. In both products, regarding the first dimension representing the IEF, 
more than one spot was detectable for the single chain (1), the heavy chain (2) and the light chain (3 
and 4). This was probably due to differences in the post-translational modification, as glycosylation and 
sulfation influence the pI. Regarding the light chain, ReFacto AF and Nuwiq showed more than one band 
in the second dimension, the separation by molecular weight. This was expected as more than one band 
was already detected by 1D-SDS-PAGE (Figure 4-24). These differences were probably also due to 
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different glycosylation patterns as well as slight differences in processing of the light chain. Additionally, 
ReFacto AF revealed two heavy chain bands in the second dimension. These two bands were also 
detectable in the Western Blot detecting the FVIII heavy and light chain (Figure 4-24) but not as clear 
as on this Blot of the 2D-DIGE. These two chains might have been derived from different processing of 
the heavy chain. A second heavy chain was also detectable for Nuwiq. However, the intensity of this 
band was much lower compared to ReFacto AF and not yet identified in the Western Blots before. Figure 
4-27 C displays the overlay of ReFacto AF and Nuwiq. This picture shows that the original colours of 
ReFacto AF and Nuwiq were turquoise and pink, only resulting in green and red, when overlayed with 
the yellow signal. In the areas where ReFacto AF and Nuwiq overlayed, the color changed to blue. This 
was especially the case for the major part of the light chain (3), whereas the minor parts of the light 
chain (4) were slightly different. The major parts of the heavy chain (2) were also similar, except for the 
upper bands. The overlay confirms that the amount of the upper heavy chain is higher for ReFacto AF. 
Additionally, the upper heavy chains of ReFacto AF and Nuwiq slightly differ in the first dimension, 
indicating different pIs. Altogether the Western Blot of the 2D-DIGE revealed that ReFacto AF and Nuwiq 
were very similar regarding heavy and light chain. The singlchain FVIII was only detectable by the anti-
FVIII antibody, as the amounts were very low. None of the products revealed contamininations with 
other proteins. 
 
 
Figure 4-27: Western Blot of a 2D-DIGE. ReFacto AF was labelled with DY-680 and Nuwiq was labelled with DY-780. FVIII was 
detected with the primary polyclonal sheep anti-human Factor VIII antibody and the secondary donkey anti-sheep IgG CF488A. 
(A) Overlay of the ReFacto AF signal (green) and the polyclonal anti-FVIII signal (yellow). (B) Overlay of the Nuwiq signal (red) 
and the polyclonal anti-FVIII signal (yellow). (C) Overlay of the ReFacto AF signal (turquoise) and the Nuwiq signal (pink). The 
overlaying regions are colored in blue. 
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In Figure 4-28 the Western Blot of the 2D-DIGE with labelled FVIII-19M and FVIII-6rs is displayed. 
As for ReFacto AF and Nuwiq, FVIII was specifically detected on the Blot with the polyclonal anti-FVIII 
antibody. In contrast to the commercially available products Nuwiq and ReFacto AF, the Blot revealed 
that FVIII-19M and FVIII-6rs still contained contaminating proteins. In Figure 4-28 A and B pink or 
turquoise spots were detectable, which were not overlaid with the yellow signal of the anti-FVIII 
antibody. In addition to the spots for the single chain (1), the heavy chain (2) and the variants of the 
light chain (4 and 5), spots were detectable below the main spots of the heavy chain (3). These spots 
probably represented heavy chain with differently processed B domain, leading to a lower molecular 
weight. Compared to the Blot of ReFacto AF and Nuwiq, the amount of single chain was higher, which 
made it possible to detect an overlay of the FVIII antibody signal and the signal of the labelled proteins. 
This was expected, as a high amount of single chain was already visible on the Blots of the 1D-SDS-PAGE 
(Figure 4-24). Figure 4-28 C shows the overlay of the FVIII-19M and the FVIII-6rs. As expected, the spots 
were very similar and overlapping, leading to the blue color. Slight shifts were seen in the first dimension 
which might have been due to the slightly reduced pI of the FVIII-19M, because of the incorporation of 
the 19 mutations. 
 
 
Figure 4-28: Western Blot of a 2D-DIGE with labelled FVIII-6rs and FVIII-19M. FVIII-19M was labelled with DY-680 and FVIII-6rs 
was labelled with DY-780. FVIII was detected with the primary polyclonal sheep anti-human Factor VIII antibody and the 
secondary donkey anti-sheep IgG CF488A. (A) Overlay of the FVIII-6rs signal (red) and the polyclonal anti-FVIII signal (yellow). 
(B) Overlay of the FVIII-19M signal (green) and the polyclonal anti-FVIII signal (yellow). (C) Overlay of the FVIII-19M signal 
(turquoise) and the FVIII-6rs signal (pink). The overlaying regions are colored in blue. 
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Figure 4-29 represents the overlay of ReFacto AF, FVIII-19M and FVIII-6rs. All three FVIII products 
were labeled with different flurochromes before the IEF. Due to this, the gel was not blotted after the 
SDS-PAGE but directly scanned, leading to the detection of the three proteins. As seen before, no single-
chain form of ReFacto AF (yellow) was visible, whereas FVIII-19M (turquoise) and FVIII-6rs (pink) single 
chain was detectable (1). The main spots for the light chain mainly overlapped, although the resolution 
was impaired due to an air bubble (3). The lighter spots of the light chain were very diverse and mostly 
overlapping for FVIII-19M and FVIII-6rs, resulting in the blue color (4). The main differences were 
detectable for the heavy chain (2). The ReFacto AF heavy chain was in the second dimension clearly 
separated from the heavy chain of FVIII-6rs and FVIII-19M, because ReFacto AF lacked a larger part of 
the B domain. 
 
 
Figure 4-29: 2D-DIGE with labelled FVIII-6rs, FVIII-19M and ReFacto AF. The picture represents the overlay of the FVIII-6rs signal 
(pink), the FVIII-19M signal (turquoise) and the ReFacto AF signal (yellow). The blue regions represent an overlap of signal from 
FVIII-6rs and FVIII-19M. The red regions represent an overlap of signal from FVIII-6rs and ReFacto AF. The green regions 
represent an overlap of signal from FVIII-19M and ReFacto AF. ReFacto AF was labelled with Cy-2, FVIII-19M was labelled with 
Cy-3 and FVIII-6rs was labelled with Cy-5. 
 
In total, the 2D-DIGE made it possible to detect similarities and differences between the FVIII 
variants 19M and 6rs, between ReFacto AF and Nuwiq and between ReFacto AF, FVIII-19M and FVIII-
6rs. The method confirmed results, which were already seen in different Western Blots and gave insights 
regarding the pI of the different products. In addition, it revealed that impurities were still present in 
the purified FVIII-19M and FVIII-6rs products. 
 
 
4.4.3. Functional analyses 
 
Several analyses were performed, in order to compare FVIII-19M and FVIII-6rs to ReFacto AF and 
Nuwiq, regarding their functionality. At first, all products were analyzed on a Western Blot before and 
after the activation with thrombin (3.5.3). The thrombin activation occurred as described in 3.5.2.1. The 
treatment of the samples was the same for activated and non-activated samples, except that no thrombin 
was added to the non-activated samples. After blotting, the FVIII fragments were detected with the 
polyclonal anti-FVIII antibody. All four products were spliced by thrombin and characteristic fragments 
were detectable (Figure 4-30). The thrombin cleavage of the heavy chain, at R391 and R759, led to the 
fragments of A1 and A2, which were visible between 40 and 50 kDa. More than one band was visualized 
for each domain, which was probably due to different glycosylation and processing and was consistent 
with the two bands seen in the non-activated heavy chain of ReFacto AF and Nuwiq especially on the 
Blot of the 2D-DIGE (Figure 4-27). The remaining part of the B domain, resulting from the cleavage at 
R759, was too small to be detected. The cleavage of the light chain at R1708 led to the large fragment, 
comprising the A3, C1 and C2 domain, at around 70 kDa. The a3 domain, also resulting from this 
cleavage, was too small to be detected. Two fragments were additionally detected in the FVIII-19M and 
FVIII-6rs variants. The fragment consisting of the remaining B domain and a3, detected around 20 kDa, 
was probably derived from the single-chain variant. The single chain was cleaved at all three thrombin 
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cleavage sites but due to missing furin cleavage, the combination of B domain and a3, too small to be 
detectable individually, was still visible on the Blot. These fragment might also have been existent for 
ReFacto AF and Nuwiq but the amount of single chain was too low, compared to FVIII-19M and FVIII-
6rs, so that the visualization was not possible. The fragment of about 90 kDa probably consisted of A1 
and A2 domain and was derived either from incomplete activation of the heavy chain or from the single 
chain, missing the cleavage at R391. In general, all products were activated by thrombin and revealed 
the expected band patterns. 
 
 
Figure 4-30: FVIII products activated by thrombin. Each product was applied in its non-activated and activated form. In the non-
activated form, the typical bands for the single chain (≈ 200 kDa), heavy chain (≈ 95-110 kDa) and light chain (≈ 80-90 kDa) were 
detectable. After thrombin cleavage additional bands for A1A2 (≈ 90 kDa), A3C1C2 (≈ 70 kDa), A1 (≈ 50 kDa), A2 (≈ 40 kDa) 
and Ba3 (≈ 20 kDa) were detectable. FVIII was detected with the primary polyclonal sheep anti-human Factor VIII antibody and 
the secondary donkey anti-sheep IgG IRDye 800CW. 
 
The clotting time for the different FVIII products was determined using the ROTEM method 
(3.4.6). During this analysis, the clotting time of plasma is analyzed depending on the amount and the 
functionality of the applied FVIII. The FVIII products were added to FVIII-deficient plasma and the 
clotting was initiated via the intrinsic pathway. The time until a clot was starting to form was measured. 
By adding different concentrations of FVIII, an increase of the clotting time was detected in correlation 
to decreasing concentrations of FVIII. When comparing the different products, ReFacto AF and Nuwiq 
revealed very similar clotting times, whereas the clotting times were slightly prolonged for FVIII-6rs and 
even more for FVIII-19M (Figure 4-31). However, all clotting times only varied between 120 seconds 
and 160 seconds at 1 U/ml FVIII, which was still in the normal clotting time range of 100-240 seconds 
in healthy people222. 
 
 Results  83 
 
Figure 4-31: Clotting time for different FVIII products. The clotting time for FVIII-19M and FVIII-6rs was measured in comparison 
to the clotting times for ReFacto AF and Nuwiq. Different FVIII concentrations were analyzed. The measurements were 
performed in duplicates and the mean values are displayed. 
 
In addition to the determination of the clotting time, a TGA was performed. This assay measures 
the amount of generated thrombin. As it is performed in FVIII-deficient plasma, the amount of generated 
thrombin depends on the amount and functionality of the added FVIII products. In contrast to the 
initiation via the intrinsic pathway in the ROTEM measurement, the clotting cascade in the TGA is started 
with tissue factor, pursuing the extrinsic pathway. All FVIII products were diluted to 0.25 U/ml, 
0.063 U/ml and 0.016 U/ml FVIII, depending on their chromogenic activity. Due to the high sensitivity 
of the assay, it was performed four times and the median was calculated for each product and 
concentration (3.4.5). Three different values were calculated: the amount of generated peak thrombin, 
the area under the curve and the time to peak thrombin generation. For the calculations the first 
deviation of the original curve was used (Figure 4-32). The amount of generated peak thrombin was 
calculated based on a thrombin standard. The area under the curve and the time to peak thrombin 
generation made it possible to detect differences not only in the amount of generated peak thrombin but 
also in the velocity and the whole clotting process, including inactivation. The area under the curve is 
equivalent to the total amount of generated thrombin. The results are presented in Figure 4-33 (detailed 
statistical results Table A-3 to Table A-5). Comparable to the analysis of the clotting times, ReFacto AF 
and Nuwiq revealed similar results regarding peak thrombin generation, area under the curve and time 
to peak thrombin generation. FVIII-6rs resembled ReFacto AF and Nuwiq regarding the amount of 
generated peak thrombin and the time to peak thrombin generation but showed a slightly reduced area 
under the curve. Unfortunately, FVIII-19M revealed significantly lower results for generated peak 
thrombin, area under the curve and time needed to reach peak thrombin generation, especially 
compared to ReFacto AF and Nuwiq. However, these results were comparable with the ROTEM results 
(Figure 4-31), revealing a prolonged clotting time for FVIII-19M. Concentrations above 0.25 U/ml FVIII 
were not analyzed, as it is published that from 0.5 U/ml on FVIII is no longer rate limiting223. 
Unfortunately, as the assay is so variable, no standardized value for the amount of generated peak 
thrombin was available. Due to this, only the comparison between the different FVIII products was 
possible and these were consistent with the results of the clotting times, revealing slightly reduced 
activity of the FVIII-19M compared to its reference FVIII-6rs. 
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Figure 4-32: Exemplary TGA curve for ReFacto AF, Nuwiq, FVIII-6rs and FVIII-19M. The graph indicates the amount of 
generated peak thrombin, the area under the curve and the time to peak thrombin generation. 
 
 
Figure 4-33: Results of the TGA for ReFacto AF, Nuwiq, FVIII-19M and FVIII-6rs. All products were diluted to 0.25 U/ml, 
0.063 U/ml and 0.016 U/ml FVIII activity. Each point indicates the results from one TGA. The line indicates the median of the 
four performed assays. Statistical analysis was performed using the Friedman test. (A) Amount of generated peak thrombin for 
each product at the given concentration based on a thrombin standard. (B) Area under the curve for each product at the given 
concentration. (C) Time to peak thrombin generation for each product at the given concentration. 
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As the interaction with vWF is important for FVIII, the binding potency of FVIII-19M and FVIII-6rs 
to vWF was determined in an ELISA-based approach (3.4.4). ReFacto AF was used as a reference and 
the potency of the binding of ReFacto AF to vWF was set to 1. All other potencies were calculated in 
relation to ReFacto AF. The data revealed that the vWF binding was similar for ReFacto AF and Nuwiq 
but impaired for FVIII-6rs and FVIII-19M (Figure 4-34). However, the only significant difference could 
be detected between Nuwiq and FVIII-19M (Table A-6). The reduced binding, also of FVIII-6rs, might 
have been due to different post-translational modifications made by the CAP-T cells. This could be 
correlated with the reduced sulfation detected in the in the Western Blot (Figure 4-26). Missing sulfation 
might have influenced the vWF binding, as especially the sulfation at Y1699 is important for the binding 
of vWF. However, decreased sulfation could not have been the only reason for the reduced vWF-binding, 
as ReFacto AF revealed nearly no sulfation on the Western Blot but good vWF-binding. The reduction in 
the potency of FVIII-19M in comparison to FVIII-6rs might have been due to additional structural 
changes, derived from the incorporated mutations, influencing the vWF binding. 
 
 
Figure 4-34: Potency of the vWF binding of the different FVIII products. The potency of ReFacto AF binding to vWF was set to 1 
and was the reference for the other products. Each point indicates the results from one ELISA. The line indicates the median of 
the three performed assays. Statistical analysis was performed using the Friedman test. 
 
In total, the analyses revealed similar band patterns for FVIII-19M and FVIII-6rs, regarding heavy, 
light and single chain amounts, as well as after deglycosylation and thrombin activation. In comparison 
to that, the amount of single chain was lower for Nuwiq and ReFacto AF. The shift of the heavy chain 
bands of ReFacto AF and Nuwiq compared to FVIIII-19M and FVIII-6rs were expected, as a larger part 
of the B domain was deleted in these constructs. The deglycosylation revealed a band shift for all four 
FVIII products, indicating that glycosylation took place during production of all FVIII variants. The band 
patterns after thrombin activation were also similar for all products, except for the two additional bands 
derived from the cleavage of the single chain forms of FVIII-19M and FVIII-6rs. The main differences 
between the controls and FVIII-19M and FVIII-6rs were detectable regarding sulfation. The Western Blot 
revealed nearly no sulfation in the heavy and light chain of FVIII-19M and FVIII-6rs, only slight sulfation 
in ReFacto AF and high sulfation in Nuwiq. The reduced sulfation in the heavy and light chain of FVIII-
19M and FVIII-6rs might explain the detected reduced potency to bind vWF. Nevertheless, this cannot 
be the only explanation as the slightly sulfated ReFacto AF revealed good vWF-binding. Regarding 
clotting time, all four products were similar, although a slight prolongation was detected for FVIII-6rs 
and FVIII-19M. Nevertheless, these prolonged clotting times were still in the regular range. The TGA 
results were similar to the clotting times, revealing a slightly lower amount of generated thrombin with 
FVIII-19M compared to ReFacto AF, Nuwiq and FVIII-6rs. These results indicated, together with the 
reduced clotting activity, that the generated FVIII variant containing 19 amino acid mutations had a 
slightly reduced activity compared to the other products. However, FVIII-19M proved to be functional in 
all performed assays. 
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4.5. In vitro immunogenicity assay 
 
In order to determine whether less CD4+ T cells become activated, due to a reduced presentation 
of FVIII-19M peptides on the surface of DCs, an in vitro DC-T cell Assay was established. The assay 
consisted of DCs, derived from monocytes, and CD4+CD25- T cells. The CD4+CD25+ T cells were depleted 
prior to co-cultivation, as this subpopulation comprised mainly regulatory T cells. This was important, 
due to the fact that the cells for the assay were derived from healthy donors and expected to contain 
regulatory T cells, suppressing the FVIII-specific CD4+ T cells which were not depleted during 
ontogeny190. Consequently, as the aim of the assay was to stimulate these FVIII-specific T cells, the 
regulatory T cells had to be depleted. The approach to use only DCs as APCs, was chosen due to two 
reasons. On the one hand, the focus was on the activation of CD4+ T cells based on the interaction with 
the presented FVIII epitopes. Influences due to interaction with other immune cells might have distorted 
the results. On the other hand, the assay was planned to be performed also with cells derived from 
Hemophilia A patients. These patients might still have naïve T cells and the activation of naïve T cells 
primarily occurs by DCs. In the case of choosing a general PBMCs assay, the amount of DCs would 
probably have been too low to activate the naïve CD4+ T cells.  
The assay was developed in several steps. In the beginning the cells were co-cultured in 24-well 
plates. Using this approach, it was possible to harvest and analyze the adherent DCs and determine 
whether differentiation to mDCs occurred. In order to reduce the amount of cells, the assay was then set 
to a 48-well format. In this setup the DCs were no longer harvested and the CD4+CD25- T cells were 
directly added to the mDCs. The cells for each experiment were purified from PBMCs. These PBMCs, 
derived from either whole blood donations or leukapheresis, were frozen after purification (3.2.4.2). As 
the generation of mature DCs took 6 days whereas the CD4+CD25- T cells were only cultured for 2 days 
prior to co-cultivation, purification of the two cell types occurred at different days. A scheme of the assay 
structure is illustrated in Figure 4-35. The monocytes were purified from PBMCs as described in 3.2.4.3 
and further on differentiated to iDCs, using IL-4 and GM-CSF, and finally stimulated for 24 hours, in 
order to obtain mDCs (3.2.4.6). In parallel, the CD4+CD25- T cells were purified from PBMCs two days 
prior to the co-cultivation with the mDCs (3.2.4.4). After the purification, the CD4+CD25- T cells were 
labelled with CFSE (3.2.4.5) and cultured for 2 days, in order to recover from the purification and 
labeling process (3.2.4.7). Co-cultivation finally occurred as described in 3.2.4.8. After 9 days of co-
cultivation, the cells were analyzed by flow cytometry (3.3.1) and the remaining supernatant was frozen 
for cytokine arrays (3.3.2). 
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Figure 4-35: Scheme of the DC-T cell Assay. DCs and T cells were processed in parallel. Monocytes were purified from PBMCs, 
differentiated to iDCs and finally stimulated to become mDCs. CD4+CD25- T cells were also purified from PBMCs and cultivated 
prior to co-cultivation, in order to regenerate. The co-culture occurred for 9 days and afterwards the cells were analyzed by flow 
cytometry and the remaining supernatant was applied to a cytokine array. 
 
In order to determine the appropriate stimulus for the maturation of the monocyte-derived iDCs, 
different approaches were tested. These approaches comprised stimulation with 0.05 µg/ml LPS, an IL-
Mix consisting of IL-1β, IL-6, IL-8 and TNF-α and an IL-Mix consisting only of IL-1β, IL-6 and TNF-α. All 
interleukins were applied to a final concentration of 10 ng/ml, except for IL-6, which was applied to a 
final concentration of 20 ng/ml. All stimuli were also tested in combination with either 1 mg/ml OVA or 
5 U/ml ReFacto AF. The cells were harvested after 24 hours of stimulation and the expression of the 
surface receptors HLA-DR, CD40, CD80 and CD86 was analyzed by flow cytometry (3.3.1), using the DC 
stain (Table 3-2). As a reference, unstimulated iDCs were also analyzed. The gating strategies for the 
DCs after 24 hours of stimulation is depicted in Figure 4-36. 
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Figure 4-36: Gating strategy for DCs. In the first step, the lymphocyte population was determined via sideward and forward 
scatter. In the next step, only single cells were selected. Further on, viable DCs were detected by the expression of CD209 and a 
low signal for the viability dye Zombie Violet. This population was used for the determination of the expression of HLA-DR, 
CD40, CD80 and CD86.  
 
The results of the mean fluorescence intensities (MFI), for the fluorochrome-coupled antibodies 
detecting the different receptors on the DCs, are summarized in Figure 4-37 (median of MFIs see Table 
A-7). Only the MFIs of viable CD209+ DCs were used based on the gating presented in Figure 4-36. The 
floating bars represent the results of three to five healthy donors. The bars range from the lowest to the 
highest value and the middle line indicates the median of the results. For all receptors, except for CD86, 
the MFI results were widely spread, which was due to the natural diversity of the different donors. In 
general, all receptors were upregulated upon the addition of the maturation stimuli. This indicates that 
the iDCs differentiated to mDCs and were able to present peptides via HLA-DR as well as to provide co-
stimulatory signals via CD40 and CD80/CD86. However, no significant differences were detectable 
between LPS and the two IL-Mixes (Table A-8). Upon the addition of the proteins OVA and ReFacto AF 
a slight but not significant decrease in the expression of CD80 and CD86 were detectable, especially 
when the DCs were stimulated with LPS. The reason for this was not further investigated. Without the 
addition of an IL-Mix or LPS the antigens OVA and ReFacto AF led to nearly no increase of the co-
stimulatory receptors. Only a slight increase in HLA-DR was detectable indicating that antigen 
presentation might have occurred without additional stimuli. However, as the co-stimulatory signals 
were required, LPS or an IL-Mix had to be added to the iDCs. Depending on the results, all three stimuli 
would have been appropriate for the maturation of iDCs, as all revealed a clear although not significant 
difference in the MFIs, compared to the unstimulated iDCs. 
 
 Results  89 
 
Figure 4-37: MFI of fluorochrome-coupled antibodies against the indicated surface receptors. The floating bars represent the 
MFI values of three to five healthy donors, indicating the minimum, maximum and median value. Only the MFI of viable, single-
cell CD209+ DCs were used for the analysis. (A) Expression of HLA-DR detected with the antibody anti-HLA-DR FITC. (B) 
Expression of CD40 detected with the antibody anti-CD40 APC-H7. (C) Expression of CD80 detected with the antibody anti-CD80 
APC. (D) Expression of CD86 detected with the antibody anti-CD86 PerCP-Vio700. 
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The viability of the DCs after 24 hours of stimulation was also determined using the DC stain. The 
results are displayed in Figure 4-38 and Table 4-4. The viabilities ranged between 78 % and 92 %. 
Reduced viabilities were mainly detected for the stimulated DCs, however the differences were not 
significant (Table A-9) and the values were still appropriated for cells cultured for 6 days and also for 
further co-cultivation with T cells. The addition of OVA led to the largest reduction of viability in all 
setups. This was not expected, however it might have been due to the preparation of the OVA, although 
an endotoxin-free preparation was used. Nevertheless, this preparation might still have contained 
additional substances, influencing the viability of the cells. 
 
 
Figure 4-38: Viability of the DCs after 24 hours of stimulation. The floating bars represent the viability of three to five healthy 
donors, indicating the minimum, maximum and median value. The viability was detected using the viability dye Zombie Violet. 
The viability was calculated on all single lymphocytes. 
 
Table 4-4: Median viability of the differently stimulated DCs. The median was calculated from the viability of three to five healthy 
donors per DC stimulation condition. 
DC stimulus Added protein Median viability of DCs 
No stimulus 
No protein 90.9 % 
OVA 82.4 % 
ReFacto AF 91.7 % 
LPS 
No protein 86.7 % 
OVA 83.7 % 
ReFacto AF 89.8 % 
IL-Mix 
No protein 87.3 % 
OVA 85.5 % 
ReFacto AF 87.8 % 
IL-Mix (w/o IL-8) 
No protein 87.8 % 
OVA 78.4 % 
ReFacto AF 88.2 % 
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The stimulated DCs were further on co-cultivated with CD4+CD25- T cells. As the co-cultivation 
occurred in fresh medium, no proteins or interleukins from the DC stimulation were present that could 
have influenced the T cell proliferation. Due to low amounts of available CD4+CD25- T cells, not all 
differently stimulated DCs could be tested in combination with CD4+CD25- T cells for every donor. 
However, three to six co-cultures, with cells from different donors, were performed for every stimulation 
approach. After 9 days of co-cultivation the CD4+ T cells were harvested and analyzed by flow cytometry 
(3.3.1), using the T cell proliferation stain (Table 3-5). The DCs remained in the plates, attached to the 
surface. The proliferation of the T cells was determined by the fluorescence reduction of the incorporated 
dye CFSE, as the amount of CFSE was equally split during cell division. Additionally, the expression of 
CD25 indicated activated T cells. The gating strategy is illustrated in Figure 4-39. 
 
 
Figure 4-39: Gating strategy for T cells. In the first step, the lymphocyte population was determined via sideward and forward 
scatter. In the next step, only single cells were selected. Further on viable CD4+ T cells were detected by the expression of CD4 
and a low signal for the viability dye 7-AAD. This population was used for the determination of the expression of CD25. 
Proliferation was determined for the populations of CD4+ T cells, CD4+CD25- T cells and CD4+CD25+ T cells via CFSE intensity. 
 
The analyses of the T cells after 9 days of co-cultivation revealed that the proliferation of all CD4+ 
T cells was increased when the DCs were previously stimulated with one of the IL-Mixes (Figure 4-40 A 
and Table 4-5). When stimulated with LPS an increase in proliferation was detectable, however the 
response did not reach the results generated with IL-Mix-stimulated DCs. When comparing the influence 
of the added proteins, OVA led to an increase in T cell proliferation in combination with all stimuli 
compared to the addition of ReFacto AF or no protein. Interestingly, the addition of ReFacto AF led to a 
reduction of T cell proliferation in the group with LPS stimulation and in the group without any further 
stimulation compared to the stimulation containing no additional protein. In the groups stimulated with 
the two IL-Mixes, the addition of ReFacto AF however led to an increase in T cell proliferation compared 
to the stimulation containing no additional protein. When investigating the T cell response in more 
detail, the data revealed that most of the proliferating CD4+ T cells were also CD25+, indicating T cell 
activation, whereas the CD25- T cells revealed nearly no proliferation (Figure 4-40 B and C and Table 
4-5). In line with the results of low receptor expression on DCs that were not stimulated with LPS or an 
IL-Mix (Figure 4-37), CD4+ T cell proliferation was also very low in these co-cultivations. In general, no 
DC stimulation condition led to significantly increased CD4+ T cell proliferation (Table A-10). 
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Nevertheless, LPS could be excluded as stimulus, due to the lower proliferation results. The differences 
in proliferation in response to the IL-Mixes with and without IL-8 were only small. Due to this, the IL-
Mix without IL-8 was further on used for DC stimulation, as it was comparable to the published DC 
stimulation protocols. In order to be in line with the published concentrations of the given interleukins, 
the added concentration of IL-6 was reduced to 10 ng/ml207,210. This stimulus was further on called IL-
Mix. The published Prostaglandin E2 (PGE2) was not added to the IL-Mix, as PGE2 was mainly added to 
induce homing of the generated DCs to secondary lymphoid organs and this was not necessary in the 
DC-T cell Assay208,224. 
 
 
Figure 4-40: Floating bars representing the proliferation of CD4+ T cells. The floating bars represent the proliferation of the CD4+ 
T cells of three to six healthy donors, indicating the minimum, maximum and median value. The proliferation was calculated on 
all viable CD4+ T cells. (A) Proliferation of all CD4+ T cells. (B) Proliferation of CD4+CD25+ T cells. (C) Proliferation of CD4+CD25- T 
cells. 
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Table 4-5: Median of proliferation of the different T cell populations in response to the differently stimulated DCs. The median 
was calculated from the response of three to six healthy donors per DC stimulation condition. 
DC stimulus Added protein 
Median 
proliferation of 
CD4+ T cells 
Median 
proliferation of 
CD4+CD25+ T cells  
Median 
proliferation of 
CD4+CD25- T cells  
No stimulus 
No protein 3.5 % 0.2 % 2.7 % 
OVA 6.8 % 3.2 % 3.6 % 
ReFacto AF 2.5 % 0.3 % 2.1 % 
LPS 
No protein 13.2 % 5.0 % 5.2 % 
OVA 21.7 % 14.2 % 4.5 % 
ReFacto AF 8.5 % 5.3 % 2.7 % 
IL-Mix 
No protein 37.0 % 31.6 % 5.4 % 
OVA 56.1 % 48.0 % 7.1 % 
ReFacto AF 45.2 % 40.1 % 6.6 % 
IL-Mix 
(w/o IL-8) 
No protein 32.4 % 26.5 % 5.9 % 
OVA 41.4 % 33.2 % 8.1 % 
ReFacto AF 38.4 % 30.6 % 7.8 % 
 
The next step in the development of the assay was the reduction of the culture volume from 600 µl 
in a 24-well plate to 300 µl in a 48-well plate, in order to reduce the amount of cells. A reduction to 
100 µl in a 96-well plate was not possible, because this volume would have been too small to perform 
cytokine arrays after the co-cultivation. As the 48-wells were too small to harvest the DCs using a cell 
scraper, the CD4+CD25- T cells were directly added to the adherent DCs after removal of the cell culture 
supernatant. In order to ensure a DC:T cell ratio of at least 1:10, the amount of DCs of five healthy 
donors after differentiation and stimulation was determined by counting the adherent cells. Prior to 
counting, the supernatant was removed and fresh X-VIVO 15 was added, in order to remove dead cells. 
Initially 3·105 monocytes were seeded in each well. The results of the cell count after 5 days of 
differentiation and 24 hours of stimulation is shown in Figure 4-41. The cells were counted in an area 
of 1.4 mm2. The chosen area comprised neither the middle of the well nor the borders, in order not to 
distort the results. The final cell number was calculated for the full area of 87.5 mm2. The cell numbers 
varied between 1·104 DCs and 7·104 DCs with medians of 3·104 DCs and 4·104 DCs, depending on donor 
and stimulus. Excluding the highest and the lowest value, which only occurred once, the amount of 
added CD4+CD25- T cells per well was set to 6·105 cells for all further experiments. This ensured a DC:T 
cell ratio of at least 1:10, assuming a maximum of 6·104 DCs.  
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Figure 4-41: Cell number of mDCs per well of a 48-well plate. A defined area of each well was counted and the total cell number 
was calculated for the whole area. The cell number was calculated for different maturation stimuli and for five different healthy 
donors. The lines indicate the median cell number for each maturation stimulus. 
 
After the determination of the assay conditions, the DC-T cell Assay was performed with FVIII-19M 
and FVIII-6rs. The cells were purified from PBMCs of healthy donors (3.2.4.3 and 3.2.4.4). The DCs were 
stimulated after differentiation either with the previously determined IL-Mix alone or with the IL-Mix 
and additional proteins. The additional proteins were ReFacto AF as a positive control for FVIII-specific 
CD4+ T cell proliferation and FVIII-6rs and FVIII-19M as the proteins of interest. Based on published 
data, the concentration of the FVIII products was increased to 15 U/ml190. The co-cultivation occurred 
in 48-well plates, as described in 3.2.4.8 leading to a DC:T cell ratio of at least 1:10. All cells were 
analyzed by flow cytometry (3.3.1) after their purification (Table 3-2 to Table 3-4), in order to ensure 
purity, prior to co-cultivation, in order to exclude pre-activation, and after 9 days of co-cultivation (Table 
3-5).  
The results from the flow cytometric analyses of the T cells after 9 days of co-cultivation were 
further analyzed. The proliferation of all CD4+ T cells was determined for every approach. In total 23 
different healthy donors were analyzed. Donors, which revealed a higher CD4+ T cell response to DCs 
only treated with the IL-Mix than with the IL-Mix and ReFacto AF or FVIII-6rs, were excluded form the 
final analysis. These healthy donors were assumed not to react to FVIII, which was expected, as not all 
healthy donors possess CD4+ T cells against FVIII. Based on this selection, the results of 17 healthy 
donors were taken to the final statistical analysis (detailed proliferation results Table A-11). Additionally, 
when comparing the viabilities of the differently stimulated T cells after 9 days of co-cultivation, seven 
donors revealed a difference in the amount of viable T cells stimulated with either IL-Mix plus FVIII-19M 
or IL-Mix plus FVIII-6rs larger than 50 % (detailed viability results Table A-12). This was not detectable 
for the other donors and the reason could not be identified. 
Figure 4-42 displays the difference between the CD4+ T cell proliferation to DCs stimulated with 
IL-Mix plus FVIII-19M and the CD4+ T cell proliferation to DCs stimulated with IL-Mix plus FVIII-6rs. 
Results below 0 indicate a reduced CD4+ T cell response to FVIII-19M compared to FVIII-6rs. The 
turquoise bars indicate the seven donors with the high difference in the amount of viable T cells. A 
reduced response to FVIII-19M was detected in most donors. However, results above 0 were detected in 
five donors. Even though, the differences in proliferation were below 10 % for these donors, whereas 
even higher differences were detected in the group of donors, showing a reduced response to FVIII-19M. 
Altogether the amount of donors revealing a reduced response to FVIII-19M was larger, leading to a 
significant reduction in CD4+ T cell proliferation to DCs stimulated with IL-Mix and FVIII-19M when 
comparing all 17 donors (Table A-13). However, even after the exclusion of the seven indicated donors 
the result was still significant, only leading to a slight increase of the P value (Table A-13). 
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Figure 4-42: Difference between the CD4+ T cell proliferation against DCs stimulated with IL-Mix plus FVIII-19M and DCs 
stimulated with IL-Mix plus FVIII-6rs. The bars below 0 indicate a reduced CD4+ T cell response to FVIII-19M. The green bars 
indicate donors with a huge difference in the viability of the differently stimulated T cells. The lower CD4+ T cell response to 
FVIII-19M compared to FVIII-6rs is significant using the Wilcoxon test. 
 
The supernatants of the co-cultivations were further analyzed in a cytokine array (3.3.2). The 
cytokine profiles for the co-cultivations stimulated with IL-Mix plus FVIII-19M and IL-Mix plus FVIII-6rs 
were determined. In total, the cytokines were analyzed for 14 of the 17 donors, missing Donor #4, #13 
and #14. Due to the small volume of available supernatant and the preparation of a control, only 100 µl 
of supernatant were applied to a membrane. For a better comparability of the results, the signals for the 
different cytokines were normalized to the signal of the control. Unfortunately, no meaningful conclusion 
could be drawn from the array (Figure A-5). For nearly all cytokines, relative signals between 30-40 % 
were detected (Table A-14). This was independent of the FVIII variant present in the co-cultivation. The 
signals for cytokines expressed by macrophages, monocytes and all different T helper cell lines were 
similar. As this was also true for the five cytokines with significant differences in the signal between co-
cultivations containing FVIII-6rs and FVIII-19M, these results were not considered meaningful. In 
general, the similar results for all cytokines might have been a consequence of the artificial assay setup 
or the small volume applied, which was only 10 % of the recommended volume. In vivo a larger amount 
of different cytokines and cells would interact, probably leading to a more meaningful cytokine profile. 
For five of the donors included in the final proliferation analysis, the HLA genotype was available. 
This was used to calculate the Individual T cell Epitope Measure (iTEM) scores. The iTEM scores were 
calculated using the same tools as described in 3.1. However, whereas the previous analyses were 
performed for HLA class II supertype alleles, the iTEM score indicates the immunogenicity of a protein 
for the specific genotype of one person. This was performed for the FVIII-19M and FVIII-6rs for Donors 
#1, #2, #3, #6, #8 and #10. The difference in the iTEM scores between FVIII-19M and FVIII-6rs for 
each donor was plotted against the corresponding difference in CD4+ T cell proliferation (Figure 4-43). 
This revealed that with an increasing difference in iTEM score, corresponding to a higher influence of 
the deimmunization on the given genotype, the difference in proliferation increased too. This was the 
case for Donor #2, #8 and #10. Donor #1 and #6 revealed a lower influence of the deimmunization 
on the proliferation than expected based on iTEM score. This shows that immunogenicity is not only 
dependent on the sequence of the peptides. Donor #3, who showed an increase in CD4+ T cell 
proliferation to FVIII-19M, was however the one with the lowest difference in iTEM scores, indicating 
the lowest influence of the incorporation of the 19 mutations on the immunogenicity. These data 
revealed that the in silico analyses could be confirmed with the developed in vitro DC-T cell Assay. 
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Figure 4-43: Relation between the differences in iTEM scores and proliferation. The iTEM scores for FVIII-19M and FVIII-6rs were 
calculated for donor #1, #2, #3, #6, #8 and #10, based on their HLA genotype. The differences of the iTEM scores were plotted 
against the differences in CD4+ T cell proliferation, determined in the DC-T cell Assay. 
 
Altogether, the results from the in vitro DC-T cell Assay revealed a reduced CD4+ T cell 
proliferation in response to the deimmunized FVIII variant containing the 19 amino acid mutations. 
However, some donors showed an increase in CD4+ T cell proliferation to FVIII-19M. Unfortunately, the 
HLA genotype of only one of these donors was available. Nevertheless, the iTEM analysis for this donor 
revealed that the incorporation of the 19 mutations only led to a slight reduction in immunogenicity 
with the given HLA genotype. This might have been one reason why no reduction in CD4+ T cell 
proliferation was detectable. Nevertheless, not only the HLA genotype had an influence on the presented 
peptides but also other factors, like the expression of intracellular proteases and the available CD4+ T 
cell pool, which differ between persons. This is the reason why even patients with the same HLA 
genotype do not present the same peptides of a protein174. Even though, the assay demonstrated to be a 
useful tool to determine immunogenicity of a protein in vitro and indicated a correlation to the in silico 
modelled immunogenicity. 
Unfortunately, it was not possible to determine the proliferation of CD4+ T cell derived from 
Hemophilia A patients. This was because the amount of available blood was even smaller than expected 
and the amount of available PBMCs was not sufficient to perform the established DC-T cell Assay. 
 
 
 
4.6. In vivo mouse models 
 
For the first in vivo experiments, the E16 FVIII KO model was used. All experiments were 
performed by EpiVax. Prior to the study an in silico analysis was performed, in order to determine how 
many epitopes were present in the FVIII-19M, FVIII-6rs and ReFacto AF, taking into account the murine 
HLA background. The results are presented in Table 4-6. The analysis revealed that the deimmunized 
FVIII-19M contained 86 immunogenic epitopes compared to 94 epitopes in the FVIII-6rs. Due to this, a 
reduction in immunogenicity might be detectable in these mice, however no large differences were 
expected. ReFacto AF was found to have one epitope less compared to FVIII-6rs, which was due to the 
differences in the B domain deletion. However, the total immunogenicity score of FVIII-6rs was lower 
than the immunogenicity score of ReFacto AF. This was also due to the larger B domain deletion in 
ReFacto AF compared to FVIII-6rs and FVIII-19M, as the immunogenicity score was calculated in relation 
to the size of the protein.  
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Table 4-6: In silico analysis of the different FVIII products based on the HLA background of the E16 FVIII KO mice. The total 
amount of epitopes and the immunogenicity score was calculated for FVIII-19M, FVIII-6rs and ReFacto AF. 
Amount of epitopes Immunogenicity score 
FVIII-19M FVIII-6rs ReFacto AF FVIII-19M FVIII-6rs ReFacto AF 
86 94 93 4.89 16.89 22.58 
 
The mice were immunized with FVIII-19M, FVIII-6rs, ReFacto AF or FVIII Formulation Buffer, as 
described in 3.6.1.2. Each product was applied to ten mice. After four injections of 4 U FVIII product or 
FVIII Formulation Buffer and a fifth injection of 8 U FVIII or FVIII Formulation Buffer per mouse, the 
mice were euthanized. The plasma was isolated for the determination of the generation of anti-FVIII 
antibodies and the splenocytes were purified and restimulated in an in vitro assay, in order to determine 
whether FVIII-specific CD4+ T cells had evolved. 
The anti-FVIII antibody ELISA was performed as described in 3.6.2.3, using the goat anti-mouse 
IgG-Peroxidase as secondary detection antibody. The results are presented in Figure 4-44. The ELISA 
revealed anti-FVIII antibodies in at least four of ten mice, regardless whether they were immunized with 
ReFacto AF, FVIII-19M or FVIII-6rs. Only the mice injected with FVIII Formulation Buffer developed no 
antibodies, showing that the response was FVIII-specific. Although the antibody titers were slightly 
higher for ReFacto AF and FVIII-6rs compared to FVIII-19M no significant difference was detectable 
(Table A-15).  
 
 
Figure 4-44: Anti-FVIII antibody ELISA for the immunized E16 FVIII KO mice. Plasma samples were applied in 1:3 serial dilutions. 
The detection of the bound antibodies occurred via a goat anti-mouse IgG-Peroxidase secondary antibody. (A) Results for mice 
injected with FVIII Formulation Buffer. ReFacto AF was coated to the plate. Two mice died during the experiment. (B) Results 
for mice injected with ReFacto AF. (C) Results for mice injected with FVIII-6rs. (D) Results for mice injected with FVIII-19M. 
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The isolated splenocytes of the mice were cultivated as described in 3.6.2.2. This in vitro assay was 
performed directly after the isolation of the cells, avoiding freezing and thawing of the cells. The 
splenocytes of each mouse were stimulated with either PBS or the FVIII product used for immunization. 
The control mice, which were immunized with FVIII Formulation Buffer, were stimulated with ReFacto 
AF. After 4 days of cultivation, the cells were harvested and analyzed by flow cytometry. The 
proliferation of the CD4+ T cells is displayed in Figure 4-45. A restimulation of the CD4+ T cells with 
FVIII was possible when the mice were initially immunized with FVIII. When PBS was used for 
restimulation no proliferation was detectable, indicating that the proliferation was FVIII-specific. When 
comparing the median of CD4+ T cell proliferation for PBS- and FVIII-restimulation for each FVIII 
product, ReFacto AF and FVIII-6rs led to a significant increase in proliferation (Table A-16). In contrast 
to that, only a slight but not significant increase in CD4+ T cell proliferation was detectable when FVIII-
19M was used for restimulation compared to PBS. The restimulation of CD4+ T cells derived from the 
control mice with ReFacto AF also revealed no significant proliferation compared to PBS restimulation. 
These results matched the antibody titers determined in the ELISA and hint towards a reduced 
immunogenicity of the FVIII-19M. 
 
 
Figure 4-45: Proliferation of CD4+ T cells derived from splenocytes of E16 FVIII KO mice. The amount of proliferating CD4+ T cells 
is indicated for every mouse restimulated with either PBS or FVIII, depending on their initial immunization. The line indicates 
the median for each group. Statistical analysis was performed using the Wilcoxon test. 
 
Based on the results of the anti-FVIII antibody ELISA and the CD4+ T cell restimulation assay a 
slightly reduced immunogenicity of the FVIII-19M in the E16 FVIII KO model was detected. However, a 
higher reaction of the murine immune system to the applied FVIII products was expected, as E16 FVIII 
KO mice do not produce functional FVIII. Generating a higher response might have led to a greater range 
in which differences in response to the FVIII products would have been easier to detect. However, it is 
known that non-functional parts of the murine FVIII heavy chain are present in these mice225. Probably 
these peptides induced tolerance, leading to the low response to the applied FVIII products. When 
repeating the study, nearly no response to the positive control ReFacto AF was detectable. This may have 
been due to the fact that the final boost of the murine immune system with 8 U FVIII was replaced by 
an application of 4 U FVIII per mouse. 
In the second in vivo experiment, BRGSF mice were immunized with ReFacto AF, FVIII-6rs and 
FVIII-19M. These mouse experiments were performed by Axenis. Compared to the E16 FVIII KO mice, 
the BGRSF mice had a human immune system and due to this, human MHC class II. Therefore, the 
originally calculated immunogenicity scores (Figure 4-14) were applicable to this mouse model. 
Unfortunately, the BRGSF mice were not FVIII-deficient and were expected to be able to develop 
tolerance to the murine FVIII. Three different stem cell donors were used for the generation of the BRGSF 
mice. Five mice were immunized per FVIII product as described in 3.6.1.1. For each group, mice with 
two to three different HLA backgrounds were used. After four injections of 200 U FVIII product per kg 
body weight and a final injection of 400 U/kg FVIII the mice were euthanized. The plasma was isolated 
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and the splenocytes were purified. Plasma and splenocytes were frozen for shipment and stored at 
-150 °C for the anti-FVIII antibody ELISA and the in vitro CD4+ T cell restimulation assay. 
The anti-FVIII antibody ELISA was performed similar to the ELISA with the plasma of the E16 FVIII 
KO mice, except that the plasma samples were initially applied undiluted (3.6.2.3). Additionally, mouse 
anti-human IgM-HRP and mouse anti-human IgG-HRP were used as secondary detection antibodies, as 
humanized mice were expected to produce IgM as well as IgG. The detection of anti-FVIII IgG and IgM 
was performed in parallel for each mouse. The results for the study are presented in Figure 4-46. 
Unfortunately, no anti-FVIII-IgG were detectable in any of the three groups of mice. A detection of very 
low amounts of anti-FVIII-IgM was possible, however as a mouse was considered to be antibody-negative 
when the absorbance was below 0.2, only one mouse at all, immunized with FVIII-19M, revealed anti-
FVIII-IgM. Even for this mouse the absorbance was below 0.4 at a sample dilution of 1:30, indicating 
only a very low amount of anti-FVIII antibodies.  
 
 
Figure 4-46: Anti-FVIII antibody ELISA for the immunization experiment with BRGSF mice. Plasma samples were applied in 1:3 
serial dilutions. The detection of the bound antibodies occurred via a mouse anti-human IgG-HRP or a mouse anti-human IgM-
HRP secondary antibody. 17001, 17002, 17003 and 17014 indicate the three different human stem cell donations used for the 
transplantation, whereof 17001 and 17002 are based on the same donor. The numbers 0-21 indicate a specific mouse in a group 
with identical stem cell background. (A) Results for mice injected with ReFacto AF. (B) Results for mice injected with FVIII-6rs. 
(C) Results for mice injected with FVIII-19M. 
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The isolated splenocytes were thawed and cultivated as described in 3.6.2.1 and 3.6.2.2. The 
splenocytes of each mouse were restimulated with either cell culture medium or the FVIII product used 
for immunization. Due to the freezing and thawing, a loss of cells was inevitable, which made it 
impossible to perform both stimulations for some splenocyte preparations. In these cases, the 
restimulation with the FVIII product was preferred. After 4 days of cultivation, the cells were harvested 
and analyzed by flow cytometry (3.3.1), using the T cell proliferation stain for humanized mouse 
splenocytes (Table 3-6). The proliferation of the CD4+ T cells is illustrated in Figure 4-47. Unfortunately, 
nearly no proliferation of CD4+ T cells was detectable. Due to this no significant differences could be 
detected (Table A-17). Only CD4+ T cells of 1 out of 15 mice revealed proliferation comparable to the 
results with the E16 FVIII KO mice. 
 
 
Figure 4-47: Proliferation of CD4+ T cells derived from splenocytes of BRGSF mice. The amount of proliferating CD4+ T cells is 
indicated for every mouse restimulated with either medium or FVIII depending on their initial immunization. The line indicates 
the median for each group. 
 
The anti-FVIII antibody and the CD4+ T cell restimulation results from the BRGSF mice indicate 
that this mouse model is not appropriate for the detection of an immune response to FVIII. Only one 
mouse revealed a low amount of anti-FVIII antibodies and one mouse showed a slight proliferation in 
response to FVIII. Although both mice were of the FVIII-19M-immunized group, the mouse producing 
antibodies and the mouse revealing CD4+ T cell proliferation were not the same. The absence of an 
immune response indicates that the BRGSF mice developed tolerance to the murine FVIII, which seemed 
to suppress an immune response to human FVIII. 
In total, the humanized immune system of the BRGSF mice is preferred over the murine immune 
system of the E16 FVIII KO mice. Due to the human MHC class II, this model is the only possibility to 
prove the influence of the incorporated mutations on the presentation of peptides on the surface of 
antigen-presenting cells. However, the results of both mouse models also revealed the importance of the 
total absence of FVIII in these mice. In both mouse models, tolerance to FVIII seemed to be present, 
which suppressed the immune response to FVIII, especially in the BRGSF mice. Based on these results a 
humanized mouse model with a total knockout of the FVIII gene is required, in order to be able to 
determine an influence of a deimmunized FVIII variant on the immune response. 
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5. Discussion 
 
One of the major drawbacks in FVIII therapy is the development of inhibitors against the 
therapeutic FVIII product. Although the rFVIII product by Bioverativ, Eloctate, might be less 
immunogenic, due to immune regulatory sequences in the attached Fc-part108, no deimmunized FVIII 
was yet developed. It was the aim of this thesis to develop such a FVIII molecule, in order to improve 
the FVIII therapy and by this the life of the patients. 
The in silico analyses were performed with the EpiMatrix tools provided by EpiVax. This system 
was chosen, as it not only provides the detection of immunogenic peptides but also additional tools 
leading to a recommendation of mutations for deimmunization. Additionally, the system was already 
successfully used to deimmunize other proteins184,185. For deimmunization, the sequence of a B domain-
deleted FVIII was chosen. B domain deletion is implemented since second generation rFVIII products, as 
it reduces the size of the protein without impairing its functionality89,226,227. In addition to that, potential 
immunogenic peptides in the B domain were already removed without the need to insert mutations. 
The EpiMatrix tool revealed many immunogenic clusters throughout the whole molecule (4.1). 
This was expected, as the antibody repertoire of the patients is known to be very diverse121. Of the 52 
detected immunogenic clusters 36 overlapped with already published, experimentally determined 
peptides84,174,228,229. In these publications, peptides were eluted from the MHC class II, derived from 
different Hemophilia A donors with different HLA types, and subsequently sequenced. Taking into 
consideration that the immunogenic clusters are larger than the eluted peptides, 28 peptides overlapped 
completely with the in silico determined clusters and eight overlapped by two to eight amino acids. 
Thirteen of the clusters deimmunized in the FVIII-19M were still overlapping with the experimentally 
defined peptides. Nine peptides overlapped completely and four overlapped partly with the mutated 
clusters in the FVIII-19M. In addition to the exact determination of presented peptides, restimulation 
experiments of CD4+ T cells with FVIII peptides were published127,230–232. Peptides from the A2, A3, C1 
and C2 domain were used for the restimulation of T cells either only derived from Hemophilia A patients 
with inhibitors or from Hemophilia A patients with and without inhibitors, acquired Hemophilia A 
patients and healthy donors. Although differences were detectable among the different groups, dominant 
peptides, leading to a high CD4+ T cell response in several groups, could be detected. Only two of the 
14 published dominant peptides were not detected during the in silico calculations. Finally, three of the 
19 mutations in FVIII-19M laid within these peptide sequences. Another study already indicated that the 
incorporation of amino acid mutations into FVIII leads to a reduced binding to MHC class II in vitro and 
to a reduced immunogenicity in vivo173. The experiments were performed with the C2 domain of FVIII. 
The in silico analyses were conducted with the previously describes tools (3.1) and up to three mutations 
were incorporated into different C2 peptides. The in vitro binding assays revealed reduced binding for 
most of the mutated peptides and a reduced immunogenicity was detectable for some peptides in 
different mouse models. In vitro as well as in vivo the peptides containing more mutations led to a greater 
reduction in binding and immunogenicity. Although the experimental setup was artificial, due to the 
addition of peptides and not a full protein, the results indicated that the in silico calculated mutations 
influenced the binding to the MHC class II and by that the immunogenicity. Three of these mutated 
amino acids were part of the initially tested 57 mutations, which were recommended for the FVIII 
deimmunization, although different amino acids were selected for substitution. Unfortunately, none of 
the three mutations from the publication was incorporated into the final FVIII-19M. This was mainly 
because in the publication only peptides were investigated, not taking into consideration whether the 
mutations disrupt the FVIII activity. Additionally, the publication only focused on the C2 domain. In 
general, deimmunizations based on in silico analyses were already successfully performed for other 
proteins like erythropoietin178 and the bispecific, FVIII-mimicking antibody Emicizumab184. Altogether 
these published results hint towards a clinical relevance of the identified immunogenic clusters and 
indicate that the used in silico method was appropriate for the analysis of immunogenic FVIII peptides 
and the deimmunization of FVIII. 
Nevertheless, the results also revealed that some clusters could not be altered, neither in silico nor 
experimentally (4.2). In silico alterations failed in cases where immunogenic clusters comprised cleavage 
or binding sites or where possible mutations were known to lead to Hemophilia A. Only one alteration 
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near a cleavage site was tested. As expected the incorporation of mutation F1710H near the thrombin 
cleavage site at R1708 led to a strong reduction in activity, probably due to impaired thrombin cleavage 
(Figure 4-3 C). Although in this case an aromatic amino acid was replaced by another aromatic amino 
acid, a histidine is naturally not very common in this position233. For some clusters, the insertion of up 
to three different mutations was tested. However, in some cases none of the single mutations could be 
incorporated into the FVIII sequence (Figure 4-3). Although none of these mutations were associated 
with Hemophilia A or in close proximity to sites of post-translational modification, cleavage or binding, 
the incorporations led to reduced activities or the total absence of the FVIII variants. The reasons for this 
remain to be elucidated but most likely the mutations had a negative influence on the structure of FVIII, 
impairing proper folding and due to this functionality. This indicates how important further 
investigations on the secondary and tertiary structure of FVIII are. A high-resolution model of FVIII 
would provide the possibility to model the incorporation of mutations in silico, revealing mutations that 
might impair the structure. 
When comparing the amount of immunogenic clusters per domain, taking into account the size of 
the domain, no large differences were detectable between the domains. Only the C2 domain revealed a 
slightly higher amount of immunogenic clusters. However, after identifying the mutations that could be 
incorporated into the FVIII molecule, it became obvious that most of the 19 mutations were located in 
the A1 and A2 domain. These results might be due to the importance of the A3, C1 and C2 domain for 
the functionality of FVIII. Especially in the tenase complex these domains are essential for interactions. 
The FVIII antigen results also support this theory, as the variants with more mutations in the A3C1C2 
domain were mostly expressed but revealed reduced activity (Figure 4-8 to Figure 4-10). This indicated 
that production and secretion of these FVIII molecules was not impaired by the mutations. 
Whether the incorporated 19 amino acid mutations also disrupt B cell epitopes was not further 
investigated. It is known that T and B cell epitopes can cluster within a short sequence127,234. Based on 
the known B cell epitopes for FVIII, the mutations S507E, F555H and K1837E are also part of B cell 
epitopes235–237. Additionally, the mutations S2315T and V2333A are in close proximity to B cell 
epitopes238,239. However, apart from disrupting B cell epitopes, the incorporation of amino acid mutations 
can also generate new ones. However, further work is needed, in order to determine whether the 
mutations have an influence on B cell epitopes. 
In general, the introduction of the mutations into the FVIII sequence was feasible and the chosen 
strategy to perform several rounds was very successful (Figure 4-13). The decision to transfer only one 
mutation per immunogenic cluster to the second screening round was made, in order to reduce the 
probability of an inactive FVIII, and was based on the calculations indicating that the introduction of 
both mutations would not further reduce the immunogenicity score. The DOE matrices proved to be a 
good tool, in order to detect the mutations that interfered with the activity of the FVIII molecule (Figure 
4-8). Finally, a combination of mutations could be found for the A2 and A3C1C2 domain, using this tool 
(Figure 4-10). Further variants with alternative mutations were not generated, as for most of the 
excluded mutations no alternatives were available. Nevertheless, it would be interesting to determine, 
whether the incorporation of more than one mutation per cluster would still lead to a functional FVIII 
molecule and whether this would result in a further reduction of the immunogenicity of the molecule, 
although in silico calculations indicate that the influence is marginal. However, based on the findings 
from the three rounds, adding more mutations would be associated with the need to produce many 
variants, in order to find a combination of mutations not interfering with the activity of FVIII. 
The final FVIII-19M was calculated to have an immunogenicity score of -10.55 compared to an 
initial score of 7.01 for the FVIII-6rs, revealing a reduction by 17.56 points (Figure 4-14). Taking into 
consideration that this reduction was achieved by changing only 1.25 % of the FVIII amino acid 
sequence, the process was very efficient. Additionally, a negative immunogenicity score corresponds to 
a lower amount of immunogenic epitopes compared to a protein with a random sequence. This and the 
proximity to the immunogenicity score of albumin, a well tolerated endogenous protein, supports the 
assumption that FVIII-19M would be better tolerated by the immune system. 
For the production of FVIII-19M and FVIII-6rs the cell line was switched from HEK 293-F to CAP-
T. This cell line was shown to be superior in the production of high amounts of large and complex 
proteins198,240,241. This was confirmed, as up to 2 U/ml FVIII were produced by CAP-T cells whereas only 
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about 1 U/ml were reached using HEK 293-F cells. The applied production and purification methods 
were appropriate for this stage of development (4.3). Due to the high amounts of FVIII produced by the 
CAP-T cells after transient transfection, the yield of about 50 % after purification was still enough for 
further experiments. However, these techniques have to be improved for large-scale productions. On the 
one hand, a stable transfection of CAP cells and the selection of single cell clones, highly expressing the 
FVIII molecule, will increase the amount of produced FVIII-19M. On the other hand, adaptions during 
chromatography and concentration of the purified product will increase the yield. Adaptions in the 
chromatography buffers and the replacement of spin columns for concentration by tangential flow 
filtration might already lead to an improvement, as seen with other FVIII molecules. 
The different structural and functional analyses of the FVIII-19M and FVIII-6rs proved to be useful 
for the characterization of the two molecules (4.4). The comparison to the already approved products 
ReFacto AF and Nuwiq provided encouraging results. However, the analyses also revealed where further 
investigations are needed.  
The detection of the different FVIII products on a Western Blot, with antibodies specifically 
detecting the heavy and the light chain of FVIII, revealed the first similarities and differences between 
the products (Figure 4-24). In general, heavy chain, light chain and single chain of FVIII was present in 
all four products, however the ratios were different. Whereas Nuwiq and ReFacto AF consisted mainly 
of double-chain FVIII, detected as heavy and light chain, nearly no single-chain FVIII was present. In 
contrast to that, the FVIII-19M and FVIII-6rs samples revealed about 50 % single chain. As neither the B 
domain deletion nor the incorporated mutations interfered with the furin cleavage site responsible for 
the generation of the double-chain variant, it is unlikely that the high amount of single chain was due to 
variations in the amino acid sequence. The strongest influence, on whether single- or double-chain FVIII 
was secreted, might have had the cell line in which the FVIII was produced. Different expression levels 
of furin or other intracellular proteases in the different cell lines HEK, CHO and CAP-T, might have led 
to different cleavage patterns of FVIII. Another reason for the low amounts of single chain in ReFacto 
AF and Nuwiq might have been due to a depletion of single-chain FVIII during the purification process, 
as this is more extensive than for FVIII-19M and FVIII-6rs. However, this issue was not further followed, 
as the activation by thrombin was not impaired in the single-chain variant compared to the double-chain 
variant. In addition to this, the rFVIII product Afstyla, by CSL Behring, which is especially designed to 
be secreted as a single chain, is already approved as a therapeutic FVIII product103,106. This indicates that 
the presence of FVIII as a single-chain variant is not a negative result. The development of future FVIII 
products might even concentrate on single-chain variants, as it facilitates production and purification of 
the FVIII product, due to the fact that the molecule is more stable than the double-chain variant, which 
is mainly held together by a divalent cation. 
In addition to the different amounts of single and double chain, the blot revealed the different 
molecular weights of the heavy chains between the four products (Figure 4-24). The FVIII-19M and 
FVIII-6rs heavy chains revealed a higher molecular weight compared to the heavy chains of ReFacto AF 
and Nuwiq. This was expected as more amino acids of the B domain were deleted in ReFacto AF and 
Nuwiq. Additionally, two slightly distinct heavy chains were detected for ReFacto AF, due to proteolytic 
variations at the C-terminus227. These differences were not detectable for any of the other products and 
might have been due to the different production cell lines. In contrast to that, more than one light chain 
band was detectable for every product. Differences in the molecular weight of the light chain were 
probably based on slight differences at the N-terminus and on post-translational modifications227. These 
modifications were most likely different glycosylations242,243 as the difference between a Tyrosine and a 
Sulfotyrosine is only 80 Da and due to that not detectable on the presented Western Blot. In total, four 
different bands for the light chain were identified, considering that the light chains with a higher 
molecular weight contained a higher amount of glycosylation. FVIII-19M and FVIII-6rs revealed to posses 
light chains with high molecular weights whereas Nuwiq and ReFacto AF possessed mainly one high and 
one lower molecular weight light chain. The lower molecular weight light chain was more dominant in 
ReFacto AF whereas the high molecular weight light chain was more dominant in Nuwiq. The amount 
of the two light chain forms in FVIII-19M and FVIII-6rs were similar. The light chain with the lowest 
molecular weight could only be detected for Nuwiq and ReFacto AF. The results were consistent with 
the published characteristics for ReFacto AF and Nuwiq227,243. In general, these were the first results 
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hinting towards differences in the glycosylation of FVIII-19M, FVIII-6rs and Nuwiq compared to ReFacto 
AF. All three products were produced in human cell lines whereas ReFacto AF was produced in a non-
human mammalian cell line. Still, the Western Blot did not reveal whether this was due to different 
glycosylation patterns or due to more glycosylated sites in general. In order to determine this, a detailed 
mass spectrometric analysis of the glycosylations is required.  
The Western Blot presenting the FVIII products in their glycosylated and deglycosylated form 
supported the assumptions made from the Western Blot detecting the heavy and light chain of FVIII. A 
clear band shift was detectable after deglycosylation for each band of every FVIII product, indicating 
that glycosylation occurred in every cell line (Figure 4-25). Unfortunately, the deglycosylation of the 
products was not complete, as even after the deglycosylation, light chains with different molecular 
weights were still detectable. In the case of a complete deglycosylation a maximum of two bands for the 
light chain were expected based on published results for ReFacto227. As before, no conclusion could be 
drawn regarding the amount and kind of glycosylations. Different glycosylation patterns are expected 
for the different cell lines and were already proven for ReFacto AF and Nuwiq42,227. These analyses also 
revealed that only four of the available six N-glycosylations sites were occupied, similar to pFVIII. 
Additionally, different glycosylation patterns for the same glycosylation site occurred within one cell 
line. Detailed glycosylation analyses for FVIII-19M and FVIII-6rs are outstanding and new production 
and purification of the two variants is required for this, as high amounts of protein are needed for 
glycosylation analyses. Still, these analyses are expected to reveal diverse glycosylation patterns, as the 
production is not yet restricted to a single cell clone. 
Most of the findings from the Western Blot detecting heavy and light chain of FVIII were also 
shown in the 2D-DIGE results (Figure 4-27 to Figure 4-29). This method provided an even more detailed 
analysis of the different products, as a direct overlay was possible. Regarding ReFacto AF and Nuwiq, 
the 2D-DIGE confirmed the existence of two heavy chains in ReFacto AF and also revealed a second 
heavy chain for Nuwiq, though in an even lower amount compared to ReFacto AF. In addition to the 
differences in molecular weight, the FVIII was also separated based on the pI. Unfortunately, the IEF 
was not very clear but it revealed that different pIs were present in the heavy and light chains probably 
due to different post-translational modifications. Additionally it might indicate the slightly reduced pI of 
the FVIII-19M compared to FVIII-6rs, as some spots, especially of the light chain, differed in this first 
dimension (Figure 4-28 C). In order to be able to draw more conclusions from the IEF, the method has 
to be improved for FVIII. The main differences detected on the 2D-DIGE were impurities. Whereas 
ReFacto AF and Nuwiq revealed no contaminating proteins, the purifications of FVIII-19M and FVIII-6rs 
still contained proteins other than FVIII (Figure 4-28 A and B). This was expected, as the purification 
method was not adapted to the clinical standard of the commercially available products. Due to this, it 
is highly likely that these contaminating proteins were host cell proteins, which were not removed during 
purification. Mass spectrometric analysis could be used, in order to identify these spots. 
The last analysis of the FVIII proteins confirmed the presence of sulfotyrosines in all tested FVIII 
products (Figure 4-26). However, the Western Blot did not indicate how many tyrosines were sulfated. 
In general, the lowest signal was detected in the light chains, containing only two of the six sulfation 
sites. The highest signal was detected for the single chain, as this form contains all six sulfation sites. 
Compared to the other products, the detected amount of sulfotyrosines appeared to be lower in ReFacto 
AF. This was in line with published data, investigating the sulfation of the most important site Y1699. 
The mass spectrometric data revealed that non-sulfated Y1699 is present in ReFacto but not in Nuwiq42. 
In order to confirm the Western Blot results, the detection of the sulfotyrosines has to be improved and 
repeated. For more detailed analyses of FVIII-19M and FVIII-6rs, mass spectrometric analyses are 
required. 
As the FVIII-19M demonstrated to be functional after production and purification, no differences 
in structure and post-translational modifications were expected compared to the other FVIII products. 
This was confirmed by the different SDS-PAGE and Western Blots. The main difference was the amount 
of single chain present in the FVIII-19M and FVIII-6rs, however this is not expected to have an influence 
on the functionality of these variants. Sulfation and glycosylation was similar for the different products, 
confirming post-translational modification of the FVIII products produced in the CAP-T cells. Whether 
these modifications match the ones on pFVIII in structure and amount has to be confirmed. In general, 
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these modifications are very important in vivo. Although glycosylation patterns of rFVIII products are no 
longer considered to be the main reason for the immunogenicity, glycosylation is important for the 
proper function of FVIII244,245. However, it cannot be excluded that potentially immunogenic 
glycosylation patterns derive from non-human mammalian cell lines like BHK and CHO. In contrast to 
that, correct sulfation, especially at Y1699, is important for vWF-binding and due to this for a reduced 
immunogenicity. The shielding of FVIII from uptake by APCs is one of the many advantages of the FVIII-
vWF interaction. As only FVIII taken up and presented by APCs can elicit an immune response, vWF-
binding can reduce the amount of FVIII presented to the immune system and based on this the immune 
response56,244. Additionally, a study revealed that the binding to vWF not only reduces the uptake of 
FVIII but also alters the presented peptides84. The profile of presented peptides of cells pulsed with FVIII-
vWF revealed missing but also additional peptides in comparison to cells only pulsed with FVIII. The 
study also revealed that the amount of peptides, which are no longer presented, increased with 
increasing vWF concentrations. Further analyses with FVIII-19M and FVIII-6rs will reveal the detailed 
glycosylation and sulfation patterns and indicate whether they are more similar to Nuwiq than ReFacto 
AF, due to the production in a human cell line. 
The first analysis regarding functionality of the FVIII-19M was the determination of the thrombin-
cleavage pattern (Figure 4-30). Cleavage by thrombin was expected, as the FVIII-19M was active. 
However, the detailed cleavage pattern was unknown. In general, the fragments of FVIII after thrombin 
cleavage were similar for all four FVIII products and comprised all expected fragments227. In contrast to 
ReFacto AF and Nuwiq, FVIII-19M and FVIII-6rs showed two additional bands on the Western Blot which 
probably resulted from the cleavage of the single chain. As for the deglycosylation, the thrombin 
activation was not complete, revealing a low amount of bands not cleaved by thrombin. Even though, 
the thrombin activation showed the expected pattern of FVIII fragments, confirming that the insertion 
of the mutations did not influence the thrombin cleavage. 
First indications for influences of the 19 mutations on the functionality of FVIII were received from 
the ROTEM and TGA analyses. Whereas the ROTEM indicated a prolonged clotting time for FVIII-19M 
in contrast to FVIII-6rs and especially to ReFacto AF and Nuwiq, the TGA confirmed significantly lower 
amounts of generated peak thrombin, area under the curve and a longer time to peak thrombin 
generation with FVIII-19M compared to ReFacto AF and Nuwiq (Figure 4-31, Figure 4-33 and Table A-3 
to Table A-5). For both assays, the differences were less pronounced with FVIII concentrations around 
0.01 U/ml. This was probably due to the highly reduced clotting capacity at this concentration, 
resembling severe Hemophilia A, which made differences less obvious. The reason for the differences in 
thrombin generation and clotting time with FVIII-19M compared to the other products is not clear. Either 
the mutations really influenced the functionality of the FVIII-19M or the determined chromogenic 
activity values for FVIII-19M were overestimated. When comparing the specific activities based on the 
chromogenic activities between FVIII-19M and FVIII-6rs the results were similar (Figure 4-23) and in 
line with published specific activities for Nuwiq and ReFacto243. When the specific activities were based 
on the clotting activities, the results were generally reduced compared to the specific activities based on 
the chromogenic activity. Additionally, a discrepancy between the specific activities of FVIII-19M and 
FVIII-6rs became obvious (Figure 4-23). That the chromogenic assay leads to higher activity results for 
rFVIII products compared to the clotting assay is known31,221, nevertheless the chromogenic assay is 
preferred over the clotting assay and commonly used. Clotting activity:chromogenic activity ratios of 
0.88 for Nuwiq and 0.75 for ReFacto are published243 and in line with the ratio of 0.78 for FVIII-6rs. The 
reduction of the ratio to 0.51 for FVIII-19M was not expected. These results hint towards an 
overestimation of the FVIII-19M activity with the chromogenic assay. As the activities for all analyses 
were based on these chromogenic activities, less active FVIII-19M might have been present in the ROTEM 
and TGA analyses compared to the other FVIII products. Considering the clotting activities, in these 
experiments only 50-70 % active FVIII-19M, depending on the used production and purification, were 
present compared to FVIII-6rs. This might be one explanation for the potentially impaired functionality 
of the FVIII-19M. However, it is not clear why the two activity assays lead to different results. Further 
work is needed, in order to determine the reason for the different results. Additionally, TGA and ROTEM 
should be replicated with FVIII activities based on the clotting method. 
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Comparable to the ROTEM and TGA results, also the FVIII-binding to vWF was impaired for FVIII-
19M (Figure 4-34 and Table A-6). This was not expected as the primary structure and the post-
translational modifications, especially the sulfation, were proven to be present in the FVIII-19M and 
comparable to FVIII-6rs. The overestimation of the FVIII-19M activity is unlikely to be a reason for this 
result, as the same reagents were used for the chromogenic assay and the development of the vWF-FVIII 
ELISA. Due to this, the overestimation would be expected in both assays. The only difference was the 
dilution of FVIII in FVIII-deficient plasma for the chromogenic assay and in Tris-NaCl Buffer for the 
ELISA. As all required clotting factors, except FVIII, were present in sufficient amounts in the Coatest SP 
FVIII Kit, the FVIII-deficient plasma might only have had an influence on the stability of FVIII. This 
influence could not be ruled out as a reason for reduced vWF binding, as all other assays were always 
performed with FVIII diluted in this plasma. Nevertheless, this would indicate that FVIII-19M is more 
instable than the other FVIII products. Another reason for reduced vWF-binding could be a slightly 
different folding of the protein, which has an influence on the binding to vWF. This would not have been 
detected with the Western Blot analyses. Due to the important impact of vWF-binding on FVIII, further 
work is needed, in order to determine the kinetics and affinity of the binding between FVIII-19M and 
vWF. Using the surface plasmon resonance method, these parameters were already published for Nuwiq 
and ReFacto, revealing no significant difference between these two products243. 
In general, these analyses prove that the FVIII-19M is functional and structural intact, possessing 
all expected post-translational modifications. These are the first results for a FVIII molecule containing 
deliberately incorporated mutations in the whole molecule, which is still functional. However further 
investigations are needed. On the one hand, mass spectrometric analyses have to be performed, in order 
to reveal glycosylation and sulfation in detail. On the other hand, the presumably reduced activity of 
FVIII-19M has to be further evaluated and the functional assays should be repeated based on the clotting 
activities. Nevertheless, these results prove that the incorporation of mutations into FVIII for 
deimmunization is feasible without disrupting the structure and functionality of the molecule. 
The in vitro DC-T cell Assay was developed, in order to determine whether the incorporation of 
the 19 amino acid mutations led to a reduction in CD4+ T cell response (4.5). Originally, the assay was 
designed to consist of naïve CD4+ T cells and DCs, in order to monitor the initial response to FVIII. The 
development of this assay was feasible with cells derived from healthy donors, using Ovalbumin as the 
antigenic protein. However, for the final analysis PBMCs derived from PUPs would have been required. 
Unfortunately, it proved to be impossible to receive sufficient amounts of blood from these patients, as 
they are mainly babies and toddlers, leading to blood donation samples of about 3 ml. Combining 
different samples of one patient, collected at different time points, was not possible as the patients were 
mostly treated after the detection of the disease. Combination of blood donations from different patients 
was also impossible, as this would have led to a mixture of different HLA types, leading to invalid results. 
However, it was published that anti-FVIII antibodies123,159 as well as FVIII-reactive CD4+ T cells124,187 can 
be detected in healthy people. A response to FVIII by CD4+ T cells derived from healthy donors was even 
shown to be enhanced when regulatory T cells were depleted190. Probably, these self-reactive CD4+ T 
cells were not depleted during ontogeny and regulatory mechanisms evolved, in order to protect the 
immune system from an autoimmune response. Based on this, the T cell population of the assay was 
switched from a naïve CD4+ T cell population to a regulatory T cell-depleted CD4+ T cell population. 
Due to this modification, the use of cells derived from healthy donors became possible. However, not all 
healthy donors were expected to have CD4+ T cells reacting to FVIII. In addition to the cells derived 
from healthy donors, also cells from PTPs could be tested with this assay setup. As these patients’ immune 
system has already been in contact with FVIII, PTPs without inhibitors are expected to be tolerant to the 
therapeutic FVIII. These patients either developed tolerance during ontogeny in the case that they are 
expressing endogenous FVIII or developed regulatory T cells, in order to suppress an immune response 
to therapeutic FVIII. The group of PTPs with inhibitors is expected to have CD4+ T cells reacting to FVIII, 
as they are required for the development of the high-affinity antibodies. Unfortunately, it is not yet 
understood which mechanisms lead to a successful ITI. Different theories are published, considering the 
development of anti-idiotypic antibodies and regulatory B and T cells as well as the death of the reacting 
B and T cells112,155,156,246. Except for the case that the CD4+ T cells were deleted during ITI, also cells 
from inhibitor patients could be tested in the DC-T cell Assay after the depletion of the regulatory T cells.  
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All experiments during the development of the assay revealed good results. Differentiation and 
maturation of the DCs was successful and the widely published IL-Mix207,210 proved to lead to a good 
expression of HLA-DR and co-stimulating receptors (Figure 4-37), resulting in the published phenotype 
of mature monocyte-derived DCs210,247. These mDCs were further on able to stimulate the proliferation 
of CD4+CD25- T cells (Figure 4-40). The T cells revealed to be pure and viable after purification and 
prior to the co-cultivation. Neither CD4+CD25+ T cells nor unspecific proliferation was detected after 
two days of cultivation. In order to reduce the amount of required cells, the DCs were not harvested for 
the final assays. This was possible as the cells tightly attached to the surface of the cell culture plate. 
However, due to this no exact DC:T cell ratios were available for the experiments. Nevertheless, based 
on the pre-experiments, a minimum of ten CD4+ T cells per DC was ensured (Figure 4-41). This was 
appropriate, as one DC was considered to be sufficient for the activation of up to 20 CD4+ T cells248. 
The results of the DC-T cell Assay with the healthy donors revealed a reaction to FVIII in more 
than 70 % of the patients, which was in line with the literature124. However, as expected, CD4+ T cells 
derived from some donors did not show any reaction to FVIII. The final analysis of proliferating cells 
was based on all CD4+ T cells. Statistical analyses were performed on the one hand for all 17 healthy 
donors, which responded to FVIII, and on the other hand, for a smaller group containing only 10 healthy 
donors, excluding donors, which revealed large differences in the amount of viable CD4+ T cells. A 
reason for the differences in viability could not be found, as none of the used materials was changed and 
no contaminations were detectable. Nonetheless, the statistical analysis revealed a significantly reduced 
proliferative response of CD4+ T cells to FVIII-19M compared to FVIII-6rs for both groups (Figure 4-42 
and Table A-13). However, a reaction to FVIII-19M was not completely absent. Even though, this was 
expected, as some regions of FVIII could not be altered and were still immunogenic. Unfortunately, the 
assay could not be performed with cells from PTPs, as the volume of received blood was less than 
expected and for most donors the amount of available cells was too low to perform the assay. 
Additionally, a replication of the results with cells derived from the same healthy donors was not 
possible, due to the limited numbers of available cells. Therefore, the DC-T cell Assay should be repeated 
either with fresh cells from the same donors or with cells from additional donors, in order to rule out 
assay variabilities and to further validate the determined significant difference in immunogenicity of 
FVIII-19M and FVIII-6rs. 
The performed cytokine arrays with the supernatants derived from the co-cultivations did not lead 
to meaningful results. Similar signals were detected for nearly all cytokines, even for cytokines not 
expected to be present like IL-28A, which is naturally expressed upon viral infection249,250. One reason 
for this might have been deviations from the manufacturer’s protocol. On the one hand, the amount of 
cell culture supernatant applied to the membrane was only 10 % of the recommended volume, as the 
amount of available supernatant was low. On the other hand, the samples were labeled with the 
fluorescent dyes prior to application to the membrane, in order to enable the detection of the differently 
labeled sample and control on one blot. Another reason might have been the artificial setup of the assay. 
In vivo CD4+ T cells also interact with other immune cells especially by secretion and uptake of different 
cytokines. As no cytokines derived from cells other than DCs were present, this might have led to the 
highly variable results. 
The iTEM scores calculated for the five donors with the known HLA genotype supported the results 
of the DC-T cell Assay (Figure 4-43). For all donors a reduced iTEM score for FVIII-19M compared to 
FVIII-6rs was calculated. Donor #3 showed the lowest difference in the iTEM scores. Consistent with 
this result, this was a donor revealing a slightly higher proliferation to FVIII-19M than to FVIII-6rs. For 
Donors #2, #8 and #10 the in silico calculated deimmunization of FVIII-19M was clearly confirmed in 
the in vitro assay. Higher differences in the iTEM scores corresponded with higher differences in 
proliferation. However, Donors #1 and #6 proved that in silico analyses are limited. Although a high 
difference between the iTEM scores were calculated, only low differences in the proliferation to FVIII-
19M and FVIII-6rs were detectable. This was expected, as the available CD4+ T cell pool of a donor and 
the expression of proteases cleaving the protein also influence the in vitro results174. Nevertheless, a 
repetition of the DC-T cell Assay with cells from these donors would be beneficial. The correlation might 
become significant when assay variabilities can be ruled out due to sufficient replicates.  
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Taking into consideration the results from the functional analysis, indicating that the FVIII-19M 
activity might has been overestimated with the chromogenic assay, this might also have influenced the 
DC-T cell Assay. The added amounts of FVIII-19M and FVIII-6rs were based on the chromogenic activity 
results, whereas the amount of ReFacto AF was based on the activity indicated on the package insert. 
The activity values and not the antigen values were used for the assay, as this is analogous to the clinical 
treatment, where FVIII is applied according to the activity. In the case that the chromogenic activity 
values for FVIII-19M were actually overestimated, less FVIII-19M would have been added to the cells 
compared to FVIII-6rs. However, when comparing the antigen values, the added amounts of FVIII-19M 
and FVIII-6rs were nearly similar. Due to this, possibly incorrect FVIII-19M activity values might not 
have had an influence on the assay, as the FVIII did not have to be active in the DC-T cell Assay. 
Altogether the DC-T cell Assay confirmed a reduced immunogenicity of the FVIII-19M compared 
to FVIII-6rs in healthy donors. This in vitro analysis supported the in silico calculations. Based on this, 
the established DC-T cell Assay proved to be a useful tool in the determination of FVIII immunogenicity 
in vitro. The possibility to be able to perform this assay with cells derived from healthy donors and 
Hemophilia A patients, PTPs as well as PUPs, is a huge advantage. Although PBMCs are not the optimal 
cell population for this assay, cells derived from spleen or lymph nodes are not available, neither from 
healthy donors nor from patients. Nevertheless, the results revealed a restimulation of CD4+ T cells, 
which was high enough to lead to reliable results. The only drawback of the assay is the high amount of 
cells, which is needed to perform this assay. This is mainly due to the need to split monocyte and 
CD4+CD25- T cell purification and the loss of cells during purification and CFSE labeling. Further 
development might solve this problem. If possible, the cells could be sorted by FACS and the proliferation 
dye could be changed. Another possibility would be the shift from DCs and T cells to an assay containing 
all PBMCs. A purification of monocytes would no longer be required, as DCs and especially B cells, acting 
as APCs, would be already present. This would reduce the amount of cells and the total time needed to 
perform the assay. However, in this setup a depletion of regulatory T cells as well as a labeling with a 
proliferation dye would still be needed. 
Whether the results from the DC-T cell Assay can be used to predict the response to the different 
FVIII variants in vivo needs to be elucidated. Although the assay is very artificial compared to the complex 
interactions in vivo, the most important cell types were present. In order to gain further proof of the 
concept and to support the in vitro results, a detailed analysis of the presented peptides would be very 
beneficial. However, as this is dependent on the purification of the MHC class II from the cells, elution 
of the bound peptides and mass spectrometric analyses, high amounts of FVIII are needed. Nevertheless, 
this is a very effective method, in order to prove that the peptides containing the mutations are no longer 
presented. In the case that this mass spectrometric analysis corresponds to the in vitro DC-T cell Assay 
results, a success in vivo with a deimmunized FVIII-19M would be likely.  
The confirmation of the in vitro results in vivo was limited, due to the lack of an appropriate mouse 
model (4.6). Although the results from the E16 FVIII KO model hinted towards a reduced 
immunogenicity of FVIII-19M, no explicit results could be detected in any of the two mouse models. In 
the E16 FVIII KO model, a reaction to ReFacto AF and FVIII-6rs as well as to FVIII-19M was expected 
based on in silico calculations, taking into consideration the murine HLA background. Nevertheless, the 
in silico tools still calculated a slightly reduced immunogenicity for FVIII-19M compared to FVIII-6rs and 
ReFacto AF (Table 4-6). The study revealed slightly lower but not significantly different anti-FVIII 
antibody titers in FVIII-19M immunized mice compared to ReFacto AF or FVIII-6rs immunized mice 
(Figure 4-44 and Table A-15). However, a significant lower amount of proliferating CD4+ T cells was 
detected upon restimulation with FVIII-19M (Figure 4-45 and Table A-16). Unfortunately, these results 
could not be confirmed in a second study, as the positive control ReFacto AF did not lead to an immune 
reaction in these mice. This might have been due to a change in the immunization protocol, injecting 
4 U FVIII instead of 8 U FVIII at the last time point. As pre-experiments with ReFacto AF and the protocol 
containing the 8 U FVIII injection revealed antibodies to FVIII in all mice, which is in line with published 
data251, this change in protocol might have led to the lack of an immune response. In general, only about 
50 % of the mice revealed an immune response at all. Especially for ReFacto AF and FVIII-6rs, a clear 
immune response was expected in most of the mice, based on the in silico immunogenicity calculations 
in which the murine HLA background was taken into consideration. One reason for this weak immune 
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response might have been the endogenous expression of parts of the FVIII heavy chain225, which might 
have induced tolerance to parts of FVIII. Based on this, these mice are not the appropriate model, in 
order to determine differences in immune response to deimmunized and non-deimmunized human FVIII 
variants. Nevertheless, the study should be repeated, in order to confirm the results from the first study. 
The results from the BRGSF mice did not correspond to the in vitro results, although the mice were 
humanized and three different HLA backgrounds were available. Whereas only a low response to FVIII-
19M was expected, the absent response to FVIII-6rs and ReFacto AF did not match the immunogenicity 
scores (Figure 4-14). However, as these mice produce endogenous murine FVIII, which has a homology 
to human FVIII of about 74 %245, tolerance can be expected. This corresponds to the results, revealing 
no anti-FVIII antibodies and no CD4+ T cell proliferation upon restimulation with FVIII in 14 of 15 mice 
(Figure 4-46 and Figure 4-47). A low titer antibody and a slight proliferative response were detected 
once each. However, these two results occurred in different mice. Although this might be possible, as 
the CD4+ T cells in the one mouse might not yet have let to a stimulation of B cells and antibody 
production whereas the generation of the anti-FVIII antibody in the other mouse might have been T cell-
independent, it is more likely that these results were artefacts. The detected antibody titer and the 
amount of CD4+ T cell proliferation were even lower than most of the results gained with the E16 FVIII 
KO mice. Nevertheless, the experiment has to be replicated, in order to confirm this assumption. 
In general, these two mouse models prove how important a total absence of FVIII is, in order to 
detect an evaluable response. A mouse model with total absence of FVIII (F8TKO)252, as well as HLA 
transgenic E16 FVIII KO mouse models173 are already available. Although HLA transgenic versions of the 
F8TKO model might also lead to evaluable results, different models would have to be generated, as one 
model is only transgenic for one HLA-type. This can be avoided by using the BRGSF mice, transplanted 
with cells from different donors. Additionally, BRGSF mice are the best available model of humanized 
mice, additionally providing human DCs, T, B and NK cells. Due to this, a BRGSF F8TKO model would be 
optimal, in order to determine differences in immune response to different human FVIII variants. These 
mice would not have established any tolerance to FVIII and would provide a humanized immune system. 
Based on this it would be possible to directly confirm the in silico calculations without having to take a 
murine HLA background into consideration. The current absence of such a mouse model underlines the 
importance of a reliable in vitro assay with human cells for the determination of FVIII immunogenicity. 
Taking together all results, the data revealed that in silico calculated amino acid mutations can be 
incorporated into FVIII, still leading to a functional molecule. The FVIII-19M can be produced and 
purified similar to the reference FVIII and different methods comparing the protein structure and 
functionality revealed only minor differences to FVIII-6rs and commercially available products. In an in 
vitro DC-T cell Assay the incorporation of 19 mutations, changing only 1.25 % of the whole FVIII 
sequence, were confirmed to lead to a significant reduction in CD4+ T cell proliferation compared to the 
reference FVIII molecule without mutations. Due to this, FVIII-19M is the first FVIII molecule, which was 
deimmunized throughout the whole sequence, revealing reduced immunogenicity while retaining its 
functionality.  
Finally, if these results can be confirmed in vitro with cells derived from Hemophilia A patients as 
well as in an appropriate in vivo mouse model, this FVIII variant is capable of improving the FVIII therapy. 
The FVIII-19M will be a safer FVIII product for PUPs by reducing their risk of developing antibodies at 
all. Due to the lowered immunogenicity, a switch to FVIII-19M would also be expedient for PTPs without 
inhibitors, as it is known that inhibitors can still arise after years of treatment253. In the case of patients 
with inhibitors the FVIII-19M could be used after an ITI therapy or in case that an ITI therapy with a 
conventional FVIII failed. Although the mechanism underlying a successful ITI therapy is not yet clearly 
identified156,246, a deimmunized FVIII would support the aim to downregulate an immune response by 
reducing the amount of activated T helper cells and thereby the amount of newly emerging B cells. 
Patients with acquired Hemophilia A, although a very rare and diverse population3, might also benefit 
from this reduced T helper cell activation upon treatment with FVIII-19M. It could provide a possible 
therapy after the elimination of the inhibitor. Due to this the FVIII-19M will be a huge improvement of 
which nearly all Hemophilia A patients can benefit. In the long-term, this deimmunized variant can 
reduce the number of patients with inhibitors and the need for ITI therapy. By this, the FVIII-19M will 
not only improve the life of the patients but also reduce the costs for therapy. 
 References  111 
References 
 
1. Oldenburg, J., Ananyeva, N. M. & Saenko, E. L. Molecular basis of haemophilia A. Haemophilia 10 
Suppl 4, 133–139 (2004). 
2. Sharma, V., Khalid, A. & Cohen, A. J. Management of Pregnancy in a Patient with Severe Hemophilia 
Type A. AJP reports 3, 29–32 (2013). 
3. Mo, L. & Bao, G. C. Acquired factor VIII deficiency: two case reports and a review of literature. 
Experimental hematology & oncology 6, 1–7 (2017). 
4. Cugno, M., Gualtierotti, R., Tedeschi, A. & Meroni, P. L. Autoantibodies to coagulation factors: from 
pathophysiology to diagnosis and therapy. Autoimmunity Reviews 13, 40–48 (2014). 
5. Plug, I. et al. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood 104, 3494–
3500 (2004). 
6. Kemball-Cook, G., Tuddenham, Edward G. D. & Wacey, A. I. The Factor VIII Structure and Mutation 
Resource Site: HAMSTeRS Version 4. Nucleic Acids Research 26, 216–219 (1998). 
7. Hoyer Leon W. Hemophilia A. The New England Journal of Medicine 330, 38-47 (1994). 
8. Mann, K. G. Biochemistry and Physiology of Blood Coagulation. Thrombosis and Haemostasis 82, 
165–174 (1999). 
9. White II, G. C. et al. Definitions in Hemophilia. Recommendation of the Scientific Subcommittee on 
Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society 
on Thrombosis and Haemostasis. Thromb Haemost 85, 560 (2001). 
10. Fischer, K. et al. Changes in treatment strategies for severe haemophilia over the last 3 decades: 
effects on clotting factor consumption and arthropathy. Haemophilia 7, 446–452 (2001). 
11. Peyvandi, F., Garagiola, I. & Young, G. The past and future of haemophilia. Diagnosis, treatments, 
and its complications. The Lancet 388, 187–197 (2016). 
12. Chen, S.-L. Economic Costs of Hemophilia and the Impact of Prophylactic Treatment on Patient 
Management. American Journal of Managed Care 22, S126-S133 (2016). 
13. Key, N. S. & Negrier, C. Coagulation factor concentrates. Past, present, and future. The Lancet 370, 
439–448 (2007). 
14. Tiede, A. Half-life extended factor VIII for the treatment of hemophilia A. Journal of thrombosis and 
haemostasis : JTH 13 Suppl 1, 176-179 (2015). 
15. Björkman, S., Folkesson, A. & Jönsson, S. Pharmacokinetics and dose requirements of factor VIII over 
the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic 
treatment for haemophilia A. European journal of clinical pharmacology 65, 989–998 (2009). 
16. Berntorp, E. & Shapiro, A. D. Modern haemophilia care. The Lancet 379, 1447–1456 (2012). 
17. Gringeri, A., Wolfsegger, M., Steinitz, K. N. & Reininger, A. J. Recombinant full-length factor VIII 
(FVIII) and extended half-life FVIII products in prophylaxis - new insight provided by 
pharmacokinetic modelling. Haemophilia 21, 300–306 (2015). 
18. Gouw, S. C. et al. F8 gene mutation type and inhibitor development in patients with severe 
hemophilia A: systematic review and meta-analysis. Blood 119, 2922–2934 (2012). 
19. Scandella, D. Human Anti-Factor VIII Antibodies: Epitope Localization and Inhibitory Function. Vox 
Sanguinis 70, 9–14 (1996). 
20. van den Berg, H. Marijke. Different impact of factor VIII products on inhibitor development? 
Thrombosis J 14, 55-58 (2016). 
 112  References 
21. Hay, C. R. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Haemophilia 4, 558–
563 (1998). 
22. DiMichele, D. M., Hoots, W. K., Pipe, S. W., Rivard, G. E. & Santagostino, E. International workshop 
on immune tolerance induction: consensus recommendations. Haemophilia 13 Suppl 1, 1–22 (2007). 
23. Dekoven, M. et al. Health-related quality of life in haemophilia patients with inhibitors and their 
caregivers. Haemophilia 19, 287–293 (2013). 
24. Lindvall, K. et al. Increased burden on caregivers of having a child with haemophilia complicated by 
inhibitors. Pediatric blood & cancer 61, 706–711 (2014). 
25. Hollestelle, M. J. et al. Tissue Distribution of Factor VIII Gene Expression In Vivo - A Closer Look. 
Thromb Haemost 86, 855–861 (2001). 
26. Shahani, T. et al. Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII. J 
Thromb Haemost 12, 36–42 (2014). 
27. Wood, W. I. et al. Expression of active human factor VIII from recombinant DNA clones. Nature 312, 
330-337 (1984). 
28. Koedam, J. A., Hamer, R. J., Beeser-Visser, N. H., Bouma, B. N. & Sixma, J. J. The effect of von 
Willebrand factor on activation of factor VIII by factor Xa. Eur J Biochem 189, 229–234 (1990). 
29. Schaub, R. G. Recent advances in the development of coagulation factors and procoagulants for the 
treatment of hemophilia. Biochemical Pharmacology 82, 91–98 (2011). 
30. Oldenburg, J. & El-Maarri, O. New Insight into the Molecular Basis of Hemophilia A. International 
Journal of Hematology 83, 96–102 (2006). 
31. Orfeo, T., Elsman, R., Gissel, M., Mann, K. G. & Butenas, S. Activation, activity and inactivation of 
factor VIII in factor VIII products. Haemophilia 22, 462–473 (2016). 
32. Thompson, A. R. Structure and Function of the Factor VIII Gene and Protein. Semin Thromb Hemost 
29, 11–22 (2003). 
33. Gitschier, J. et al. Characterization of the human factor VIII gene. Nature 312, 326-330 (1984). 
34. Toole, J. J. et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 312, 
342–347 (1984). 
35. Vehar, G. A. et al. Structure of human factor VIII. Nature 312, 337–342 (1984). 
36. Bontempo, F. A. et al. Liver Transplantation in Hemophilia A. Blood 69, 1721–1724 (1987). 
37. Wion, K. L., Kelly, D., Summerfield, J. A., Tuddenham, Edward G. D. & Lawn, R. M. Distribution of 
factor VIII mRNA and antigen in human liver and other tissues. Nature 317, 726-729 (1985). 
38. Everett, L. A., Cleuren, A. C. A., Khoriaty, R. N. & Ginsburg, D. Murine coagulation factor VIII is 
synthesized in endothelial cells. Blood 123, 3697–3705 (2014). 
39. Fahs, S. A., Hille, M. T., Shi, Q., Weiler, H. & Montgomery, R. R. A conditional knockout mouse 
model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. 
Blood 123, 3706–3713 (2014). 
40. Fay, P. Factor VIII Structure and Function. International Journal of Hematology 83, 103–108 (2006). 
41. Ngo, Jacky Chi Ki, Huang, M., Roth, D. A., Furie, B. C. & Furie, B. Crystal Structure of Human Factor 
VIII: Implications for the Formation of the Factor IXa-Factor VIIIa Complex. Structure 16, 597–606 
(2008). 
42. Kannicht, C. et al. Characterisation of the post-translational modifications of a novel, human cell line-
derived recombinant human factor VIII. Thrombosis Research 131, 78–88 (2013). 
 References  113 
43. Pipe, S. W. Differential Interaction of Coagulation Factor VIII and Factor V with Protein Chaperones 
Calnexin and Calreticulin. Journal of Biological Chemistry 273, 8537–8544 (1998). 
44. Dorner, A. J., Bole, D. G. & Kaufman, R. J. The Relationship of N-linked Glycosylation and Heavy 
Chain-binding Protein Association with the Secretion of Glycoproteins. The Journal of Cell Biology 
105, 2265–2674 (1987). 
45. Michnick, D. A., Pittman, D. D., Wise, R. J. & Kaufman, R. J. Identification of Individual Tyrosine 
Sulfation Sites within Factor VIII Required for Optimal Activity and Efficient Thrombin Cleavage. 
Journal of Biological Chemistry 269, 20095–20102 (1994). 
46. Pittman, D. D., Wang, J. H. & Kaufman, R. J. Identification and Functional Importance of Tyrosine 
Sulfate Residues within Recombinant Factor VIII. Biochemistry 31, 3315–3325 (1992). 
47. Leyte, A. et al. Sulfation of Tyr1680 of Human Blood Coagulation Factor VIII Is Essential for the 
Interaction of Factor VIII with von Willebrand Factor. Journal of Biological Chemistry 266, 740–746 
(1991). 
48. Siner, J. I. et al. Circumventing furin enhances factor VIII biological activity and ameliorates bleeding 
phenotypes in hemophilia models. JCI Insight 1, 1–17 (2016). 
49. Wakabayashi, H., Koszelak, M. E., Mastri, M. & Fay, P. J. Metal Ion-independent Association of Factor 
VIII Subunits and the Roles of Calcium and Copper Ions for Cofactor Activity and Inter-Subunit 
Affinity. Biochemistry 40, 10293–10300 (2001). 
50. Bihoreau, N., Pin, S., Kersabiec, A.-M., Vidot, F. & Fontaine-Aupart, M.-P. Copper-atom identification 
in the active and inactive forms of plasma-derived FVIII and recombinant FVIII-ΔII. Eur J Biochem 
222, 41–48 (1994). 
51. Tagliavacca, L., Moon, N., Dunham, W. R. & Kaufman, R. J. Identification and Functional 
Requirement of Cu(I) and Its Ligands within Coagulation Factor VIII. Journal of Biological Chemistry 
272, 27428–27434 (1997). 
52. Shen, B. W. et al. The tertiary structure and domain organization of coagulation factor VIII. Blood 
111, 1240–1247 (2007). 
53. Saenko, E. L. & Scandella, D. The Acidic Region of the Factor VIII Light Chain and the C2 Domain 
Together Form the High Affinity Binding Site for von Willebrand Factor. Journal of Biological 
Chemistry 272, 18007–18014 (1997). 
54. Jacquemin, M. et al. A human antibody directed to the factor VIII C1 domain inhibits factor VIII 
cofactor activity and binding to von Willebrand factor. Blood 95, 156-163 (2000). 
55. Koedam, J. A., Meijers, J. C., Sixma, J. J. & Bouma, B. N. Inactivation of human factor VIII by 
activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. The 
Journal of clinical investigation 82, 1236–1243 (1988). 
56. Dasgupta, S. et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent 
presentation to immune effectors. Blood 109, 610–612 (2007). 
57. Lenting, P. J. et al. The Light Chain of Factor VIII Comprises a Binding Site for Low Density 
Lipoprotein Receptor-related Protein. Journal of Biological Chemistry 274, 23734–23739 (1999). 
58. Over, J. et al. Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. 
Observations on the heterogeneity of human Factor VIII. The Journal of clinical investigation 62, 223–
234 (1978). 
59. Nesheim, M. et al. The Effect of Plasma von Willebrand Factor on the Binding of Human Factor VIII 
to Thrombin-activated Human Platelets. Journal of Biological Chemistry 266, 17815–17820 (1991). 
60. Saenko, E. L. & Scandella, D. A Mechanism for Inhibition of Factor VIII Binding to Phospholipid by 
von Willebrand Factor. Journal of Biological Chemistry 270, 13826–13833 (1996). 
 114  References 
61. Lenting, P. J., Donath, Marie-José S. H., van Mourik, Jan A. & Mertens, K. Identification of a Binding 
Site for Blood Coagulation Factor IXa on the Light Chain of Human Factor VIII. Journal of Biological 
Chemistry 269, 7150–7155 (1994). 
62. Butenas, S. & Mann, K. G. Blood Coagulation. Biochemistry 67, 3–12 (2002). 
63. Bombeli, T. & Spahn, D. R. Updates in perioperative coagulation: physiology and management of 
thromboembolism and haemorrhage. British journal of anaesthesia 93, 275–287 (2004). 
64. Gailani, D. & Renné, T. Intrinsic pathway of coagulation and arterial thrombosis. Arteriosclerosis, 
Thrombosis, and Vascular Biology 27, 2507–2513 (2007). 
65. Pieters, J., Lindhout, T. & Hemker, H. C. In Situ-Generated Thrombin Is the Only Enzyme That 
Effectively Activates Factor VIII and Factor V in Thromboplastin-Activated Plasma. Blood 74, 1021–
1024 (1989). 
66. Eaton, D., Rodriguez, H. & Vehar, G. A. Proteolytic processing of human factor VIII. Correlation of 
specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of 
factor VIII coagulant activity. Biochemistry 25, 505–512 (1986). 
67. Fay, P. J. & Smudzin, T. M. Characterization of the Interaction between the A2 Subunit and A1/A3-
C1-C2 Dimer in Human Factor VIIIa. Journal of Biological Chemistry 267, 13246–13250 (1992). 
68. Monaghan, M., Wakabayashi, H., Griffiths, A. E. & Fay, P. J. Stabilizing interactions between D666-
S1787 and T657-Y1792 at the A2-A3 interface support factor VIIIa stability in the blood clotting 
pathway. Journal of Thrombosis and Haemostasis 14, 1021–1030 (2016). 
69. Wakabayashi, H., Monaghan, M. & Fay, P. J. Cofactor Activity in Factor VIIIa of the Blood Clotting 
Pathway Is Stabilized by an Interdomain Bond between His281 and Ser524 Formed in Factor VIII. 
Journal of Biological Chemistry 289, 14020–14029 (2014). 
70. Bloem, E., Meems, H., van den Biggelaar, Maartje, Mertens, K. & Meijer, A. B. A3 domain region 
1803-1818 contributes to the stability of activated factor VIII and includes a binding site for activated 
factor IX. The Journal of biological chemistry 288, 26105–26111 (2013). 
71. Wakabayashi, H., Schmidt, K. M. & Fay, P. J. Ca2+ Binding to Both the Heavy and Light Chains of 
Factor VIII Is Required for Cofactor Activity. Biochemistry 41, 8485–8492 (2002). 
72. Wakabayashi, H., Zhen, Z., Schmidt, K. M. & Fay, P. J. Mn2+ binding to factor VIII subunits and its 
effect on cofactor activity. Biochemistry 42, 145–153 (2003). 
73. Fay, P. J., Mastri, M., Koszelak, M. E. & Wakabayashi, H. Cleavage of Factor VIII Heavy Chain is 
Required for the Functional Interaction of A2 Subunit with Factor IXa. The Journal of biological 
chemistry 276, 12434–12439 (2001). 
74. Lollar, P., Hill-Eubanks, D. C. & Parker, C. G. Association of the Factor VIII Light Chain with von 
Willebrand Factor. Journal of Biological Chemistry 263, 10451-10455 (1988). 
75. Andersson, L. O. & Brown, J. E. Interaction of factor VIII-von Willebrand Factor with phospholipid 
vesicles. Biochem. J. 200, 161–167 (1981). 
76. Nogami, K. A novel mechanism of factor VIII protection by von Willebrand factor from activated 
protein C-catalyzed inactivation. Blood 99, 3993–3998 (2002). 
77. Lapan, K. A. & Fay, P. J. Localization of a Factor X Interactive Site in the A1 Subunit of Factor VIIIa. 
Journal of Biological Chemistry 272, 2082–2088 (1997). 
78. Lenting, P. J., van Schooten, C. J. & Denis, C. V. Clearance mechanisms of von Willebrand factor and 
factor VIII. J Thromb Haemost 5, 1353–1360 (2007). 
 References  115 
79. Bovenschen, N., Rijken, D. C., Havekes, L. M., van Vlijmen, B. J. M. & Mertens, K. The B domain of 
coagulation factor VIII interacts with the asialoglycoprotein receptor. Journal of Thrombosis and 
Haemostasis 3, 1257–1265 (2005). 
80. Gangadharan, B. et al. The C1 and C2 domains of blood coagulation factor VIII mediate its 
endocytosis by dendritic cells. Haematologica 102, 271–281 (2017). 
81. Pool, J. G., Hershgold, E. J. & Pappenhagen, A. R. High-potency Antihaemophilic Factor Concentrate 
prepared from Cryoglobulin Precipitate. Nature 203, 312 (1964). 
82. Kingdon, H. S. & Lundblad, R. L. An adventure in biotechnology: the development of haemophilia A 
therapeutics -- from whole-blood transfusion to recombinant DNA to gene therapy. Biotechnology and 
applied biochemistry 35, 141–148 (2002). 
83. Ettingshausen, C. E. & Kreuz, W. Recombinant vs. plasma-derived products, especially those with 
intact VWF, regarding inhibitor development. Haemophilia 12 Suppl 6, 102–106 (2006). 
84. Sorvillo, N. et al. von Willebrand factor binds to the surface of dendritic cells and modulates peptide 
presentation of factor VIII. Haematologica 101, 309–318 (2016). 
85. van den Berg, H. M., Pipe, S. & Ljung, R. Plasma products do not solve the inhibitor problem. 
Haemophilia 23, 346–347 (2017). 
86. Mazurkiewicz-Pisarek, A., Plucienniczak, G., Ciach, T. & Plucienniczak, A. The factor VIII protein and 
its function. Acta biochimica Polonica 63, 11–16 (2016). 
87. United Kingdom Haemophilia Centre Doctors' Organisation. Guidelines on the selection and use of 
therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia 9, 
1–23 (2003). 
88. Recht, M. et al. Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted 
recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, 
efficacy, and pharmacokinetic equivalence to full-length recombinant factor VIII. Haemophilia 15, 
869–880 (2009). 
89. Pittman, D. D. et al. Biochemical, Immunological, and In Vivo Functional Characterization of B-
Domain-Deleted Factor VIII. Blood 81, 2925–2935 (1993). 
90. Toole, J. J. et al. A large region (=95 kDa) of human factor VIII is dispensable for in vitro 
procoagulant activity. Proceedings of the National Academy of Sciences 83, 5939–5942 (1986). 
91. Eaton, D. L. et al. Construction and Characterization of an Active Factor VIII Variant Lacking the 
Central One-Third of the Molecule. Biochemistry 25, 8343-8347 (1986). 
92. Bihoreau, N. et al. Structural and functional characterization of Factor VIII-ΔII, a new recombinant 
Factor VIII lacking most of the B-domain. Biochem. J. 277, 23–31 (1991). 
93. Miao, H. Z. Bioengineering of coagulation factor VIII for improved secretion. Blood 103, 3412–3419 
(2004). 
94. Casademunt, E. et al. The first recombinant human coagulation factor VIII of human origin: human 
cell line and manufacturing characteristics. Eur J Haematol 89, 165–176 (2012). 
95. Nielsen, P. F., Bak, S. & Vandahl, B. Characterization of tyrosine sulphation in rFVIII (turoctocog 
alfa) expressed in CHO and HEK-293 cells. Haemophilia 18, e397-8 (2012). 
96. Gouw, S. C. et al. Recombinant versus plasma-derived factor VIII products and the development of 
inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 
109, 4693–4697 (2007). 
97. Gouw, S. C. et al. Factor VIII Products and Inhibitor Development in Severe Hemophilia A. N Engl J 
Med 368, 231–239 (2013). 
 116  References 
98. Fischer, K. et al. Inhibitor development in haemophilia according to concentrate. Four-year results 
from the European HAemophilia Safety Surveillance (EUHASS) project. Thrombosis and Haemostasis 
113, 968–975 (2015). 
99. Peyvandi, F. et al. New findings on inhibitor development: from registries to clinical studies. 
Haemophilia 23 Suppl 1, 4–13 (2017). 
100. Peyvandi, F. et al. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. 
The New England Journal of Medicine 374, 2054–2064 (2016). 
101. Goudemand, J., Peyvandi, F. & Lacroix-Desmazes, S. Key insights to understand the 
immunogenicity of FVIII products. Thrombosis and Haemostasis 116 Suppl 1, S2-9 (2016). 
102. Giangrande, P. et al. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety 
in severe haemophilia A. Thrombosis and Haemostasis 117, 252–261 (2017). 
103. Mahlangu, J. et al. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter 
clinical trial in severe hemophilia A. Blood 128, 630–637 (2016). 
104. Powell, J. S. et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in 
hemophilia A patients. Blood 119, 3031–3037 (2012). 
105. Zollner, S. et al. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a 
novel recombinant single-chain factor VIII. Thrombosis Research 134, 125–131 (2014). 
106. Schmidbauer, S. et al. Physicochemical characterisation of rVIII-SingleChain, a novel recombinant 
single-chain factor VIII. Thrombosis Research 136, 388–395 (2015). 
107. Pipe, S. W., Montgomery, R. R., Pratt, K. P., Lenting, P. J. & Lillicrap, D. Life in the shadow of a 
dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood 
128, 2007–2016 (2016). 
108. Krishnamoorthy, S. et al. Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces 
immunogenicity and induces tolerance in hemophilia A mice. Cellular Immunology 301, 30–39 
(2016). 
109. Jawa, V. et al. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and 
mitigation. Clinical Immunology 149, 534–555 (2013). 
110. Oldenburg, J. & Pavlova, A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 
12 Suppl 6, 15–22 (2006). 
111. Astermark, J. Inhibitor development: patient-determined risk factors. Haemophilia 16, 66–70 
(2010). 
112. Reipert, B. M., van Helden, Pauline M. W., Schwarz, H.-P. & Hausl, C. Mechanisms of action of 
immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor 
VIII inhibitors. British Journal of Haematology 136, 12–25 (2007). 
113. De Groot, Anne S. & Scott, D. W. Immunogenicity of protein therapeutics. Trends in Immunology 
28, 482–490 (2007). 
114. Wroblewska, A., Reipert, B. M., Pratt, K. P. & Voorberg, J. Dangerous liaisons: how the immune 
system deals with factor VIII. Journal of Thrombosis and Haemostasis 11, 47–55 (2013). 
115. André, S. et al. A Cellular Viewpoint of Anti-FVIII Immune Response in Hemophilia A. Clinic Rev 
Allerg Immunol 37, 105–113 (2009). 
116. Scandella, D. H. et al. In Hemophilia A and Autoantibody Inhibitor Patients: The Factor VIII A2 
Domain and Light Chain Are Most Immunogenic. Thrombosis Research 101, 377–385 (2001). 
117. Nguyen, P.-C. T. et al. High-resolution mapping of epitopes on the C2 domain of factor VIII by 
analysis of point mutants using surface plasmon resonance. Blood 123, 2732–2739 (2014). 
 References  117 
118. Lubahn, B. C., Ware, J., Stafford, D. W. & Reisner, H. M. Identification of a F.VIII epitope recognized 
by a human hemophilic inhibitor. Blood 73, 497–499 (1989). 
119. Lebreton, A. et al. Discontinuous epitopes on the C2 domain of coagulation Factor VIII mapped by 
computer-designed synthetic peptides. British Journal of Haematology 155, 487–497 (2011). 
120. Gilles, J. G., Arnout, J., Vermylen, J. & Saint-Remy, J. M. Anti-factor VIII antibodies of hemophiliac 
patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic 
restriction. Blood 82, 2452–2461 (1993). 
121. Prescott, R. et al. The Inhibitor Antibody Response Is More Complex in Hemophilia A Patients Than 
in Most Nonhemophiliacs With Factor VIII Autoantibodies. Blood 89, 3663–3671 (1997). 
122. Cannavo, A. et al. Nonneutralizing antibodies against factor VIII and risk of inhibitor development 
in severe hemophilia A. Blood 129, 1245–1250 (2017). 
123. Algiman, M. et al. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. 
Proceedings of the National Academy of Sciences 89, 3795–3799 (1992). 
124. Hu, G.-L., Okita, D. K., Diethelm-Okita, B. M. & Conti-Fine, B. M. Recognition of coagulation factor 
VIII by CD4+ T cells of healthy humans. J Thromb Haemost 1, 2159–2166 (2003). 
125. Ghosh, K. & Shetty, S. Immune Response to FVIII in Hemophilia A: An Overview of Risk Factors. 
Clinic Rev Allerg Immunol 37, 58–66 (2009). 
126. Carcao, M., Re, W. & Ewenstein, B. The role of previously untreated patient studies in 
understanding the development of FVIII inhibitors. Haemophilia 22, 22–31 (2016). 
127. Hu, G.-L., Okita, D. K. & Conti-Fine, B. M. T cell recognition of the A2 domain of coagulation factor 
VIII in hemophilia patients and healthy subjects. J Thromb Haemost 2, 1908–1917 (2004). 
128. Scott, D. W. Inhibitors - cellular aspects and novel approaches for tolerance. Haemophilia 20, 80–
86 (2014). 
129. Van Helden, P. M. W., van Haren, S. D., Fijnvandraat, K., van den Berg, M. H. & Voorberg, J. Factor 
VIII-specific B cell responses in haemophilia A patients with inhibitors. Haemophilia 16, 35–43 
(2010). 
130. Hartholt, R. B., Peyron, I. & Voorberg, J. Hunting down factor VIII in the immunopeptidome. 
Cellular Immunology 301, 59–64 (2016). 
131. Oldenburg, J. et al. Environmental and genetic factors influencing inhibitor development. Seminars 
in Hematology 41, 82–88 (2004). 
132. Mueller, R. et al. Evaluation of the immuno-stimulatory potential of stopper extractables and 
leachables by using dendritic cells as readout. Journal of pharmaceutical sciences 98, 3548–3561 
(2009). 
133. Gouw, S. C., van den Berg, H. M., Le Cessie, S. & van der Bom, J. G. Treatment characteristics and 
the risk of inhibitor development: a multicenter cohort study among previously untreated patients 
with severe hemophilia A. Journal of Thrombosis and Haemostasis 5, 1383–1390 (2007). 
134. Lillicrap, D., Fijnvandraat, K. & Santagostino, E. Inhibitors - genetic and environmental factors. 
Haemophilia 20, 87–93 (2014). 
135. Kempton, C. L., Soucie, J. M. & Abshire, T. C. Incidence of inhibitors in a cohort of 838 males with 
hemophilia A previously treated with factor VIII concentrates. Journal of Thrombosis and Haemostasis 
4, 2576–2581 (2006). 
136. Astermark, J. et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in 
patients with hemophilia A. Blood 108, 3739–3745 (2006). 
 118  References 
137. Astermark, J., Oldenburg, J., Pavlova, A., Berntorp, E. & Lefvert, A.-K. Polymorphisms in the IL10 
but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with 
hemophilia A. Blood 107, 3167–3172 (2006). 
138. Astermark, J., Wang, X., Oldenburg, J., Berntorp, E. & Lefvert, A.-K. Polymorphisms in the CTLA-4 
gene and inhibitor development in patients with severe hemophilia A. Journal of Thrombosis and 
Haemostasis 5, 263–265 (2007). 
139. Franchini, M. et al. Blood Group O Protects against Inhibitor Development in Severe Hemophilia A 
Patients. Seminars in thrombosis and hemostasis 43, 69–74 (2017). 
140. Viel, K. R. et al. Inhibitors of Factor VIII in Black Patients with Hemophilia. N Engl J Med 361, 1618-
1627 (2009). 
141. Carpenter, S. L., Michael Soucie, J., Sterner, S. & Presley, R. Increased prevalence of inhibitors in 
Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database. 
Haemophilia 18, e260-e265 (2012). 
142. Astermark, J. FVIII inhibitors: pathogenesis and avoidance. Blood 125, 2045–2051 (2015). 
143. Brackmann, H. H. & Gormsen, J. Massive Factor-VIII Infusion In Haemophiliac With Factor-VIII 
Inhibitor, High Responder. The Lancet, 933 (1977). 
144. Chang, Sher, Blanchette & Teitel. The impact of inhibitors on the cost of clotting factor replacement 
therapy in haemophilia A in Canada. Haemophilia 5, 247–252 (1999). 
145. Ullman, M. & Hoots, W. K. Assessing the costs for clinical care of patients with high-responding 
factor VIII and IX inhibitors. Haemophilia 12 Suppl 6, 74-80 (2006). 
146. Di Minno, M. N. D., Di Minno, G., Di Capua, M., Cerbone, A. M. & Coppola, A. Cost of care of 
haemophilia with inhibitors. Haemophilia 16, e190-e201 (2010). 
147. Hay, C. R. M. & DiMichele, D. M. The principal results of the International Immune Tolerance 
Study: a randomized dose comparison. Blood 119, 1335–1344 (2012). 
148. Valentino, L. A. et al. US Guidelines for immune tolerance induction in patients with haemophilia 
a and inhibitors. Haemophilia 21, 559–567 (2015). 
149. Kempton, C. L. & Meeks, S. L. Toward optimal therapy for inhibitors in hemophilia. Blood 124, 
3365–3372 (2014). 
150. Minno, G. D., Santagostino, E., Pratt, K. & Königs, C. New predictive approaches for ITI treatment. 
Haemophilia 20, 27–43 (2014). 
151. Mariani, G. & Kroner, B. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of 
success. Haematologica 86, 1186–1193 (2001). 
152. DiMichele, D. M. & Kroner, B. L. The North American Immune Tolerance Registry: Practices, 
Outcomes, Outcome Predictors. Thrombosis and Haemostasis 87, 52–57 (2002). 
153. Coppola, A. et al. Factor VIII gene ( F8 ) mutations as predictors of outcome in immune tolerance 
induction of hemophilia A patients with high-responding inhibitors. Journal of Thrombosis and 
Haemostasis 7, 1809–1815 (2009). 
154. Waters, B. & Lillicrap, D. The molecular mechanisms of immunomodulation and tolerance 
induction to factor VIII. Journal of Thrombosis and Haemostasis 7, 1446–1456 (2009). 
155. Gilles, J. G., Desqueper, B., Lenk, H., Vermylen, J. & Saint-Remy, J. M. Neutralizing antiidiotypic 
antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. J. Clin. Invest. 
97, 1382–1388 (1996). 
 References  119 
156. Pautard, B. et al. Successful immune tolerance induction by FVIII in hemophilia A patients with 
inhibitor may occur without deletion of FVIII-specific T cells. Journal of Thrombosis and Haemostasis 
9, 1163–1170 (2011). 
157. Mancuso, M. E. & Cannavò, A. Immune tolerance induction in hemophilia. Clinical Investigation 5, 
321–335 (2015). 
158. Jacquemin, M. G. et al. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 
monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 92, 496–506 (1998). 
159. Whelan, S. F. J. et al. Distinct characteristics of antibody responses against factor VIII in healthy 
individuals and in different cohorts of hemophilia A patients. Blood 121, 1039–1048 (2013). 
160. Reding, M. T. et al. Distribution of Th1- and Th2-induced Anti-factor VIII IgG Subclasses in 
Congenital and Acquired Hemophilia Patients. Thromb Haemost 88, 568–575 (2002). 
161. Germain, R. The Biochemistry and Cell Biology of Antigen Processing and Presentation. Annual 
review of immunology 11, 403–450 (1993). 
162. Georgescu, M. T., Lai, J. D., Hough, C. & Lillicrap, D. War and peace: Factor VIII and the adaptive 
immune response. Cellular Immunology 301, 2–7 (2016). 
163. Lenschow, D. J., Walunas, T. L. & Bluestone, J. A. CD28/B7 system of T cell costimulation. Annual 
review of immunology 14, 233–258 (1996). 
164. Wieczorek, M. et al. Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: 
Conformational Plasticity in Antigen Presentation. Frontiers in immunology 8, 1–16 (2017). 
165. Godkin, A. J. et al. Naturally Processed HLA Class II Peptides Reveal Highly Conserved 
Immunogenic Flanking Region Sequence Preferences That Reflect Antigen Processing Rather Than 
Peptide-MHC Interactions. The Journal of Immunology 166, 6720–6727 (2001). 
166. Southwood, S. et al. Several Common HLA-DR Types Share Largely Overlapping Peptide Binding 
Repertoires. Journal of Immunology 160, 3363–3373 (1998). 
167. Lippolis, J. D. et al. Analysis of MHC Class II Antigen Processing by Quantitation of Peptides that 
Constitute Nested Sets. The Journal of Immunology 169, 5089–5097 (2002). 
168. Sadegh-Nasseri, S. & Kim, A. MHC Class II Auto-Antigen Presentation is Unconventional. Frontiers 
in immunology 6, 1–5 (2015). 
169. Weaver, J. M. et al. Immunodominance of CD4 T Cells to Foreign Antigens Is Peptide Intrinsic and 
Independent of Molecular Context. Implications for Vaccine Design. The Journal of Immunology 181, 
3039–3048 (2008). 
170. Lazarski, C. A. et al. The Kinetic Stability of MHC Class II:Peptide Complexes Is a Key Parameter 
that Dictates Immunodominance. Immunity 23, 29–40 (2005). 
171. Sturniolo, T. et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA 
microarrays and virtual HLA class II matrices. Nature Biotechnology 17, 555–561 (1999). 
172. De Groot, A S, McMurry, J. & Moise, L. Prediction of immunogenicity: in silico paradigms, ex vivo 
and in vivo correlates. Current Opinion in Pharmacology 8, 620–626 (2008). 
173. Moise, L. et al. Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. Clinical 
Immunology 142, 320–331 (2012). 
174. van Haren, Simon D. et al. Limited promiscuity of HLA-DRB1 presented peptides derived of blood 
coagulation factor VIII. PLoS ONE 8, 1-11 (2013). 
175. Navarrete, A. et al. Splenic marginal zone antigen-presenting cells are critical for the primary allo-
immune response to therapeutic factor VIII in hemophilia A. Journal of Thrombosis and Haemostasis 
7, 1816–1823 (2009). 
 120  References 
176. van Haren, Simon D., Wroblewska, A., Fischer, K., Voorberg, J. & Herczenik, E. Requirements for 
immune recognition and processing of factor VIII by antigen-presenting cells. Blood Reviews 26, 43–
49 (2012). 
177. Lacroix-Desmazes, S. et al. Dynamics of factor VIII interactions determine its immunologic fate in 
hemophilia A. Blood 112, 240–249 (2008). 
178. Tangri, S. et al. Rationally Engineered Therapeutic Proteins with Reduced Immunogenicity. The 
Journal of Immunology 174, 3187–3196 (2005). 
179. Weber, C. A. et al. T cell epitope: Friend or Foe? Immunogenicity of biologics in context. Advanced 
Drug Delivery Reviews 61, 965–976 (2009). 
180. De Groot, Anne S. & Moise, L. Prediction of immunognicity for therapeutic proteins: State of the 
art. Current Opinion in Drug Discovery & Development 10, 1–9 (2007). 
181. Davenport, M. P., Ho Shon, Ivan A. P. & Hill, Adrian V. S. An empirical method for the prediction 
of T-cell epitopes. Immunogenetics 42, 392–397 (1995). 
182. Paul, S. et al. Evaluating the Immunogenicity of Protein Drugs by Applying In Vitro MHC Binding 
Data and the Immune Epitope Database and Analysis Resource. Clinical and Developmental 
Immunology 2013, 1–7 (2013). 
183. National Institute of Allergy and Infectious Diseases. Immune Epitope Database and Analysis 
Resource (IEDB). Available at http://www.iedb.org/. 
184. Sampei, Z. et al. Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG 
Antibody Mimicking the Function of Factor VIII Cofactor Activity. PLoS ONE 8, 1-13 (2013). 
185. Mufarrege, E. F. et al. De-immunized and Functional Therapeutic (DeFT) versions of a long lasting 
recombinant alpha interferon for antiviral therapy. Clinical Immunology 176, 31–41 (2017). 
186. Steere, A. C. et al. Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that 
bind a Borrelia burgdorferi peptide. The Journal of experimental medicine 203, 961–971 (2006). 
187. Reding, M. T. et al. Sensitization of CD4+ T Cells to Coagulation Factor VIII: Response in 
Congenital and Acquired Hemophilia Patients and in Healthy Subjects. Thromb Haemost 84, 643–
652 (2000). 
188. Bouneaud, C., Kourilsky, P. & Bousso, P. Impact of negative selection on the T cell repertoire 
reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 13, 829–
840 (2000). 
189. Bluestone, J. A. & Abbas, A. K. Natural versus adaptive regulatory T cells. Nat Rev Immunol 3, 253–
257 (2003). 
190. Kamate, C., Lenting, P. J., van den Berg, H. M. & Mutis, T. Depletion of CD4+/CD25high regulatory 
T cells may enhance or uncover factor VIII-specific T-cell responses in healthy individuals. Journal of 
Thrombosis and Haemostasis 5, 611–613 (2007). 
191. Depil, S. et al. Peptide-binding assays and HLA II transgenic Abeta degrees mice are consistent and 
complementary tools for identifying HLA II-restricted peptides. Vaccine 24, 2225–2229 (2006). 
192. Shirai, M. et al. CTl Responses of HLA-A2.1-Transgenic Mice Specific for Hepatitis C Viral Peptides 
Predict Epitopes for CTL of Humans Carrying HLA-A2.1. Journal of Immunology 154, 2733–2742 
(1995). 
193. Man, S. et al. Definition of a human T cell epitope from influenza A non-structural protein 1 using 
HLA-A2.1 transgenic mice. Int Immunol 7, 597–605 (1995). 
194. Traggiai, E. et al. Development of a Human Adaptive Immune System in Cord Blood Cell–
Transplanted Mice. Science 304, 104-107 (2004). 
 References  121 
195. Ishikawa, F. et al. Development of functional human blood and immune systems in NOD/SCID/IL2 
receptor γ chainnull mice. Blood 106, 1565–1573 (2005). 
196. Li, Y. et al. A novel Flt3-deficient HIS mouse model with selective enhancement of human DC 
development. European journal of immunology 46, 1291–1299 (2016). 
197. Thermo Fisher Scientific. FreeStyleTM 293 Expression System. Available at 
https://www.thermofisher.com/de/de/home/references/protocols/cell-culture/transfection-
protocol/freestyle-293-expression-system.html (2007). 10.04.2018. 
198. Fischer, S. et al. Transient recombinant protein expression in a human amniocyte cell line: the CAP-
T® cell system. Biotechnology and bioengineering 109, 2250–2261 (2012). 
199. Wang, P. et al. A systematic assessment of MHC class II peptide binding predictions and evaluation 
of a consensus approach. PLoS computational biology 4, 1-10 (2008). 
200. De Groot, Anne S. & Martin, W. Reducing risk, improving outcomes: Bioengineering less 
immunogenic protein therapeutics. Clinical Immunology 131, 189–201 (2009). 
201. Anthony Marcello. DeFT: Immune Engineering Functional Therapeutics. Available at 
http://www.epivax.com/protein-engineering/deft-including-how-tregitope-can-be-used-in-a-deft-
project/ (2010). 20.08.2017. 
202. Graham, F. L., Smiley, J., Russell, W. C. & Nairn, R. Characteristics of a Human Cell Line 
Transformed by DNA from Human Adenovirus Type 5. Journal of General Virology 36, 59–72 (1977). 
203. Quah, Ben J C, Warren, H. S. & Parish, C. R. Monitoring lymphocyte proliferation in vitro and in 
vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc 
2, 2049–2056 (2007). 
204. Miller, L. et al. Danger signal-dependent activation of human dendritic cells by plasma-derived 
factor VIII products. Thromb Haemost 114, 268–276 (2015). 
205. Böhnlein, K. Master Thesis. Is FVIII in combination with other hemorrhage associated factors 
sufficient for DC maturation to rais an immune response against FVIII? Philipps-Universität Marburg, 
2014. 
206. Jonuleit, H. et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent 
immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27, 3135–
3142 (1997). 
207. Trepiakas, R. et al. Comparison of α-Type-1 polarizing and standard dendritic cell cytokine cocktail 
for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients. 
Vaccine 26, 2824–2832 (2008). 
208. Jeras, M., Bergant, M. & Repnik, U. In vitro preparation and functional assessment of human 
monocyte-derived dendritic cells—potential antigen-specific modulators of in vivo immune 
responses. Transplant Immunology 14, 231–244 (2005). 
209. Schlienger, K., Craighead, N., Lee, K. P., Levine, B. L. & June, C. H. Efficent priming of protein 
antigen-specific human CD4+ T cells by monocyte-derived dendritic cells. Blood 96, 3490–3498 
(2000). 
210. Dauer, M. et al. Mature Dendritic Cells Derived from Human Monocytes Within 48 Hours: A Novel 
Strategy for Dendritic Cell Differentiation from Blood Precursors. The Journal of Immunology 170, 
4069–4076 (2003). 
211. Qadura, M. et al. Reduction of the immune response to factor VIII mediated through tolerogenic 
factor VIII presentation by immature dendritic cells. Journal of Thrombosis and Haemostasis 6, 2095–
2104 (2008). 
 122  References 
212. Pascolo, S. et al. HLA-A2.1–restricted Education and Cytolytic Activity of CD8+ T Lymphocytes 
from β2 Microglobulin (β2m) HLA-A2.1 Monochain Transgenic H-2Db β2m Double Knockout Mice. 
Journal of Experimental Medicine 185, 2043–2051 (1997). 
213. Shultz, L. D., Brehm, M. A., Garcia-Martinez, J. V. & Greiner, D. L. Humanized mice for immune 
system investigation: progress, promise and challenges. Nature reviews. Immunology 12, 786–798 
(2012). 
214. Mackarehtschian, K. et al. Targeted Disruption of the flk2/flt3 Gene Leads to Deficiencies in 
Primitive Hematopoietic Progenitors. Immunity 3, 147–161 (1995). 
215. Legrand, N. et al. Functional CD47/signal regulatory protein alpha (SIRPα) interaction is required 
for optimal human T- and natural killer- (NK) cell homeostasis in vivo. Proceedings of the National 
Academy of Sciences of the United States of America 108, 13224–13229 (2011). 
216. Chen, Q., He, F., Kwang, J., Chan, J. K. Y. & Chen, J. GM-CSF and IL-4 stimulate antibody responses 
in humanized mice by promoting T, B, and dendritic cell maturation. Journal of Immunology 189, 
5223–5229 (2012). 
217. Aban, I. B. & George, B. Statistical considerations for preclinical studies. Experimental neurology 
270, 82–87 (2015). 
218. Nahm, F. S. Nonparametric statistical tests for the continuous data: the basic concept and the 
practical use. Korean journal of anesthesiology 69, 8–14 (2016). 
219. Dayhoff, M. O., Schwartz, R. M. & Orcutt, B. C. A Model of Evolutionary Change in Proteins. Atlas 
of Protein Sequence and Structure, 345-352 (1978). 
220. Nakamura, Y., Gojobori, T. & Ikemura, T. Codon usage tabulated from international DNA sequence 
databases: status for the year 2000. Nucleic Acids Research 28, 292 (2000). 
221. Barrowcliffe, T. W., Raut, S., Sands, D. & Hubbard, A. R. Coagulation and Chromogenic Assays of 
Factor VIII Activity: General Aspects, Standardization, and Recommendations. Semin Thromb Hemost 
28, 247–255 (2002). 
222. Lang, T. & Depka, M. von. Diagnostische Möglichkeiten und Grenzen der Thrombelastometrie/-
graphie. Hämostaseologie 3a, 20–29 (2006). 
223. van Veen, J. J., Gatt, A. & Makris, M. Thrombin generation testing in routine clinical practice: are 
we there yet? British Journal of Haematology 142, 889–903 (2008). 
224. McIlroy, D. & Gregoire, M. Optimizing dendritic cell-based anticancer immunotherapy: maturation 
state does have clinical impact. Cancer Immunology, Immunotherapy 52, 583–591 (2003). 
225. Sarkar, R., Gao, G. P., Chirmule, N., Tazelaar, J. & Kazazian, H. H. Partial correction of murine 
hemophilia A with neo-antigenic murine factor VIII. Human Gene Therapy 11, 881–894 (2000). 
226. Lind, P. et al. Novel Forms of B-Domain-Deleted Recombinant Factor VIII Molecules. European 
Journal of Biochemistry 232, 19–27 (1995). 
227. Sandberg, H. et al. Structural and Functional Characterization of B-Domain Deleted Recombinant 
Factor VIII. Seminars in Hematology 38, 4–12 (2001). 
228. van Haren, Simon D. et al. HLA-DR-presented peptide repertoires derived from human monocyte-
derived dendritic cells pulsed with blood coagulation factor VIII. Molecular & cellular proteomics : 
MCP 10, M110.002246 (2011). 
229. Peyron, I. et al. Comparative profiling of HLA-DR and HLA-DQ associated factor VIII peptides 
presented by monocyte-derived dendritic cells. Haematologica 103, 172–178 (2018). 
 References  123 
230. Reding, M. T., Okita, D. K., Diethelm-Okita, B. M., Anderson, T. A. & Conti-Fine, B. M. Epitope 
repertoire of human CD4+ T cells on the A3 domain of coagulation factor VIII. Thromb Haemost 2, 
1385–1394 (2004). 
231. Jones, T. D. et al. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 
domain of factor VIII. J Thromb Haemost 3, 991–1000 (2005). 
232. Reding, M. T., Okita, D. K., Diethelm-Okita, B. M., Anderson, T. A. & Conti-Fine, B. M. Human 
CD4+ T-cell epitope repertoire on the C2 domain of coagulation factor VIII. Journal of Thrombosis 
and Haemostasis 1, 1777–1784 (2003). 
233. Gallwitz, M., Enoksson, M., Thorpe, M., Hellman, L. & Xu, W. The Extended Cleavage Specificity 
of Human Thrombin. PLoS ONE 7, 1-16 (2012). 
234. Bellone, M., Karachunski, P. I., Ostlie, N., Lei, S. & Conti-Tronconi, B. M. Preferential pairing of T 
and B cells for production of antibodies without covalent association of T and B epitopes. Eur J 
Immunol 24, 799–804 (1994). 
235. Healey, J. F. et al. Residues 484-508 Contain a Major Determinant of the Inhibitory Epitope in the 
A2 Domain of Human Factor VIII. The Journal of biological chemistry 270, 14505–14509 (1995). 
236. Griffiths, A. E., Wang, W., Hagen, F. K. & Fay, P. J. Use of affinity-directed liquid chromatography-
mass spectrometry to map the epitopes of a factor VIII inhibitor antibody fraction. Journal of 
Thrombosis and Haemostasis 9, 1534–1540 (2011). 
237. Zhong, D., Saenko, E. L., Shima, M., Felch, M. & Scandella, D. Some Human Inhibitor Antibodies 
Interfere With Factor VIII Binding to Factor IX. Blood 92, 136–142 (1998). 
238. Nogami, K. et al. Identification of a factor VIII peptide, residues 2315-2330, which neutralizes 
human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum 
effect. British Journal of Haematology 107, 196–203 (1999). 
239. Scandella, D. et al. Some Factor VIII Inhibitor Antibodies Recognize a Common Epitope 
Corresponding to C2 Domain Amino Acids 2248 Through 2312, Which Overlap a Phospholipid-
Binding Site. Blood 86, 1811–1819 (1995). 
240. Wölfel, J. et al. CAP-T cell expression system: a novel rapid and versatile human cell expression 
system for fast and high yield transient protein expression. BMC proceedings 5 Suppl 8, 1-2 (2011). 
241. Schiedner, G. et al. Human Cell Lines for Production of Biopharmaceuticals in Cells and Culture, 
pp. 503–511. 
242. D'Amici, G. M., Timperio, A. M., Gevi, F., Grazzini, G. & Zolla, L. Recombinant clotting factor VIII 
concentrates: Heterogeneity and high-purity evaluation. Electrophoresis 31, 2730–2739 (2010). 
243. Sandberg, H. et al. Functional characteristics of the novel, human-derived recombinant FVIII 
protein product, human-cl rhFVIII. Thrombosis Research 130, 808–817 (2012). 
244. Hartholt, R. B. et al. To serve and protect: The modulatory role of von Willebrand factor on factor 
VIII immunogenicity. Blood Reviews 31, 339–347 (2017). 
245. Kosloski, M. P., Miclea, R. D. & Balu-iyer, S. V. Role of Glycosylation in Conformational Stability, 
Activity, Macromolecular Interaction and Immunogenicity of Recombinant Human Factor VIII. AAPS 
J 11, 424–431 (2009). 
246. Hausl, C. High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with 
factor VIII inhibitors. Blood 106, 3415–3422 (2005). 
247. Bykovskaia, S. N. et al. Differentiation of Immunostimulatory Stem-Cell- and Monocyte-Derived 
Dendritic Cells Involves Maturation of Intracellular Compartments Responsible for Antigen 
Presentation and Secretion. Stem Cells 20, 380–393 (2002). 
 124  References 
248. Langenkamp, A. et al. T cell priming by dendritic cells: thresholds for proliferation, differentiation 
and death and intraclonal functional diversification. European journal of immunology 32, 2046–2054 
(2002). 
249. Kotenko, S. V. IFN-λs. Current Opinion in Immunology 23, 583–590 (2011). 
250. Lazear, H. M., Nice, T. J. & Diamond, M. S. Interferon-λ: Immune Functions at Barrier Surfaces and 
Beyond. Immunity 43, 15–28 (2015). 
251. Qian, J., Borovok, M., Bi, L., Kazazian, Haig H. Jr. & Hoyer, L. W. Inhibitor Antibody Development 
and T Cell Response to Human Factor VIII in Murine Hemophilia A. Thromb Haemost 81, 240–244 
(1999). 
252. Chao, B. N. et al. Characterization of a genetically engineered mouse model of hemophilia A with 
complete deletion of the F8 gene. Journal of Thrombosis and Haemostasis 14, 346–355 (2016). 
253. Hay, C. R. M. et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the 
United Kingdom. Blood 117, 6367–6370 (2011). 
  
 List of abbreviations  125 
List of abbreviations 
 
Abbreviation Definition 
2D-DIGE Two-dimensional difference gel electrophoresis 
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Cy Cyanine 
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DOE Design of experiment 
DTT Dithiotthreitol 
E Glutamic acid 
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FII Factor II, Prothrombin 
FIIa Activated Factor II, Thrombin 
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FIX Factor IX 
FIXa Activated Factor IX 
Flk2 Fetal liver kinase-2 
Flt3 Fms like tyrosine kinase 3  
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FV Factor V 
FVa Activated Factor V 
FVII Factor VII 
FVIIa Activated Factor VII 
FVIII Factor VIII 
FVIII-19M Factor VIII containing 19 amino acid exchanges 
FVIII-6rs Factor VIII containing six restriction sites 
FVIIIa Activated Factor VIII 
FX Factor X 
FXa Activated Factor X 
FXI Factor XI 
FXIa Activated Factor XI 
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GM-CSF Granulocyte-macrophage colony-stimulating 
factor 
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H2SO4 Sulfuric acid 
HC Heavy chain 
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HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
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HIS Human immune system 
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HRP Horseradish peroxidase 
HSPG Heparan-sulfate proteoglycans 
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iDCs Immature Dendritic cells 
IEDB Immune Epitope Database and Analysis Resource 
IEF Isoelectric focusing 
IEX Ion exchange chromatography 
IFN Interferon 
IgG Immunoglobulin G 
IgM Immunoglobulin M 
IL Interleukin 
IL-2Rγc IL-2 receptor gamma chain  
IPG Immobilized pH gradient 
IRDye Infrared dye 
iTEM Individual T cell Epitope Measure 
ITI Immune-tolerance-induction 
K Lysine 
KO Knockout 
L Leucine 
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LDS Lithium dodecyl sulfate 
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LRP1 LDL receptor-related protein 
M Methionine 
MACS Magnetic Activated Cell Sorting 
mDCs Mature Dendritic cells 
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MHC Major histocompatibility complex 
MIP Macrophage Inflammatory Protein 
MMR Macrophage mannose receptor 
Mn2+ Divalent manganese 
MOPS 3-(N-morpholino) propane sulfonic acid 
MW Molecular weight 
N Asparagine 
NaCl Sodium chloride 
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NK Natural killer 
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ns Not significant 
OVA Ovalbumin 
PAM Point accepted mutation 
PBMCs Peripheral blood mononuclear cells 
PBS Phosphate-buffered saline 
PE Phycoerythrin 
PEG Polyethylene glycol 
PerCP Peridinin-chlorophyll-protein complex 
pFVIII Plasmatic Factor VIII 
PGE2 Prostaglandin E2 
pH Potential of hydrogen 
pI Isoelectric point 
PLA Parallel line assay 
PMTs Photomultiplier tubes 
Pos Positive 
PTPs Previously treated patients 
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Q Glutamine 
R Arginine 
Rag2 Recombination activating gene 2 
RBC Red blood cell 
rFVIII Recombinant Factor VIII 
ROTEM Rotation thromboelastometry 
S Serine 
SAEx Strong anion exchange chromatography 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
SEC Size exclusion chromatography 
sgp Soluble glycoprotein 
SIRPα Signal regulatory protein α  
SIRPαNOD Signal regulatory protein α from NOD mice 
sR Soluble receptor 
SSC Sideward scatter 
SV40 Simian vacuolating virus 40 
T Threonine 
TBSA Tris-BSA 
TCR T cell receptor 
TE Tris-EDTA 
TEM Thromboelastometry 
TF Tissue factor 
TFF Tangential flow filtration 
TGA Thrombin Generation Assay 
Th T helper cell 
TMB Tetramethylbenzidine 
TNF-α Tumor necrosis factor alpha 
TRANCE TNF-related activation-induced cytokine 
UV  Ultraviolet 
V Valine 
vWF Von Willebrand Factor 
W Tryptophan 
w/o without 
Y Tyrosine 
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% Percent 
°C Degree Celsius 
BU Bethesda Unit 
Da Dalton 
IU International Unit 
kg Kilogram 
L Liter 
M Molar 
m Meter 
m2 Square meter 
min Minute 
rpm Rounds per minute 
U Unit 
V Volt 
Vh Volt hours 
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A. Appendix 
 
A.1. Additional figures 
 
 
Figure A-1: SDS-PAGE of the second FVIII-19M purification developed with Imperial Protein Stain. The samples from the 
purification were not pre-diluted, except for the FVIII-19M concentrate and the reference ReFacto AF, which were set to 
5 U/ml FVIII. 
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Figure A-2: SDS-PAGE of the second FVIII-6rs purification developed with Imperial Protein Stain. The samples from the 
purification were not pre-diluted, except for the FVIII-6rs concentrate and the reference ReFacto AF, which were set to 5 U/ml 
FVIII. 
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Figure A-3: Western Blot of the second FVIII-19M purification developed with a polyclonal sheep anti-human Factor VIII 
antibody and a donkey anti-sheep IgG IRDye 900CW. The samples from the purification were not pre-diluted, except for the 
elutions from the AC and the SEC, which were pre-diluted 1:5, and the FVIII-19M concentrate and the reference ReFacto AF, 
which were set to 5 U/ml FVIII. The upper band (≈ 200 kDa) represents single-chain FVIII, not processed by furin. The second 
band (≈ 110 kDa) represents the heavy chain and the following set of bands (≈ 80-90 kDa) are differently glycosylated forms 
of the light chain. The bands around 50 kDa represent degraded FVIII. 
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Figure A-4: Western Blot of the second FVIII-6rs purification developed with a polyclonal sheep anti-human Factor VIII 
antibody and a donkey anti-sheep IgG IRDye 800CW. The samples from the purification were not pre-diluted, except for the 
elutions from the AC and the SEC, which were pre-diluted 1:5 and the FVIII-6rs and the reference ReFacto AF, which were set 
to 5 U/ml FVIII. The upper band (≈ 200 kDa) represents single-chain FVIII, not processed by furin. The second band 
(≈ 110 kDa) represents the heavy chain and the following set of bands (≈ 80-90 kDa) are differently glycosylated forms of the 
light chain. The bands around 50 kDa represent degraded FVIII. 
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Figure A-5: Results of the cytokine arrays. The boxplots contain the cytokine signal values from all donors, except Donor #4, #13 
and #14 for which no cytokine data were available. All cytokine values were calculated in relation to the control, which was a 
mixture of supernatant of all analyzed co-cultures. The statistical analysis was performed using the Wilcoxon test. 
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A.2. Additional data and statistical analyses 
 
Table A-1: Statistical analysis of the specific activities of FVIII-19M and FVIII-6rs based on the chromogenic activities. The statistical 
analysis was performed using the Wilcoxon test with n = 4 per FVIII product. 
Comparison Significance P value 
FVIII-19M vs. FVIII-6rs Not significant 0.875 
 
Table A-2: Statistical analysis of the specific activities of FVIII-19M and FVIII-6rs based on clotting activities. The statistical analysis 
was performed using the Wilcoxon test with n = 4 per FVIII product. 
Comparison Significance P value 
FVIII-19M vs. FVIII-6rs Not significant 0.125 
 
Table A-3: Statistical analysis of the amounts of generated peak thrombin for ReFacto AF, Nuwiq, FVIII-19M and FVIII-6rs. The 
statistical analysis was performed using the Friedman test with n = 4 per FVIII product.  
Comparison Significance at  
0.25 U/ml 
Significance at 
0.063 U/ml 
Significance at 
0.016 U/ml 
ReFacto AF vs. Nuwiq Not significant Not significant Not significant 
ReFacto AF vs. FVIII-19M * Not significant * 
ReFacto AF vs. FVIII-6rs Not significant Not significant Not significant 
Nuwiq vs. FVIII-19M Not significant * Not significant 
Nuwiq vs. FVIII-6rs Not significant Not significant Not significant 
FVIII-19M vs. FVIII-6rs Not significant Not significant Not significant 
 
Table A-4: Statistical analysis of the area under the curve values for ReFacto AF, Nuwiq, FVIII-19M and FVIII-6rs. The statistical 
analysis was performed using the Friedman test with n = 4 per FVIII product. 
Comparison Significance at  
0.25 U/ml 
Significance at 
0.063 U/ml 
Significance at 
0.016 U/ml 
ReFacto AF vs. Nuwiq Not significant Not significant Not significant 
ReFacto AF vs. FVIII-19M * Not significant * 
ReFacto AF vs. FVIII-6rs Not significant Not significant Not significant 
Nuwiq vs. FVIII-19M Not significant * Not significant 
Nuwiq vs. FVIII-6rs Not significant Not significant Not significant 
FVIII-19M vs. FVIII-6rs Not significant Not significant Not significant 
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Table A-5: Statistical analysis of the time to peak thrombin generation values for ReFacto AF, Nuwiq, FVIII-19M and FVIII-6rs. 
The statistical analysis was performed using the Friedman test with n = 4 per FVIII product. 
Comparison Significance at  
0.25 U/ml 
Significance at 
0.063 U/ml 
Significance at 
0.016 U/ml 
ReFacto AF vs. Nuwiq Not significant Not significant Not significant 
ReFacto AF vs. FVIII-19M * * Not significant 
ReFacto AF vs. FVIII-6rs Not significant Not significant Not significant 
Nuwiq vs. FVIII-19M Not significant Not significant Not significant 
Nuwiq vs. FVIII-6rs Not significant Not significant Not significant 
FVIII-19M vs. FVIII-6rs Not significant Not significant * 
 
Table A-6: Statistical analysis of the potency of ReFacto AF, Nuwiq, FVIII-19M and FVIII-6rs to bind to vWF. The statistical analysis 
was performed using the Friedman test with n = 4 per FVIII product. 
Comparison Significance  
ReFacto AF vs. Nuwiq Not significant 
ReFacto AF vs. FVIII-19M Not significant 
ReFacto AF vs. FVIII-6rs Not significant 
Nuwiq vs. FVIII-19M * 
Nuwiq vs. FVIII-6rs Not significant 
FVIII-19M vs. FVIII-6rs Not significant 
 
Table A-7: Median of the MFIs of the differently stimulated DCs. The median was calculated from the response of three to five 
healthy donors per DC-stimulation condition. 
DC stimulus 
Added 
protein 
Median MFI of 
HLA-DR 
expression 
Median MFI of 
CD40 
expression 
Median MFI of 
CD80 
expression 
Median MFI of 
CD86 
expression 
No stimulus 
No protein 32 270 5563 497 3497 
OVA 52 206 7170 441 4108 
ReFacto AF 33 524 6180 471 3306 
LPS 
No protein 68 797 11 960 948 4723 
OVA 86 346 13 846 839 4022 
ReFacto AF 72 388 10 321 798 4285 
IL-Mix 
No protein 82 535 12 539 891 4896 
OVA 78 339 13 097 836 4834 
ReFacto AF 89 960 11 830 794 4708 
IL-Mix 
(w/o IL-8) 
No protein 73 316 11 748 972 4485 
OVA 66 576 11 172 969 4115 
ReFacto AF 71 876 11 244 923 4225 
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Table A-8: Statistical analysis of the MFI of the fluorochrome-coupled antibodies against different surface proteins on DCs. The 
table presents the statistical results for the MFI of anti-HLA-DR, anti-CD40, anti-CD80 and anti-CD86 antibodies at the different 
stimulation conditions. The statistical analysis was performed using the Kruskal-Wallis test with n = 3-5 per stimulation condition. 
Comparison Significance  
iDCs vs. mDCs + LPS Not significant 
iDCs vs. mDCs + IL-Mix Not significant 
iDCs vs. mDCs + IL-Mix (w/o IL-8) Not significant 
mDCs + LPS vs. mDCs + IL-Mix Not significant 
mDCs + LPS vs. mDCs + IL-Mix (w/o IL-8) Not significant 
mDCs + IL-Mix vs. mDCs + IL-Mix (w/o IL-8) Not significant 
iDCs + OVA vs. mDCs + LPS + OVA Not significant 
iDCs + OVA vs. mDCs + IL-Mix + OVA Not significant 
iDCs + OVA vs. mDCs + IL-Mix (w/o IL-8) + OVA Not significant 
mDCs + LPS + OVA vs. mDCs + IL-Mix + OVA Not significant 
mDCs + LPS + OVA vs. mDCs + IL-Mix (w/o IL-8) + OVA Not significant 
mDCs + IL-Mix + OVA vs. mDCs + IL-Mix (w/o IL-8) + OVA Not significant 
iDCs + ReFacto AF vs. mDCs + LPS + ReFacto AF Not significant 
iDCs + ReFacto AF vs. mDCs + IL-Mix + ReFacto AF Not significant 
iDCs + ReFacto AF vs. mDCs + IL-Mix (w/o IL-8) + ReFacto AF Not significant 
mDCs + LPS + ReFacto AF vs. mDCs + IL-Mix + ReFacto AF Not significant 
mDCs + LPS + ReFacto AF vs. mDCs + IL-Mix (w/o IL-8) + ReFacto AF Not significant 
mDCs + IL-Mix + ReFacto AF vs. mDCs + IL-Mix (w/o IL-8) + ReFacto AF Not significant 
iDCs vs. mDCs + OVA Not significant 
iDCs vs. mDCs + ReFacto AF Not significant 
mDCs + OVA vs. mDCs + ReFacto AF Not significant 
mDCs + LPS vs. mDCs + LPS + OVA Not significant 
mDCs + LPS vs. mDCs + LPS + ReFacto AF Not significant 
mDCS + LPS + OVA vs. mDCs + LPS + ReFacto AF Not significant 
mDCs + IL-Mix vs. mDCs + IL-Mix + OVA Not significant 
mDCs + IL-Mix vs. mDCs + IL-Mix + ReFacto AF Not significant 
mDCS + IL-Mix + OVA vs. mDCs + IL-Mix + ReFacto AF Not significant 
mDCs + IL-Mix (w/o IL-8) vs. mDCs + IL-Mix (w/o IL-8)+ OVA Not significant 
mDCs + IL-Mix (w/o IL-8) vs. mDCs + IL-Mix (w/o IL-8) + ReFacto AF Not significant 
mDCS + IL-Mix (w/o IL-8) + OVA vs. mDCs + IL-Mix (w/o IL-8) + ReFacto AF Not significant 
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Table A-9: Statistical analysis of the viability of differently stimulated DCs. The statistical analysis was performed using the 
Kruskal-Wallis test with n = 3-5 per stimulation condition. 
Comparison Significance  
iDCs vs. mDCs + LPS Not significant 
iDCs vs. mDCs + IL-Mix Not significant 
iDCs vs. mDCs + IL-Mix (w/o IL-8) Not significant 
mDCs + LPS vs. mDCs + IL-Mix Not significant 
mDCs + LPS vs. mDCs + IL-Mix (w/o IL-8) Not significant 
mDCs + IL-Mix vs. mDCs + IL-Mix (w/o IL-8) Not significant 
iDCs + OVA vs. mDCs + LPS + OVA Not significant 
iDCs + OVA vs. mDCs + IL-Mix + OVA Not significant 
iDCs + OVA vs. mDCs + IL-Mix (w/o IL-8) + OVA Not significant 
mDCs + LPS + OVA vs. mDCs + IL-Mix + OVA Not significant 
mDCs + LPS + OVA vs. mDCs + IL-Mix (w/o IL-8) + OVA Not significant 
mDCs + IL-Mix + OVA vs. mDCs + IL-Mix (w/o IL-8) + OVA Not significant 
iDCs + ReFacto AF vs. mDCs + LPS + ReFacto AF Not significant 
iDCs + ReFacto AF vs. mDCs + IL-Mix + ReFacto AF Not significant 
iDCs + ReFacto AF vs. mDCs + IL-Mix (w/o IL-8) + ReFacto AF Not significant 
mDCs + LPS + ReFacto AF vs. mDCs + IL-Mix + ReFacto AF Not significant 
mDCs + LPS + ReFacto AF vs. mDCs + IL-Mix (w/o IL-8) + ReFacto AF Not significant 
mDCs + IL-Mix + ReFacto AF vs. mDCs + IL-Mix (w/o IL-8) + ReFacto AF Not significant 
iDCs vs. mDCs + OVA Not significant 
iDCs vs. mDCs + ReFacto AF Not significant 
mDCs + OVA vs. mDCs + ReFacto AF Not significant 
mDCs + LPS vs. mDCs + LPS + OVA Not significant 
mDCs + LPS vs. mDCs + LPS + ReFacto AF Not significant 
mDCs + LPS + OVA vs. mDCs + LPS + ReFacto AF Not significant 
mDCs + IL-Mix vs. mDCs + IL-Mix + OVA Not significant 
mDCs + IL-Mix vs. mDCs + IL-Mix + ReFacto AF Not significant 
mDCs + IL-Mix + OVA vs. mDCs + IL-Mix + ReFacto AF Not significant 
mDCs + IL-Mix (w/o IL-8) vs. mDCs + IL-Mix (w/o IL-8)+ OVA Not significant 
mDCs + IL-Mix (w/o IL-8) vs. mDCs + IL-Mix (w/o IL-8) + ReFacto AF Not significant 
mDCs + IL-Mix (w/o IL-8) + OVA vs. mDCs + IL-Mix (w/o IL-8) + ReFacto AF Not significant 
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Table A-10: Statistical analysis of the proliferation of CD4+ T cells, CD4+CD25+ T cells as well as CD4+CD25- T cells in response to 
differently stimulated DCs. The statistical analysis was performed using the Kruskal-Wallis test with n = 3-6 per DC stimulation 
condition. 
Comparison Significance  
T cells + iDCs vs. T cells + mDCs + LPS Not significant 
T cells + iDCs vs. T cells + mDCs + IL-Mix Not significant 
T cells + iDCs vs. T cells + mDCs + IL-Mix (w/o IL-8) Not significant 
T cells + mDCs + LPS vs. T cells + mDCs + IL-Mix Not significant 
T cells + mDCs + LPS vs. T cells + mDCs + IL-Mix (w/o IL-8) Not significant 
T cells + mDCs + IL-Mix vs. T cells + mDCs + IL-Mix (w/o IL-8) Not significant 
T cells + iDCs + OVA vs. T cells + mDCs + LPS + OVA Not significant 
T cells + iDCs + OVA vs. T cells + mDCs + IL-Mix + OVA Not significant 
T cells + iDCs + OVA vs. T cells + mDCs + IL-Mix (w/o IL-8) + OVA Not significant 
T cells + mDCs + LPS + OVA vs. T cells + mDCs + IL-Mix + OVA Not significant 
T cells + mDCs + LPS + OVA vs. T cells + mDCs + IL-Mix (w/o IL-8) + OVA Not significant 
T cells + mDCs + IL-Mix + OVA vs. T cells + mDCs + IL-Mix (w/o IL-8) + 
OVA 
Not significant 
T cells + iDCs + ReFacto AF vs. T cells + mDCs + LPS + ReFacto AF Not significant 
T cells + iDCs + ReFacto AF vs. T cells + mDCs + IL-Mix + ReFacto AF Not significant 
T cells + iDCs + ReFacto AF vs. T cells + mDCs + IL-Mix (w/o IL-8) + ReFacto 
AF 
Not significant 
T cells + mDCs + LPS + ReFacto AF vs. T cells + mDCs + IL-Mix + ReFacto 
AF 
Not significant 
T cells + mDCs + LPS + ReFacto AF vs. T cells + mDCs + IL-Mix (w/o IL-8) + 
ReFacto AF 
Not significant 
T cells + mDCs + IL-Mix + ReFacto AF vs. T cells + mDCs + IL-Mix (w/o IL-8) 
+ ReFacto AF 
Not significant 
T cells + iDCs vs. T cells + mDCs + OVA Not significant 
T cells + iDCs vs. T cells + mDCs + ReFacto AF Not significant 
T cells + mDCs + OVA vs. T cells + mDCs + ReFacto AF Not significant 
T cells + mDCs + LPS vs. T cells + mDCs + LPS + OVA Not significant 
T cells + mDCs + LPS vs. T cells + mDCs + LPS + ReFacto AF Not significant 
T cells + mDCS + LPS + OVA vs. T cells + mDCs + LPS + ReFacto AF Not significant 
T cells + mDCs + IL-Mix vs. T cells + mDCs + IL-Mix + OVA Not significant 
T cells + mDCs + IL-Mix vs. T cells + mDCs + IL-Mix + ReFacto AF Not significant 
T cells + mDCS + IL-Mix + OVA vs. T cells + mDCs + IL-Mix + ReFacto AF Not significant 
T cells + mDCs + IL-Mix (w/o IL-8) vs. T cells + mDCs + IL-Mix (w/o IL-8)+ 
OVA 
Not significant 
 Appendix  153 
T cells + mDCs + IL-Mix (w/o IL-8) vs. T cells + mDCs + IL-Mix (w/o IL-8) + 
ReFacto AF 
Not significant 
T cells + mDCs + IL-Mix (w/o IL-8) + OVA vs. T cells + mDCs + IL-Mix (w/o 
IL-8) + ReFacto AF 
Not significant 
 
Table A-11: Amount of proliferating CD4+ T cells for each stimulation after 9 days of co-cultivation. The amount was calculated 
on all viable CD4+ T cells. 
Donor # 
Proliferating CD4+ T cells stimulated with 
DCs + IL-Mix 
DCs + IL-Mix + 
FVIII-19M 
DCs + IL-Mix + 
FVIII-6rs 
DCs + IL-Mix + 
ReFacto AF 
1 17.6 % 29.0 % 30.5 % n/a 
2 22.4 % 27.5 % 36.1 % 30.7 % 
3 41.8 % 54.4 % 52.0 % 54.7 % 
4 54.3 % 14.7 % 5.56 % 61.5 % 
5 35.5 % 52.9 % 64.8 % 61.2 % 
6 11.2 % 5.83 % 18.1 % 12.1 % 
7 34.0 % 29.3 % 23.3 % 43.2 % 
8 29.8 % 54.8 % 89.5 % 43.9 % 
9 70.6 % 69.5 % 84.9 % n/a 
10 69.6 % 22.5 % 78.2 % 77.3 % 
11 7.80 % 8.96 % 18.0 % 13.2 % 
12 16.6 % 11.4 % 17.3 % 27.1 % 
13 17.9 % 3.51 % 27.7 % 18.7 % 
14 21.2 % 17.0 % 21.3 % 34.1 % 
15 6.48 % 4.76 % 1.22 % 8.08 % 
16 2.46 % 3.78 % 6.75 % 3.48 % 
17 5.43 % 7.98 % 4.66 % 7.22 % 
18 17.5 % 5.38 % 3.55 % n/a 
19 67.3 % 48.4 % 38.5 % n/a 
20 19.3 % 11.0 % 15.5 % 13.3 % 
21 17.9 % 4.40 % 6.40 % 9.84 % 
22 15.1 % 11.8 % 14.5 % n/a 
23 6.87 % 5.05 % 4.24 % 6.12 % 
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Table A-12: Amount of viable CD4+ T cells for each stimulation after 9 days of co-cultivation. The amount was calculated on all 
detected events. 
Donor # 
Viable CD4+ T cells stimulated with 
DCs + IL-Mix 
DCs + IL-Mix + 
FVIII-19M 
DCs + IL-Mix + 
FVIII-6rs 
DCs + IL-Mix + 
ReFacto AF 
1 65.2 % 61.2 % 64.7 % n/a 
2 61.5 % 52.7 % 40.4 % 63.4 % 
3 61.6 % 62.4 % 50.7 % 59.6 % 
4 25.9 % 8.34 % 0.72 % 21.6 % 
5 21.2 % 12.8 % 2.64 % 19.4 % 
6 26.4 % 24.7 % 1.38 % 26.7 % 
7 40.9 % 36.0 % 33.9 % 42.8 % 
8 28.1 % 34.3 % 59.2 % 25.9 % 
9 48.4 % 50.4 % 44.2 % n/a 
10 42.4 % 21.5 % 34.6 % 43.7 % 
11 59.6 % 55.7 % 30.6 % 57.2 % 
12 38.8 % 23.0 % 18.2 % 40.5 % 
13 44.6 % 29.4 % 1.92 % 42.8 % 
14 25.2 % 20.2 % 1.92 % 42.8 % 
15 62.0 % 49.6 % 12.3 % 50.9 % 
16 37.0 % 23.3 % 5.93 % 37.4 % 
17 16.4 % 14.4 % 6.87 % 16.5 % 
18 13.9 % 6.51 % 5.91 % n/a 
19 36.0 % 28.7 % 11.9 % n/a 
20 44.0 % 41.2 % 21.6 % 41.3 % 
21 12.5 % 4.32 % 1.25 % 3.76 % 
22 n/a 8.32 % 7.86 % n/a 
23 16.4 % 11.7 % 6.61 % 12.9 % 
 
Table A-13: Statistical analysis of the difference in proliferation of CD4+ T cells to FVIII-19M and FVIII-6rs. Either 17 or 11 healthy 
donors were analyzed. The statistical analysis was performed using the Wilcoxon test. 
Comparison Group size Significance  P value 
T cells + DCs + IL-Mix + FVIII-6rs vs.  
T cells + DCs + IL-Mix + FVIII-19M 
17 * 0.0267 
T cells + DCs + IL-Mix + FVIII-6rs vs.  
T cells + DCs + IL-Mix + FVIII-19M 
10 * 0.0371 
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Table A-14: Statistical analysis of the difference in secreted cytokines in co-cultures with DCs stimulated with FVIII-19M and FVIII-
6rs. All cytokine values were calculated in relation to the control, which was a mixture of supernatant of all analyzed co-cultures. 
No cytokine data were available for Donor #4, #13 and #14. The statistical analysis was performed using the Wilcoxon test. 
Cytokine 
Median relative 
cytokine signal 
in % of co-
culture with 
FVIII-6rs 
stimulated DCs 
Median relative 
cytokine signal 
in % of co-
culture with 
FVIII-19M 
stimulated DCs 
Significance P value 
IL-1β 35.1 35.9 Not significant 0.5830 
IL-1sRI 36.3 37.9 Not significant > 0.9999 
IL-1sRII 37.2 35.8 Not significant 0.2166 
IL-2 33.0 35.0 * 0.0134 
IL-4 32.1 33.8 Not significant > 0.9999 
IL-5 32.5 32.2 Not significant 0.5830 
IL-6 25.9 26.3 Not significant 0.3575 
IL-6sR 35.0 36.2 Not significant 0.9032 
IL-10 42.2 42.0 Not significant 0.6698 
IL-12 p40 38.6 41.1 * 0.0419 
IL-12 p70 35.8 36.9 Not significant 0.9515 
IL-13 19.9 17.2 Not significant 0.8077 
IL-17 34.0 35.7 Not significant 0.1937 
IL-17F 29.4 28.4 Not significant 0.8552 
IL-17R 33.9 34.6 Not significant 0.5830 
IL-21 35.5 36.0 Not significant 0.7148 
IL-21R 36.0 36.5 Not significant 0.5416 
IL-22 34.8 34.6 Not significant 0.9032 
IL-23 p19 37.2 36.4 Not significant 0.7148 
IL-28A 34.6 37.3 * 0.0353 
CD30 36.4 37.8 Not significant 0.4631 
CD40 34.5 36.7 Not significant 0.1040 
CD40L 37.0 37.8 Not significant 0.2676 
GCSF 13.0 13.5 Not significant 0.6698 
GITR 36.4 36.9 Not significant 0.6698 
GM-CSF 29.0 20.3 * 0.0494 
IFN-γ 35.7 37.6 Not significant 0.1040 
MIP-3α 35.3 34.3 Not significant 0.7609 
sgp130 35.9 37.8 Not significant 0.9515 
TGF-β1 28.0 28.6 Not significant 0.8077 
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TGF-β3 35.0 35.2 Not significant 0.5416 
TNF-α 34.3 34.3 Not significant 0.1937 
TNF-β 38.5 36.1 Not significant 0.4631 
TRANCE 38.3 36.8 * 0.0107 
 
Table A-15: Statistical analysis of the antibody titers of E16 FVIII KO mice immunized with different FVIII products or FVIII 
Formulation Buffer. Either eight or ten mice were analyzed per stimulus. The statistical analysis was performed using the Kruskal-
Wallis test. 
Comparison Significance  
PBS vs. ReFacto AF Not significant 
PBS vs. FVIII-6rs Not significant 
PBS vs. FVIII-19M Not significant 
ReFacto AF vs. FVIII-6rs Not significant 
ReFacto AF vs. FVIII-19M Not significant 
FVIII-6rs vs. FVIII-19M Not significant 
 
Table A-16: Statistical analysis of the difference in proliferation of CD4+ T cells of E16 FVIII KO mice upon restimulation with FVIII 
or PBS. Either eight or ten mice were analyzed per stimulus. The statistical analysis was performed using the Wilcoxon test. 
Mice immunized with Comparison restimulation Significance  P value 
FVIII Formulation Buffer  T cells + PBS vs. T cells + ReFacto AF Not significant 0.8438 
ReFacto AF T cells + PBS vs. T cells + ReFacto AF * 0.0371 
FVIII-6rs T cells + PBS vs. T cells + FVIII-6rs * 0.0195 
FVIII-19M T cells + PBS vs. T cells + FVIII-19M Not significant 0.3828 
 
Table A-17: Statistical analysis of the difference in proliferation of CD4+ T cells of BRGSF mice upon restimulation with FVIII or 
medium. Three to five mice were analyzed per stimulus. The statistical analysis was performed using the Wilcoxon test. 
Mice immunized with Comparison restimulation Significance  P value 
ReFacto AF T cells + Medium vs. T cells + ReFacto AF Not significant 0.625 
FVIII-6rs T cells + Medium vs. T cells + FVIII-6rs Not significant 0.125 
FVIII-19M T cells + Medium vs. T cells + FVIII-19M Not significant 0.25 
 
 
  
 
